{
  "version": 1,
  "updatedAt": "2025-11-26T01:00:00Z",
  "id": "immunocompromised-infections",
  "name": "Immunocompromised Infections",
  "description": "Opportunistic infections in immunocompromised hosts including HIV/AIDS, transplant recipients, chemotherapy patients, and immunosuppressive therapy",
  "icon": "shield",
  "color": "#FFA726",
  "conditions": [
    {
      "id": "pneumocystis-pneumonia",
      "name": "Pneumocystis Pneumonia (PCP)",
      "synonyms": [
        "Pneumocystis jirovecii pneumonia",
        "PJP"
      ],
      "icd10": [
        "B59",
        "J17.3"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening opportunistic fungal pneumonia in immunocompromised hosts requiring TMP-SMX + corticosteroids (if PaO2 <70 mmHg)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening opportunistic fungal pneumonia caused by Pneumocystis jirovecii (formerly P. carinii). Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <200 cells/μL, 80-90% of PCP cases), transplant recipients (10-15%), chemotherapy patients (5-10%), prolonged corticosteroid use (>20mg prednisone daily x >1 month, 5-10%). Incidence: Rare in general population, common in HIV/AIDS (10-20% lifetime risk if no prophylaxis). Mortality: 10-20% (HIV/AIDS with treatment), 30-50% (non-HIV immunocompromised), 50-70% (if mechanical ventilation required).",
            "clinical_presentation": "Subacute onset (days to weeks): Progressive dyspnea, dry cough, fever, chest discomfort, hypoxemia (PaO2 <70 mmHg). Physical exam: Tachypnea (>20 breaths/min), tachycardia (>100 bpm), hypoxemia (O2 saturation <90% on room air), crackles (50-60%, often absent), normal chest exam (30-40%). Chest X-ray: Bilateral interstitial infiltrates (ground-glass opacities, 70-80%), normal chest X-ray (10-20%, especially early disease). CT chest: Ground-glass opacities (90-95%, more sensitive than chest X-ray), cystic changes (10-20%, risk of pneumothorax).",
            "diagnostic_criteria": "Clinical diagnosis: Progressive dyspnea + dry cough + fever + hypoxemia in immunocompromised host. Laboratory: Elevated LDH (>500 U/L, 90-95% sensitive but non-specific), elevated beta-D-glucan (>80 pg/mL, 90-95% sensitive, 80-85% specific). Definitive diagnosis: Positive Pneumocystis PCR or immunofluorescence (IF) or Gomori methenamine silver (GMS) stain on induced sputum (50-60% sensitivity) or bronchoalveolar lavage (BAL, 90-95% sensitivity, gold standard).",
            "risk_factors": [
              "HIV/AIDS with CD4 <200 cells/μL (most important risk factor, 80-90% of PCP cases)",
              "Solid organ transplant recipients (10-15%, especially lung transplant)",
              "Hematopoietic stem cell transplant (HSCT) recipients (5-10%)",
              "Prolonged corticosteroid use (>20mg prednisone daily x >1 month, 5-10%)",
              "Chemotherapy (especially hematologic malignancies, 5-10%)",
              "Immunosuppressive therapy (TNF-alpha inhibitors, rituximab, 5-10%)",
              "Congenital immunodeficiency (rare, <1%)"
            ],
            "red_flags": [
              "Severe hypoxemia - PaO2 <70 mmHg or A-a gradient >35 mmHg, requires corticosteroids (prednisone 40mg PO BID x 5 days, then taper) + ICU admission",
              "Respiratory failure - PaO2 <60 mmHg despite oxygen, requires mechanical ventilation, mortality 50-70%",
              "Pneumothorax - spontaneous pneumothorax (10-20% of PCP, especially with cystic changes), requires chest tube",
              "Immune reconstitution inflammatory syndrome (IRIS) - worsening symptoms after starting ART in HIV/AIDS (10-20%), requires corticosteroids",
              "Treatment failure - no improvement after 4-7 days of TMP-SMX, consider alternative diagnosis (CMV, fungal, bacterial) or second-line therapy (pentamidine, atovaquone + primaquine)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Progressive dyspnea + dry cough + fever + hypoxemia in immunocompromised host. Do NOT delay treatment while awaiting test results (start empiric TMP-SMX immediately if high clinical suspicion). Induced sputum (50-60% sensitivity, non-invasive) OR Bronchoalveolar lavage (BAL, 90-95% sensitivity, gold standard, requires bronchoscopy).",
            "essential_tests": [
              "Oxygen saturation: Hypoxemia (O2 saturation <90% on room air) common (80-90%). Measure at rest and with exertion (6-minute walk test).",
              "Arterial blood gas (ABG): PaO2 <70 mmHg (moderate-severe PCP, requires corticosteroids). A-a gradient >35 mmHg (severe PCP).",
              "Chest X-ray: Bilateral interstitial infiltrates (ground-glass opacities, 70-80%). Normal chest X-ray (10-20%, especially early disease).",
              "CT chest (high-resolution): Ground-glass opacities (90-95%, more sensitive than chest X-ray). Cystic changes (10-20%, risk of pneumothorax).",
              "LDH: Elevated (>500 U/L, 90-95% sensitive but non-specific). Higher LDH correlates with worse prognosis.",
              "Beta-D-glucan: Elevated (>80 pg/mL, 90-95% sensitive, 80-85% specific). Positive in PCP, Candida, Aspergillus (not specific for PCP)."
            ],
            "conditional_tests": [
              "Induced sputum: Pneumocystis PCR (70-80% sensitive) or IF (50-60% sensitive) or GMS stain (50-60% sensitive). Non-invasive, first-line diagnostic test. If negative and high clinical suspicion → proceed to BAL.",
              "Bronchoalveolar lavage (BAL): Pneumocystis PCR (90-95% sensitive, gold standard) or IF (90-95% sensitive) or GMS stain (90-95% sensitive). Requires bronchoscopy. Gold standard for diagnosis.",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, PCP risk if CD4 <200 cells/μL).",
              "CBC: Leukocytosis (WBC >10,000, 50-60%) or leukopenia (WBC <4,000, 20-30%). Non-specific.",
              "Blood cultures: Rule out bacterial co-infection (positive in 5-10%)."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting test results (start empiric TMP-SMX immediately if high clinical suspicion, mortality increases with delayed treatment). Do NOT require positive Pneumocystis test for diagnosis (clinical diagnosis + empiric treatment acceptable if high suspicion). Do NOT perform BAL if patient too unstable (severe hypoxemia, respiratory failure, start empiric treatment).",
            "turnaround_time": "Chest X-ray: Same day. CT chest: Same day. ABG: 1-2 hours. LDH: 1-2 hours. Beta-D-glucan: 1-2 days. Induced sputum PCR: 1-2 days. BAL PCR: 1-2 days. Blood cultures: 24-48 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Pneumocystis jirovecii (formerly P. carinii). Atypical fungus (lacks ergosterol in cell membrane, resistant to azoles). Obligate extracellular pathogen (cannot be cultured in vitro). Transmission: Airborne (person-to-person or environmental). Colonization: 20-30% of healthy adults (asymptomatic). Disease: Only in severely immunocompromised hosts (CD4 <200 cells/μL, transplant recipients, prolonged corticosteroids, chemotherapy).",
            "pathogenesis": "Inhalation of Pneumocystis cysts → alveolar attachment → trophozoite proliferation → alveolar filling → impaired gas exchange → hypoxemia. Host immune response: CD4 T-cells critical for clearance (PCP occurs when CD4 <200 cells/μL). Inflammatory response: Cytokine release → alveolar damage → ARDS. Complications: Pneumothorax (10-20%, cystic changes), respiratory failure (30-40%, requires mechanical ventilation), IRIS (10-20% in HIV/AIDS after starting ART).",
            "resistance_patterns": {
              "tmp_smx_resistance": "TMP-SMX: Rare resistance (<5%). Remains first-line therapy. Treatment failure (10-20%) usually due to delayed diagnosis, severe disease, or intolerance (not resistance).",
              "pentamidine_resistance": "Pentamidine: Rare resistance (<5%). Second-line therapy if TMP-SMX intolerance or failure.",
              "atovaquone_resistance": "Atovaquone: Rare resistance (<5%). Third-line therapy (less effective than TMP-SMX or pentamidine, but better tolerated)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for test results, mortality increases with delayed treatment). TMP-SMX 15-20mg/kg/day (based on TMP component) IV or PO divided TID or QID x 21 days (HIV/AIDS) or 14 days (non-HIV). Add corticosteroids (prednisone 40mg PO BID x 5 days, then taper) if PaO2 <70 mmHg or A-a gradient >35 mmHg (reduces mortality by 50%)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "TMP-SMX 15-20mg/kg/day (based on TMP component) IV or PO divided TID or QID x 21 days (HIV/AIDS) or 14 days (non-HIV). Dosing: TMP-SMX DS (160/800mg) 2 tabs PO TID (if weight 40-60 kg) OR 2 tabs PO QID (if weight >60 kg) OR TMP-SMX 5mg/kg IV q6-8h. Add corticosteroids (prednisone 40mg PO BID x 5 days, then 40mg PO daily x 5 days, then 20mg PO daily x 11 days, total 21 days) if PaO2 <70 mmHg or A-a gradient >35 mmHg (reduces mortality by 50%).",
            "second_line": "Pentamidine 4mg/kg IV daily x 21 days (if TMP-SMX intolerance or contraindication). Requires IV access, cardiac monitoring (QTc prolongation), glucose monitoring (hypoglycemia then hyperglycemia). Alternative: Atovaquone 750mg PO BID x 21 days + Primaquine 30mg PO daily x 21 days (if mild-moderate PCP, PaO2 >70 mmHg, less effective than TMP-SMX but better tolerated). Check G6PD before primaquine (risk of hemolysis if G6PD deficiency).",
            "third_line": "Clindamycin 600-900mg IV q6-8h + Primaquine 30mg PO daily x 21 days (if TMP-SMX and pentamidine intolerance). Check G6PD before primaquine. Alternative: Atovaquone 750mg PO BID x 21 days (monotherapy, less effective than combination therapy, use only if mild PCP and no other options).",
            "corticosteroids": "Prednisone 40mg PO BID x 5 days, then 40mg PO daily x 5 days, then 20mg PO daily x 11 days (total 21 days taper). Indications: PaO2 <70 mmHg OR A-a gradient >35 mmHg (moderate-severe PCP). Start corticosteroids within 72 hours of starting PCP treatment (reduces mortality by 50%, prevents respiratory failure). Do NOT use corticosteroids if mild PCP (PaO2 >70 mmHg, no benefit, increases infection risk).",
            "avoid_list": "Avoid azoles (fluconazole, voriconazole, ineffective, Pneumocystis lacks ergosterol). Avoid echinocandins (caspofungin, ineffective). Do NOT delay treatment while awaiting test results (mortality increases with delayed treatment). Do NOT use corticosteroids if mild PCP (PaO2 >70 mmHg, no benefit)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_pcp": "TMP-SMX 15-20mg/kg/day (based on TMP component) IV or PO divided TID or QID x 21 days (HIV/AIDS) or 14 days (non-HIV). Continue until clinical improvement (decreased dyspnea, improved oxygenation, afebrile). Add corticosteroids if PaO2 <70 mmHg or A-a gradient >35 mmHg.",
            "treatment_response": "Clinical improvement expected within 4-7 days (decreased dyspnea, improved oxygenation, decreased fever). If no improvement after 4-7 days: Consider alternative diagnosis (CMV pneumonitis, fungal pneumonia, bacterial pneumonia) OR Switch to second-line therapy (pentamidine 4mg/kg IV daily OR atovaquone + primaquine). Repeat chest imaging (CT chest) and bronchoscopy (BAL for CMV, fungal, bacterial cultures).",
            "hiv_aids_specific": "Duration: 21 days (HIV/AIDS, longer duration reduces relapse). Start ART (antiretroviral therapy) after 2 weeks of PCP treatment (reduces IRIS risk). Prophylaxis: TMP-SMX DS 1 tab PO daily (primary prophylaxis if CD4 <200 cells/μL, secondary prophylaxis after PCP treatment until CD4 >200 cells/μL x 3 months on ART). Alternative prophylaxis: Dapsone 100mg PO daily OR Atovaquone 1500mg PO daily OR Pentamidine 300mg inhaled monthly.",
            "non_hiv_specific": "Duration: 14 days (non-HIV, shorter duration acceptable). Continue immunosuppression taper if possible (reduce corticosteroids, hold chemotherapy temporarily). Prophylaxis: TMP-SMX DS 1 tab PO daily (if ongoing immunosuppression: transplant recipients, prolonged corticosteroids >20mg prednisone daily, chemotherapy). Discontinue prophylaxis when immunosuppression resolved.",
            "iris": "Immune reconstitution inflammatory syndrome (IRIS): Worsening symptoms (increased dyspnea, fever, infiltrates) after starting ART in HIV/AIDS (10-20%, usually 2-4 weeks after starting ART). Management: Continue PCP treatment + ART, add corticosteroids (prednisone 40mg PO BID, then taper over 4-6 weeks). Do NOT stop ART (IRIS self-limited, resolves with corticosteroids).",
            "duration": "HIV/AIDS: 21 days total. Non-HIV: 14 days total. Continue until clinical improvement (decreased dyspnea, improved oxygenation, afebrile). Switch from IV to PO when able to tolerate PO (usually after 7-10 days)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "HIV/AIDS: 21 days total (longer duration reduces relapse). Non-HIV: 14 days total. Continue until clinical improvement (decreased dyspnea, improved oxygenation, afebrile). Switch from IV to PO when able to tolerate PO (usually after 7-10 days). Corticosteroids: 21 days taper (if PaO2 <70 mmHg or A-a gradient >35 mmHg).",
            "monitoring": "Daily: Oxygen saturation, respiratory rate, temperature. Every 2-3 days: ABG (assess PaO2, A-a gradient), chest X-ray (assess infiltrates). Weekly: LDH (decreasing LDH indicates treatment response), CBC (monitor for TMP-SMX toxicity: leukopenia, thrombocytopenia, anemia), creatinine (monitor for TMP-SMX nephrotoxicity). Clinical improvement expected within 4-7 days (decreased dyspnea, improved oxygenation, decreased fever). If no improvement after 4-7 days: Consider alternative diagnosis or switch to second-line therapy.",
            "stop_criteria": "Complete 21 days (HIV/AIDS) or 14 days (non-HIV) of treatment. Continue until clinical improvement (decreased dyspnea, improved oxygenation, afebrile). Do NOT stop treatment early (increases relapse risk). Start prophylaxis after completing treatment (TMP-SMX DS 1 tab PO daily)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <200 cells/μL (most important risk factor, 80-90% of PCP cases). Duration: 21 days (longer duration reduces relapse). Start ART after 2 weeks of PCP treatment (reduces IRIS risk). Prophylaxis: TMP-SMX DS 1 tab PO daily (primary prophylaxis if CD4 <200 cells/μL, secondary prophylaxis after PCP treatment until CD4 >200 cells/μL x 3 months on ART). IRIS: Worsening symptoms after starting ART (10-20%), requires corticosteroids.",
            "transplant_recipients": "Solid organ transplant (10-15% of PCP cases, especially lung transplant). HSCT (5-10% of PCP cases). Duration: 14 days. Prophylaxis: TMP-SMX DS 1 tab PO daily (if ongoing immunosuppression). Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult.",
            "prolonged_corticosteroids": "Prolonged corticosteroid use (>20mg prednisone daily x >1 month, 5-10% of PCP cases). Duration: 14 days. Prophylaxis: TMP-SMX DS 1 tab PO daily (if ongoing corticosteroids >20mg prednisone daily). Taper corticosteroids if possible. Rheumatology consult.",
            "tmp_smx_intolerance": "TMP-SMX intolerance (rash, fever, GI upset, 20-30% of patients). Mild intolerance: Continue TMP-SMX + antihistamines (diphenhydramine) + antipyretics (acetaminophen). Severe intolerance (Stevens-Johnson syndrome, anaphylaxis, severe rash): Switch to pentamidine 4mg/kg IV daily OR atovaquone 750mg PO BID + primaquine 30mg PO daily (check G6PD before primaquine).",
            "g6pd_deficiency": "Check G6PD before primaquine (risk of hemolytic anemia if G6PD deficiency). If G6PD deficiency: Avoid primaquine, use pentamidine 4mg/kg IV daily OR atovaquone 750mg PO BID (monotherapy, less effective) OR clindamycin 600-900mg IV q6-8h (without primaquine).",
            "pregnancy": "TMP-SMX safe in pregnancy (avoid in first trimester if possible, theoretical risk of neural tube defects). Pentamidine safe in pregnancy. Avoid primaquine (risk of hemolysis in fetus if G6PD deficiency). Corticosteroids safe in pregnancy (prednisone preferred, minimal placental transfer).",
            "counseling": "PCP is life-threatening (mortality 10-20% with treatment, 50-70% if mechanical ventilation required). Treatment duration: 21 days (HIV/AIDS) or 14 days (non-HIV). Clinical improvement expected within 4-7 days. Prophylaxis REQUIRED after treatment (TMP-SMX DS 1 tab PO daily) until immune recovery. HIV/AIDS: Start ART after 2 weeks of PCP treatment. Future: Lifelong ART + prophylaxis until CD4 >200 cells/μL x 3 months."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for test results, mortality increases with delayed treatment)",
              "TMP-SMX 15-20mg/kg/day IV or PO divided TID or QID x 21 days (HIV/AIDS) or 14 days (non-HIV)",
              "Add corticosteroids (prednisone 40mg PO BID x 5 days, then taper) if PaO2 <70 mmHg or A-a gradient >35 mmHg (reduces mortality by 50%)",
              "Switch from IV to PO when able to tolerate PO (usually after 7-10 days)",
              "Start prophylaxis after completing treatment (TMP-SMX DS 1 tab PO daily)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Progressive dyspnea + dry cough + fever + hypoxemia in immunocompromised host)",
              "Are antibiotics started immediately? (TMP-SMX 15-20mg/kg/day IV or PO divided TID or QID)",
              "Are corticosteroids indicated? (PaO2 <70 mmHg or A-a gradient >35 mmHg → prednisone 40mg PO BID x 5 days, then taper)",
              "Is diagnostic testing performed? (Induced sputum or BAL for Pneumocystis PCR/IF/GMS stain)",
              "Is HIV testing performed? (If HIV status unknown, CD4 count if HIV-positive)",
              "Is clinical improvement expected? (Within 4-7 days, if no improvement → consider alternative diagnosis or switch to second-line therapy)",
              "Is prophylaxis planned? (TMP-SMX DS 1 tab PO daily after completing treatment)"
            ],
            "avoid_unnecessary_treatment": "Avoid azoles (fluconazole, voriconazole, ineffective). Avoid echinocandins (caspofungin, ineffective). Do NOT delay treatment while awaiting test results. Do NOT use corticosteroids if mild PCP (PaO2 >70 mmHg, no benefit). Do NOT stop treatment early (increases relapse risk). Do NOT stop prophylaxis until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS).",
            "diagnostic_stewardship": "Clinical diagnosis (progressive dyspnea + dry cough + fever + hypoxemia in immunocompromised host). Induced sputum (50-60% sensitivity, non-invasive, first-line) OR BAL (90-95% sensitivity, gold standard). Beta-D-glucan (90-95% sensitive, 80-85% specific, not specific for PCP). Do NOT delay treatment while awaiting test results (start empiric TMP-SMX if high clinical suspicion).",
            "prevention": "Primary prophylaxis: TMP-SMX DS 1 tab PO daily (if CD4 <200 cells/μL in HIV/AIDS, if ongoing immunosuppression in transplant recipients or prolonged corticosteroids >20mg prednisone daily). Secondary prophylaxis: TMP-SMX DS 1 tab PO daily (after PCP treatment until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS, discontinue immunosuppression for non-HIV). Alternative prophylaxis: Dapsone 100mg PO daily OR Atovaquone 1500mg PO daily OR Pentamidine 300mg inhaled monthly (if TMP-SMX intolerance)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "IDSA Clinical Practice Guideline for the Management of Patients with Pneumocystis Pneumonia (2020)",
              "url": "https://academic.oup.com/cid/article/71/6/e224/5815765"
            },
            {
              "label": "WHO Guidelines on the Treatment of Pneumocystis Pneumonia (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "cmv-infections",
      "name": "Cytomegalovirus (CMV) Infections",
      "synonyms": [
        "CMV disease",
        "CMV pneumonitis",
        "CMV retinitis",
        "CMV colitis"
      ],
      "icd10": [
        "B25.9",
        "B25.0",
        "B25.1",
        "B25.2"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening opportunistic viral infection in immunocompromised hosts requiring ganciclovir IV or valganciclovir PO (organ-specific manifestations: retinitis, pneumonitis, colitis, encephalitis)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening opportunistic viral infection caused by Cytomegalovirus (CMV, human herpesvirus 5). Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <50 cells/μL, 40-50% of CMV disease), solid organ transplant recipients (SOT, 30-40%, especially lung, kidney, liver), hematopoietic stem cell transplant (HSCT, 10-20%), prolonged immunosuppression. Seroprevalence: 50-80% of adults (latent infection, reactivates when immunocompromised). Incidence: Rare in general population, common in HIV/AIDS (10-20% lifetime risk if CD4 <50 cells/μL and no prophylaxis). Mortality: 10-20% (with treatment), 50-70% (CMV pneumonitis in HSCT, high mortality despite treatment).",
            "clinical_presentation": "Organ-specific manifestations: CMV retinitis (most common in HIV/AIDS, 70-80% of CMV disease): Painless vision loss, floaters, scotomas, fundoscopy shows retinal hemorrhages and exudates. CMV pneumonitis (most common in HSCT, 30-40%): Dyspnea, dry cough, fever, hypoxemia, bilateral interstitial infiltrates. CMV colitis (20-30%): Diarrhea (watery or bloody), abdominal pain, fever, weight loss, colonoscopy shows ulcers. CMV encephalitis (5-10%): Altered mental status, seizures, focal neurologic deficits, MRI shows periventricular enhancement. CMV esophagitis (5-10%): Odynophagia, dysphagia, chest pain, endoscopy shows ulcers.",
            "diagnostic_criteria": "Clinical diagnosis: Organ-specific symptoms + CMV viremia (positive CMV PCR in blood) + tissue diagnosis (biopsy showing CMV inclusion bodies or positive CMV immunohistochemistry). Laboratory: CMV PCR in blood (quantitative, >1,000 copies/mL suggests CMV disease, <1,000 copies/mL may be asymptomatic viremia). Tissue diagnosis: Biopsy (gold standard) showing CMV inclusion bodies (owl's eye appearance) or positive CMV immunohistochemistry. Imaging: Organ-specific (fundoscopy for retinitis, CT chest for pneumonitis, colonoscopy for colitis, MRI brain for encephalitis).",
            "risk_factors": [
              "HIV/AIDS with CD4 <50 cells/μL (most important risk factor for CMV retinitis, 70-80% of CMV disease)",
              "Solid organ transplant recipients (SOT, 30-40%, especially lung, kidney, liver, highest risk in first 3-6 months post-transplant)",
              "Hematopoietic stem cell transplant (HSCT, 10-20%, highest risk in first 100 days post-transplant)",
              "CMV seronegative recipient + CMV seropositive donor (D+/R-, highest risk, 50-70% CMV disease without prophylaxis)",
              "Prolonged immunosuppression (high-dose corticosteroids, T-cell depleting agents: alemtuzumab, ATG)",
              "Graft-versus-host disease (GVHD, increases CMV reactivation risk)"
            ],
            "red_flags": [
              "CMV pneumonitis in HSCT - high mortality (50-70% despite treatment), requires ganciclovir IV + CMV immunoglobulin (CMVIG) + reduction of immunosuppression",
              "CMV retinitis - vision-threatening, requires immediate ophthalmology consult + ganciclovir IV or valganciclovir PO + intravitreal ganciclovir (if sight-threatening)",
              "CMV encephalitis - altered mental status, seizures, focal neurologic deficits, requires ganciclovir IV + foscarnet IV (combination therapy), high mortality (30-50%)",
              "CMV colitis with perforation - abdominal pain, peritonitis, requires surgical consult + ganciclovir IV",
              "Ganciclovir-resistant CMV - persistent viremia despite ganciclovir (UL97 or UL54 mutations), requires foscarnet IV or cidofovir IV (nephrotoxic)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Organ-specific symptoms (vision loss, dyspnea, diarrhea, altered mental status) + immunocompromised host (HIV/AIDS CD4 <50 cells/μL, SOT, HSCT). CMV PCR in blood (quantitative, >1,000 copies/mL suggests CMV disease). Tissue biopsy (gold standard) if accessible (retina, lung, colon, brain).",
            "essential_tests": [
              "CMV PCR in blood (quantitative): >1,000 copies/mL suggests CMV disease (sensitivity 80-90%, specificity 70-80%). <1,000 copies/mL may be asymptomatic viremia (monitor, may not require treatment). Turnaround: 1-2 days.",
              "Tissue biopsy (gold standard): CMV inclusion bodies (owl's eye appearance) or positive CMV immunohistochemistry. Biopsy site: Retina (vitreous fluid), lung (BAL or transbronchial biopsy), colon (colonoscopy with biopsy), brain (rarely performed, high risk).",
              "Organ-specific imaging: Fundoscopy (CMV retinitis: retinal hemorrhages, exudates, perivascular sheathing). CT chest (CMV pneumonitis: bilateral interstitial infiltrates, ground-glass opacities). Colonoscopy (CMV colitis: ulcers, erosions, pseudomembranes). MRI brain (CMV encephalitis: periventricular enhancement, ventriculitis)."
            ],
            "conditional_tests": [
              "CMV antigenemia (pp65): Older test, less sensitive than CMV PCR. Positive if >5 positive cells per 200,000 leukocytes. Turnaround: Same day.",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, CMV disease risk if CD4 <50 cells/μL).",
              "CBC: Leukopenia (WBC <4,000, 30-40%, ganciclovir toxicity). Thrombocytopenia (platelets <100,000, 20-30%, ganciclovir toxicity).",
              "Creatinine: Monitor renal function (ganciclovir, foscarnet, cidofovir are nephrotoxic).",
              "Genotypic resistance testing: If persistent viremia despite ganciclovir (UL97 or UL54 mutations suggest ganciclovir resistance). Turnaround: 1-2 weeks."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting tissue biopsy if high clinical suspicion (start empiric ganciclovir, especially if CMV retinitis or CMV pneumonitis). Do NOT treat asymptomatic CMV viremia (<1,000 copies/mL) in HIV/AIDS (no benefit, increases toxicity). Do treat asymptomatic CMV viremia in SOT/HSCT (preemptive therapy reduces CMV disease).",
            "turnaround_time": "CMV PCR: 1-2 days. CMV antigenemia: Same day. Tissue biopsy: 2-3 days (histology), 1-2 days (CMV immunohistochemistry). Fundoscopy: Same day. CT chest: Same day. Colonoscopy: Same day. MRI brain: Same day. Genotypic resistance testing: 1-2 weeks."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Cytomegalovirus (CMV, human herpesvirus 5). Double-stranded DNA virus. Seroprevalence: 50-80% of adults (latent infection in monocytes, reactivates when immunocompromised). Transmission: Saliva, sexual contact, blood transfusion, organ transplantation (D+/R- highest risk). Pathogenesis: Primary infection (usually asymptomatic in immunocompetent) → latency → reactivation (when CD4 <50 cells/μL or immunosuppression). Organ tropism: Retina (CMV retinitis), lung (CMV pneumonitis), colon (CMV colitis), brain (CMV encephalitis), esophagus (CMV esophagitis).",
            "pathogenesis": "Reactivation of latent CMV (when CD4 <50 cells/μL or immunosuppression) → viremia → end-organ disease (retinitis, pneumonitis, colitis, encephalitis). CMV retinitis: Retinal necrosis → vision loss (irreversible if untreated). CMV pneumonitis: Alveolar damage → hypoxemia → respiratory failure (high mortality 50-70% in HSCT). CMV colitis: Mucosal ulceration → diarrhea, bleeding, perforation. CMV encephalitis: Ventriculitis, periventricular necrosis → altered mental status, seizures, focal deficits.",
            "resistance_patterns": {
              "ganciclovir_resistance": "Ganciclovir resistance: UL97 mutations (most common, 80-90% of resistance) or UL54 mutations (10-20%, confers cross-resistance to cidofovir). Risk factors: Prolonged ganciclovir exposure (>3 months), subtherapeutic levels, persistent viremia. Incidence: 5-10% (HIV/AIDS), 1-2% (SOT/HSCT). Treatment: Foscarnet IV 90mg/kg IV q12h OR Cidofovir 5mg/kg IV weekly (nephrotoxic, requires saline hydration + probenecid).",
              "foscarnet_resistance": "Foscarnet resistance: UL54 mutations (rare, <5%). Cross-resistance with ganciclovir if UL54 mutation. Treatment: Cidofovir IV 5mg/kg IV weekly (nephrotoxic).",
              "cidofovir_resistance": "Cidofovir resistance: UL54 mutations (rare, <5%). Cross-resistance with ganciclovir if UL54 mutation. Treatment: Experimental (maribavir, letermovir, CMV-specific T-cell therapy)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for tissue biopsy if high clinical suspicion, especially CMV retinitis or CMV pneumonitis). Ganciclovir 5mg/kg IV q12h (induction x 14-21 days, then maintenance 5mg/kg IV daily) OR Valganciclovir 900mg PO BID (induction x 14-21 days, then maintenance 900mg PO daily). Add CMV immunoglobulin (CMVIG) 150mg/kg IV if CMV pneumonitis in HSCT (reduces mortality). Reduce immunosuppression if possible (SOT/HSCT)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Ganciclovir 5mg/kg IV q12h (induction x 14-21 days, then maintenance 5mg/kg IV daily) OR Valganciclovir 900mg PO BID (induction x 14-21 days, then maintenance 900mg PO daily). Valganciclovir preferred if able to tolerate PO (bioavailability 60%, equivalent to ganciclovir IV). Adjust dose for renal function (CrCl <70 mL/min). Monitor CBC weekly (ganciclovir toxicity: leukopenia, thrombocytopenia, anemia).",
            "cmv_retinitis": "Valganciclovir 900mg PO BID x 14-21 days (induction), then 900mg PO daily (maintenance until immune recovery: CD4 >100 cells/μL x 3-6 months on ART). Alternative: Ganciclovir 5mg/kg IV q12h x 14-21 days (induction), then 5mg/kg IV daily (maintenance). Add intravitreal ganciclovir 2mg per 0.05 mL (if sight-threatening, zone 1 retinitis, or poor response to systemic therapy). Ophthalmology consult URGENT.",
            "cmv_pneumonitis": "Ganciclovir 5mg/kg IV q12h x 14-21 days + CMV immunoglobulin (CMVIG) 150mg/kg IV on days 1, 2, 7, 14 (if HSCT, reduces mortality from 70% to 50%). Reduce immunosuppression if possible. ICU admission if respiratory failure. Mechanical ventilation if PaO2 <60 mmHg (mortality 70-80% if intubated).",
            "cmv_colitis": "Ganciclovir 5mg/kg IV q12h x 14-21 days OR Valganciclovir 900mg PO BID x 14-21 days. Reduce immunosuppression if possible. Surgical consult if perforation suspected (abdominal pain, peritonitis). Continue treatment until symptoms resolve + negative CMV PCR.",
            "cmv_encephalitis": "Ganciclovir 5mg/kg IV q12h + Foscarnet 90mg/kg IV q12h (combination therapy, synergistic) x 21 days or longer. Reduce immunosuppression if possible. Neurology consult. High mortality (30-50% despite treatment). Continue treatment until symptoms improve + negative CMV PCR in CSF.",
            "avoid_list": "Avoid acyclovir or valacyclovir (ineffective against CMV, no activity). Do NOT delay treatment while awaiting tissue biopsy (start empiric ganciclovir if high clinical suspicion). Do NOT treat asymptomatic CMV viremia (<1,000 copies/mL) in HIV/AIDS (no benefit, increases toxicity)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_cmv": "Ganciclovir 5mg/kg IV q12h (induction x 14-21 days, then maintenance 5mg/kg IV daily) OR Valganciclovir 900mg PO BID (induction x 14-21 days, then maintenance 900mg PO daily). Continue until symptoms resolve + negative CMV PCR (or CMV PCR <1,000 copies/mL). Adjust dose for renal function. Monitor CBC weekly (ganciclovir toxicity: leukopenia, thrombocytopenia, anemia).",
            "hiv_aids_specific": "CMV retinitis: Valganciclovir 900mg PO BID x 14-21 days (induction), then 900mg PO daily (maintenance until immune recovery: CD4 >100 cells/μL x 3-6 months on ART). Start ART if not already on ART (immune recovery prevents relapse). Ophthalmology follow-up every 4-6 weeks (monitor for relapse, IRIS, retinal detachment). Discontinue maintenance therapy when CD4 >100 cells/μL x 3-6 months on ART.",
            "sot_hsct_specific": "Preemptive therapy: Treat asymptomatic CMV viremia (>1,000 copies/mL) to prevent CMV disease. Valganciclovir 900mg PO BID x 14-21 days, then monitor CMV PCR weekly. Continue until CMV PCR negative x 2 consecutive weeks. Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult.",
            "ganciclovir_resistant_cmv": "Foscarnet 90mg/kg IV q12h (or 60mg/kg IV q8h) x 14-21 days. Requires IV access, cardiac monitoring (QTc prolongation, electrolyte abnormalities: hypocalcemia, hypomagnesemia, hypokalemia), renal monitoring (nephrotoxic, maintain CrCl >50 mL/min with saline hydration). Alternative: Cidofovir 5mg/kg IV weekly x 2 weeks (induction), then 5mg/kg IV every 2 weeks (maintenance). Requires saline hydration (1 L NS before + 1 L NS after) + probenecid 2g PO 3 hours before + 1g PO 2 hours after + 1g PO 8 hours after (reduces nephrotoxicity). Monitor creatinine before each dose (hold if creatinine >1.5 mg/dL or proteinuria >2+).",
            "iris": "Immune reconstitution inflammatory syndrome (IRIS): Worsening CMV retinitis (increased inflammation, vitritis) after starting ART in HIV/AIDS (10-20%, usually 2-4 weeks after starting ART). Management: Continue ganciclovir + ART, add corticosteroids (prednisone 40mg PO daily, then taper over 4-6 weeks). Ophthalmology consult. Do NOT stop ART (IRIS self-limited, resolves with corticosteroids).",
            "duration": "Induction: 14-21 days (until symptoms improve + CMV PCR decreasing). Maintenance: Continue until immune recovery (CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS) OR until CMV PCR negative x 2 consecutive weeks (SOT/HSCT). CMV encephalitis: 21 days or longer (until symptoms improve + negative CMV PCR in CSF)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Induction: 14-21 days (until symptoms improve + CMV PCR decreasing). Maintenance: Continue until immune recovery (CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS) OR until CMV PCR negative x 2 consecutive weeks (SOT/HSCT). CMV encephalitis: 21 days or longer (until symptoms improve + negative CMV PCR in CSF). Switch from IV to PO (valganciclovir) when able to tolerate PO.",
            "monitoring": "Weekly: CMV PCR (monitor virologic response, goal is undetectable or <1,000 copies/mL). CBC (monitor for ganciclovir toxicity: leukopenia WBC <3,000, thrombocytopenia platelets <50,000, anemia Hgb <8 g/dL). Creatinine (monitor renal function, adjust dose if CrCl <70 mL/min). Organ-specific: Fundoscopy every 4-6 weeks (CMV retinitis, monitor for relapse, IRIS, retinal detachment). CT chest (CMV pneumonitis, monitor for improvement). Colonoscopy (CMV colitis, monitor for healing). MRI brain (CMV encephalitis, monitor for improvement).",
            "stop_criteria": "Discontinue induction therapy when symptoms improve + CMV PCR decreasing (usually 14-21 days). Discontinue maintenance therapy when immune recovery (CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS) OR CMV PCR negative x 2 consecutive weeks (SOT/HSCT). Do NOT stop maintenance therapy early (increases relapse risk)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <50 cells/μL (most important risk factor for CMV retinitis, 70-80% of CMV disease). CMV retinitis: Vision-threatening, requires immediate ophthalmology consult + valganciclovir 900mg PO BID x 14-21 days (induction), then 900mg PO daily (maintenance until CD4 >100 cells/μL x 3-6 months on ART). Start ART if not already on ART (immune recovery prevents relapse). IRIS: Worsening CMV retinitis after starting ART (10-20%), requires corticosteroids.",
            "sot_hsct": "Highest risk in first 3-6 months post-transplant (SOT) or first 100 days post-transplant (HSCT). CMV serostatus: D+/R- (highest risk, 50-70% CMV disease without prophylaxis). Preemptive therapy: Treat asymptomatic CMV viremia (>1,000 copies/mL) to prevent CMV disease. Valganciclovir 900mg PO BID x 14-21 days, then monitor CMV PCR weekly. Reduce immunosuppression if possible. CMV pneumonitis in HSCT: High mortality (50-70% despite treatment), requires ganciclovir IV + CMVIG + reduction of immunosuppression.",
            "ganciclovir_toxicity": "Leukopenia (WBC <3,000, 30-40%), thrombocytopenia (platelets <50,000, 20-30%), anemia (Hgb <8 g/dL, 10-20%). Management: Reduce ganciclovir dose OR Add G-CSF (filgrastim 5 mcg/kg SC daily) if severe leukopenia (WBC <1,000) OR Switch to foscarnet (if severe toxicity). Monitor CBC weekly.",
            "foscarnet_toxicity": "Nephrotoxicity (30-40%, maintain CrCl >50 mL/min with saline hydration 1 L NS before + 1 L NS after each dose). Electrolyte abnormalities: Hypocalcemia (20-30%, monitor calcium, magnesium, potassium before each dose, supplement if low). QTc prolongation (10-20%, monitor EKG). Genital ulcers (10-20%, painful, self-limited).",
            "cidofovir_toxicity": "Nephrotoxicity (50-60%, requires saline hydration + probenecid, monitor creatinine before each dose, hold if creatinine >1.5 mg/dL or proteinuria >2+). Neutropenia (20-30%, monitor CBC weekly). Ocular hypotony (10-20%, monitor intraocular pressure if intravitreal cidofovir).",
            "pregnancy": "Ganciclovir: Teratogenic in animals, avoid in pregnancy if possible (use only if life-threatening CMV disease). Foscarnet: Limited data, use only if life-threatening CMV disease. Valganciclovir: Teratogenic in animals, avoid in pregnancy. CMV retinitis in pregnancy: Intravitreal ganciclovir preferred (minimal systemic absorption). Infectious disease + obstetrics consult.",
            "counseling": "CMV disease is life-threatening (mortality 10-20% with treatment, 50-70% if CMV pneumonitis in HSCT). Treatment duration: Induction 14-21 days, maintenance until immune recovery (CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS) or CMV PCR negative x 2 weeks (SOT/HSCT). CMV retinitis: Vision-threatening, requires immediate ophthalmology consult + lifelong monitoring. HIV/AIDS: Start ART (immune recovery prevents relapse). SOT/HSCT: Reduce immunosuppression if possible."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for tissue biopsy if high clinical suspicion, especially CMV retinitis or CMV pneumonitis)",
              "Ganciclovir 5mg/kg IV q12h OR Valganciclovir 900mg PO BID (induction x 14-21 days, then maintenance)",
              "Switch from IV to PO (valganciclovir) when able to tolerate PO (bioavailability 60%, equivalent to ganciclovir IV)",
              "Discontinue maintenance therapy when immune recovery (CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS) OR CMV PCR negative x 2 weeks (SOT/HSCT)",
              "Do NOT treat asymptomatic CMV viremia (<1,000 copies/mL) in HIV/AIDS (no benefit, increases toxicity)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Organ-specific symptoms + CMV PCR >1,000 copies/mL + tissue diagnosis if accessible)",
              "Are antivirals started immediately? (Ganciclovir 5mg/kg IV q12h OR valganciclovir 900mg PO BID)",
              "Is CMV PCR monitored weekly? (Goal is undetectable or <1,000 copies/mL)",
              "Is CBC monitored weekly? (Ganciclovir toxicity: leukopenia, thrombocytopenia, anemia)",
              "Is immunosuppression reduced if possible? (SOT/HSCT)",
              "Is ophthalmology consult obtained? (If CMV retinitis, URGENT)",
              "Is maintenance therapy discontinued appropriately? (Immune recovery: CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS OR CMV PCR negative x 2 weeks for SOT/HSCT)"
            ],
            "avoid_unnecessary_treatment": "Avoid acyclovir or valacyclovir (ineffective against CMV). Do NOT delay treatment while awaiting tissue biopsy (start empiric ganciclovir if high clinical suspicion). Do NOT treat asymptomatic CMV viremia (<1,000 copies/mL) in HIV/AIDS (no benefit, increases toxicity). Do treat asymptomatic CMV viremia (>1,000 copies/mL) in SOT/HSCT (preemptive therapy reduces CMV disease). Do NOT stop maintenance therapy early (increases relapse risk).",
            "diagnostic_stewardship": "Clinical diagnosis (organ-specific symptoms + CMV PCR >1,000 copies/mL + tissue diagnosis if accessible). CMV PCR in blood (quantitative, >1,000 copies/mL suggests CMV disease). Tissue biopsy (gold standard) if accessible (retina, lung, colon, brain). Do NOT delay treatment while awaiting tissue biopsy if high clinical suspicion.",
            "prevention": "Primary prophylaxis: Valganciclovir 900mg PO daily (if SOT D+/R-, high-risk HSCT, or prolonged immunosuppression) x 3-6 months post-transplant. Secondary prophylaxis: Valganciclovir 900mg PO daily (after CMV disease until immune recovery: CD4 >100 cells/μL x 3-6 months on ART for HIV/AIDS). Preemptive therapy: Monitor CMV PCR weekly (SOT/HSCT), treat if >1,000 copies/mL (prevents CMV disease)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "AST Infectious Diseases Community of Practice: CMV in Solid Organ Transplant Recipients (2019)",
              "url": "https://www.astctjournal.org/article/S1083-8791(18)30726-0/fulltext"
            },
            {
              "label": "IDSA Clinical Practice Guideline for the Management of CMV in Transplant Recipients (2018)",
              "url": "https://academic.oup.com/cid/article/67/6/e1/5001677"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "invasive-aspergillosis",
      "name": "Invasive Aspergillosis",
      "synonyms": [
        "Invasive pulmonary aspergillosis",
        "IPA",
        "Aspergillus pneumonia"
      ],
      "icd10": [
        "B44.0",
        "B44.1",
        "B44.7"
      ],
      "severity": [
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening invasive fungal infection in immunocompromised hosts requiring voriconazole IV/PO or isavuconazole IV/PO (high mortality 30-50% despite treatment)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening invasive fungal infection caused by Aspergillus species (A. fumigatus 70-80%, A. flavus 10-15%, A. niger 5-10%, A. terreus 5-10%). Occurs in severely immunocompromised hosts: Prolonged neutropenia (ANC <500 cells/μL x >10 days, 50-60% of invasive aspergillosis), hematopoietic stem cell transplant (HSCT, 20-30%), solid organ transplant (SOT, 10-15%, especially lung transplant), prolonged corticosteroids (>0.3 mg/kg prednisone daily x >3 weeks, 10-15%), advanced HIV/AIDS (CD4 <50 cells/μL, 5-10%). Incidence: Rare in general population, common in HSCT (5-10% cumulative incidence). Mortality: 30-50% (with treatment), 70-90% (if untreated or disseminated disease).",
            "clinical_presentation": "Invasive pulmonary aspergillosis (IPA, most common, 80-90%): Fever (refractory to antibiotics), cough, dyspnea, pleuritic chest pain, hemoptysis (10-20%, suggests angioinvasion). Physical exam: Fever, tachypnea, crackles (50-60%). Chest CT: Nodules with halo sign (ground-glass opacity surrounding nodule, early IPA, 60-70%), air-crescent sign (crescent of air within nodule, late IPA, 30-40%, suggests recovery), cavitation (20-30%). Disseminated aspergillosis (10-20%): CNS (brain abscess, stroke), sinuses (invasive sinusitis), skin (necrotic lesions), bone (osteomyelitis).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + pulmonary infiltrates (nodules, halo sign, air-crescent sign) + immunocompromised host. Laboratory: Serum galactomannan (>0.5 index, 70-80% sensitive, 85-90% specific), serum beta-D-glucan (>80 pg/mL, 70-80% sensitive, 60-70% specific, not specific for Aspergillus). BAL galactomannan (>1.0 index, 80-90% sensitive, 85-90% specific, more sensitive than serum). Definitive diagnosis: Tissue biopsy (gold standard) showing septate hyphae with acute-angle branching (45 degrees) + positive Aspergillus culture or PCR.",
            "risk_factors": [
              "Prolonged neutropenia (ANC <500 cells/μL x >10 days, most important risk factor, 50-60% of invasive aspergillosis)",
              "Hematopoietic stem cell transplant (HSCT, 20-30%, highest risk in first 100 days post-transplant or during GVHD)",
              "Solid organ transplant (SOT, 10-15%, especially lung transplant 5-10% cumulative incidence)",
              "Prolonged corticosteroids (>0.3 mg/kg prednisone daily x >3 weeks, 10-15%)",
              "Advanced HIV/AIDS (CD4 <50 cells/μL, 5-10%, rare but increasing)",
              "Chronic granulomatous disease (CGD, 25-40% lifetime risk)",
              "Immunosuppressive therapy (TNF-alpha inhibitors, alemtuzumab, 5-10%)"
            ],
            "red_flags": [
              "Hemoptysis - suggests angioinvasion (10-20%), high risk of massive hemoptysis (life-threatening), requires bronchial artery embolization",
              "CNS aspergillosis - brain abscess, stroke (5-10%), high mortality (70-90%), requires voriconazole (good CNS penetration) + neurosurgery consult",
              "Invasive sinusitis - facial pain, nasal necrosis, orbital involvement (5-10%), requires surgical debridement + voriconazole",
              "Disseminated aspergillosis - multi-organ involvement (10-20%), high mortality (80-90%), requires voriconazole + reduction of immunosuppression",
              "Azole-resistant Aspergillus - persistent fever despite voriconazole (5-10%, especially A. terreus resistant to amphotericin B), requires susceptibility testing + alternative therapy (isavuconazole, posaconazole, liposomal amphotericin B)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever (refractory to antibiotics) + pulmonary infiltrates (nodules, halo sign, air-crescent sign) + immunocompromised host (prolonged neutropenia, HSCT, SOT, prolonged corticosteroids). Serum galactomannan (>0.5 index) + BAL galactomannan (>1.0 index) + CT chest (nodules with halo sign). Tissue biopsy (gold standard) if accessible.",
            "essential_tests": [
              "CT chest (high-resolution): Nodules with halo sign (ground-glass opacity surrounding nodule, early IPA, 60-70%, highly suggestive of invasive aspergillosis). Air-crescent sign (crescent of air within nodule, late IPA, 30-40%, suggests recovery). Cavitation (20-30%). Turnaround: Same day.",
              "Serum galactomannan: >0.5 index (70-80% sensitive, 85-90% specific). False positives: Piperacillin-tazobactam (cross-reacts with galactomannan assay), other molds (Fusarium, Histoplasma). False negatives: Antifungal prophylaxis (voriconazole, posaconazole reduces sensitivity). Turnaround: 1-2 days.",
              "BAL galactomannan: >1.0 index (80-90% sensitive, 85-90% specific, more sensitive than serum galactomannan). Requires bronchoscopy. Turnaround: 1-2 days.",
              "Serum beta-D-glucan: >80 pg/mL (70-80% sensitive, 60-70% specific, not specific for Aspergillus, positive in Candida, PCP). Turnaround: 1-2 days."
            ],
            "conditional_tests": [
              "Tissue biopsy (gold standard): Septate hyphae with acute-angle branching (45 degrees) + positive Aspergillus culture or PCR. Biopsy site: Lung (transbronchial biopsy, CT-guided biopsy), sinus (endoscopic biopsy), skin (punch biopsy). Turnaround: 2-3 days (histology), 3-5 days (culture), 1-2 days (PCR).",
              "BAL culture: Aspergillus species (A. fumigatus 70-80%, A. flavus 10-15%, A. niger 5-10%, A. terreus 5-10%). Turnaround: 3-5 days. Susceptibility testing: Azole resistance (5-10%, especially A. fumigatus with cyp51A mutations). Turnaround: 5-7 days.",
              "Aspergillus PCR (blood or BAL): Positive in 50-70% of invasive aspergillosis. Not FDA-approved, limited availability. Turnaround: 1-2 days.",
              "CBC: Neutropenia (ANC <500 cells/μL, 50-60%). Turnaround: 1-2 hours.",
              "Blood cultures: Usually negative (Aspergillus rarely grows in blood cultures, <5%)."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting tissue biopsy if high clinical suspicion (start empiric voriconazole, mortality increases with delayed treatment). Do NOT rely on blood cultures (Aspergillus rarely grows in blood cultures). Do NOT interpret galactomannan if patient on piperacillin-tazobactam (false positive).",
            "turnaround_time": "CT chest: Same day. Serum galactomannan: 1-2 days. BAL galactomannan: 1-2 days. Serum beta-D-glucan: 1-2 days. Tissue biopsy: 2-3 days (histology), 3-5 days (culture), 1-2 days (PCR). Susceptibility testing: 5-7 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Aspergillus species: A. fumigatus (70-80%, most common), A. flavus (10-15%), A. niger (5-10%), A. terreus (5-10%, intrinsically resistant to amphotericin B). Ubiquitous environmental mold (soil, decaying vegetation, air). Transmission: Inhalation of airborne conidia (spores). Pathogenesis: Inhalation → germination in alveoli → angioinvasion (if neutropenia or immunosuppression) → tissue necrosis, thrombosis, infarction → dissemination (CNS, sinuses, skin, bone).",
            "pathogenesis": "Inhalation of Aspergillus conidia → germination in alveoli (if neutropenia or immunosuppression) → hyphal invasion of blood vessels (angioinvasion) → thrombosis, infarction, tissue necrosis → pulmonary nodules, cavitation, hemoptysis → dissemination (CNS, sinuses, skin, bone). Host immune response: Neutrophils critical for clearance (invasive aspergillosis occurs when ANC <500 cells/μL x >10 days). Complications: Hemoptysis (10-20%, angioinvasion), CNS aspergillosis (5-10%, brain abscess, stroke), disseminated aspergillosis (10-20%, multi-organ involvement).",
            "resistance_patterns": {
              "azole_resistance": "Azole resistance: A. fumigatus with cyp51A mutations (5-10%, environmental resistance from azole fungicide use in agriculture). Cross-resistance to voriconazole, itraconazole, posaconazole. Treatment: Liposomal amphotericin B 5mg/kg IV daily OR Isavuconazole 372mg IV q8h x6, then 372mg IV daily (may have activity against some azole-resistant strains). Susceptibility testing REQUIRED.",
              "amphotericin_resistance": "Amphotericin B resistance: A. terreus (intrinsically resistant, 5-10% of Aspergillus isolates). Treatment: Voriconazole 6mg/kg IV q12h x2, then 4mg/kg IV q12h OR Isavuconazole 372mg IV q8h x6, then 372mg IV daily.",
              "echinocandin_resistance": "Echinocandins (caspofungin, micafungin, anidulafungin): NOT first-line for invasive aspergillosis (inferior to voriconazole). Use only as salvage therapy or combination therapy (voriconazole + echinocandin) if refractory disease."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for tissue biopsy if high clinical suspicion, mortality increases with delayed treatment). Voriconazole 6mg/kg IV q12h x2 doses (loading), then 4mg/kg IV q12h OR Isavuconazole 372mg IV q8h x6 doses (loading, 48 hours), then 372mg IV daily. Monitor voriconazole levels (target trough 1-5 mcg/mL, toxicity if >5 mcg/mL). Reduce immunosuppression if possible (taper corticosteroids, hold chemotherapy temporarily)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Voriconazole 6mg/kg IV q12h x2 doses (loading, day 1), then 4mg/kg IV q12h (maintenance). Switch to PO when able to tolerate: Voriconazole 200mg PO q12h (if weight <40 kg) OR 300mg PO q12h (if weight ≥40 kg). Monitor voriconazole trough levels (target 1-5 mcg/mL, check after 5 days of therapy, then weekly). Adjust dose if trough <1 mcg/mL (increase dose) or >5 mcg/mL (decrease dose, risk of toxicity: hepatotoxicity, visual disturbances, QTc prolongation).",
            "alternative_first_line": "Isavuconazole 372mg IV q8h x6 doses (loading, 48 hours), then 372mg IV daily (maintenance). Switch to PO when able to tolerate: Isavuconazole 372mg PO daily. No therapeutic drug monitoring required (unlike voriconazole). Fewer drug interactions than voriconazole. Similar efficacy to voriconazole (non-inferiority trial).",
            "second_line": "Liposomal amphotericin B 5mg/kg IV daily (if voriconazole intolerance or azole-resistant Aspergillus). Requires IV access, cardiac monitoring (QTc prolongation), renal monitoring (nephrotoxic, maintain CrCl >50 mL/min with saline hydration), electrolyte monitoring (hypokalemia, hypomagnesemia, supplement if low). Infusion-related reactions (fever, chills, rigors, 50-60%, premedicate with acetaminophen + diphenhydramine + hydrocortisone).",
            "combination_therapy": "Voriconazole 4mg/kg IV q12h + Echinocandin (caspofungin 70mg IV x1, then 50mg IV daily OR micafungin 100-150mg IV daily OR anidulafungin 200mg IV x1, then 100mg IV daily). Consider if refractory disease (persistent fever despite voriconazole x 7 days) OR severe disease (CNS aspergillosis, disseminated aspergillosis). Limited evidence, observational studies suggest possible benefit.",
            "avoid_list": "Avoid fluconazole (no activity against Aspergillus). Avoid itraconazole (poor bioavailability, erratic absorption, drug interactions). Avoid posaconazole (reserve for prophylaxis or salvage therapy, not first-line). Do NOT delay treatment while awaiting tissue biopsy (mortality increases with delayed treatment). Do NOT use echinocandins as monotherapy (inferior to voriconazole)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_aspergillosis": "Voriconazole 4mg/kg IV q12h OR Isavuconazole 372mg IV daily. Continue until clinical improvement (decreased fever, improved infiltrates on CT chest, decreased galactomannan) + resolution of neutropenia (ANC >500 cells/μL) + resolution of immunosuppression. Duration: Minimum 6-12 weeks (invasive pulmonary aspergillosis), longer if CNS aspergillosis (12+ weeks) or disseminated aspergillosis (12+ weeks). Switch from IV to PO when able to tolerate PO.",
            "azole_resistant_aspergillosis": "Liposomal amphotericin B 5mg/kg IV daily (if azole-resistant Aspergillus confirmed by susceptibility testing). Alternative: Isavuconazole 372mg IV daily (may have activity against some azole-resistant strains, check susceptibility). Combination therapy: Liposomal amphotericin B + echinocandin (if refractory disease). Infectious disease consult REQUIRED.",
            "cns_aspergillosis": "Voriconazole 4mg/kg IV q12h (good CNS penetration, preferred over amphotericin B). Duration: Minimum 12 weeks or longer (until resolution of brain abscess on MRI). Neurosurgery consult (consider surgical debridement if large abscess >2 cm or mass effect). Monitor voriconazole trough levels (target 1-5 mcg/mL). High mortality (70-90% despite treatment).",
            "invasive_sinusitis": "Voriconazole 4mg/kg IV q12h + Surgical debridement (REQUIRED, remove necrotic tissue). ENT consult URGENT. Duration: Minimum 6-12 weeks (until resolution of sinusitis on CT). Monitor voriconazole trough levels.",
            "treatment_response": "Clinical improvement expected within 7-14 days (decreased fever, improved infiltrates on CT chest, decreased galactomannan). If no improvement after 7-14 days: Check voriconazole trough levels (target 1-5 mcg/mL, adjust dose if subtherapeutic). Repeat CT chest (assess for progression, complications: hemoptysis, cavitation, dissemination). Repeat galactomannan (should decrease with treatment). Consider alternative diagnosis (bacterial pneumonia, other fungal infection: Mucor, Fusarium) OR Switch to alternative therapy (liposomal amphotericin B, isavuconazole) OR Add combination therapy (voriconazole + echinocandin).",
            "duration": "Invasive pulmonary aspergillosis: Minimum 6-12 weeks (until clinical improvement + resolution of neutropenia + resolution of immunosuppression). CNS aspergillosis: Minimum 12 weeks or longer (until resolution of brain abscess on MRI). Disseminated aspergillosis: Minimum 12 weeks or longer. Continue until clinical improvement (decreased fever, improved infiltrates, decreased galactomannan) + resolution of neutropenia (ANC >500 cells/μL) + resolution of immunosuppression."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Invasive pulmonary aspergillosis: Minimum 6-12 weeks (until clinical improvement + resolution of neutropenia + resolution of immunosuppression). CNS aspergillosis: Minimum 12 weeks or longer (until resolution of brain abscess on MRI). Disseminated aspergillosis: Minimum 12 weeks or longer. Switch from IV to PO (voriconazole or isavuconazole) when able to tolerate PO.",
            "monitoring": "Weekly: CT chest (assess for improvement, complications: hemoptysis, cavitation, dissemination). Serum galactomannan (should decrease with treatment, goal is <0.5 index). CBC (monitor for resolution of neutropenia, ANC >500 cells/μL). Voriconazole trough levels (target 1-5 mcg/mL, check after 5 days of therapy, then weekly, adjust dose if subtherapeutic <1 mcg/mL or supratherapeutic >5 mcg/mL). Liver function tests (monitor for voriconazole hepatotoxicity, AST/ALT >3x ULN). Creatinine (monitor renal function if liposomal amphotericin B). Electrolytes (monitor for hypokalemia, hypomagnesemia if liposomal amphotericin B).",
            "stop_criteria": "Continue until clinical improvement (decreased fever, improved infiltrates on CT chest, decreased galactomannan) + resolution of neutropenia (ANC >500 cells/μL) + resolution of immunosuppression. Minimum duration: 6-12 weeks (invasive pulmonary aspergillosis), 12+ weeks (CNS aspergillosis, disseminated aspergillosis). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "neutropenia": "Prolonged neutropenia (ANC <500 cells/μL x >10 days, most important risk factor, 50-60% of invasive aspergillosis). Duration: Minimum 6-12 weeks (until resolution of neutropenia ANC >500 cells/μL + clinical improvement). Add G-CSF (filgrastim 5 mcg/kg SC daily) if severe neutropenia (ANC <100 cells/μL) to accelerate neutrophil recovery. Hematology consult.",
            "hsct_sot": "HSCT: Highest risk in first 100 days post-transplant or during GVHD. Reduce immunosuppression if possible (taper corticosteroids, reduce tacrolimus). Infectious disease + transplant consult. SOT (especially lung transplant): Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult.",
            "voriconazole_toxicity": "Hepatotoxicity (AST/ALT >3x ULN, 10-20%, monitor LFTs weekly, reduce dose or switch to isavuconazole if severe). Visual disturbances (photopsia, blurred vision, 30-40%, usually transient, resolve with continued therapy). QTc prolongation (10-20%, monitor EKG, avoid if baseline QTc >500 ms). Photosensitivity (10-20%, avoid sun exposure, use sunscreen). Drug interactions (CYP2C19, CYP3A4 substrate, avoid rifampin, phenytoin, carbamazepine, ritonavir).",
            "voriconazole_levels": "Monitor voriconazole trough levels (target 1-5 mcg/mL, check after 5 days of therapy, then weekly). Subtherapeutic (<1 mcg/mL): Increase dose by 50mg PO or 1mg/kg IV. Supratherapeutic (>5 mcg/mL): Decrease dose by 50mg PO or 1mg/kg IV (risk of toxicity: hepatotoxicity, visual disturbances, QTc prolongation). Genetic polymorphisms (CYP2C19 poor metabolizers have higher levels, rapid metabolizers have lower levels).",
            "amphotericin_toxicity": "Nephrotoxicity (30-40%, maintain CrCl >50 mL/min with saline hydration 1 L NS before + 1 L NS after each dose, monitor creatinine daily). Electrolyte abnormalities: Hypokalemia (50-60%, monitor potassium daily, supplement if <3.5 mEq/L), hypomagnesemia (30-40%, monitor magnesium weekly, supplement if <1.5 mg/dL). Infusion-related reactions (fever, chills, rigors, 50-60%, premedicate with acetaminophen 650mg PO + diphenhydramine 25-50mg PO + hydrocortisone 50mg IV 30 minutes before infusion).",
            "pregnancy": "Voriconazole: Teratogenic in animals, avoid in pregnancy if possible (use only if life-threatening invasive aspergillosis). Isavuconazole: Limited data, avoid in pregnancy. Liposomal amphotericin B: Safe in pregnancy (preferred antifungal in pregnancy). Infectious disease + obstetrics consult.",
            "counseling": "Invasive aspergillosis is life-threatening (mortality 30-50% with treatment, 70-90% if untreated or disseminated). Treatment duration: Minimum 6-12 weeks (invasive pulmonary aspergillosis), 12+ weeks (CNS aspergillosis, disseminated aspergillosis). Clinical improvement expected within 7-14 days. Voriconazole: Monitor trough levels (target 1-5 mcg/mL), avoid sun exposure (photosensitivity), report visual disturbances (usually transient). Reduce immunosuppression if possible (taper corticosteroids, hold chemotherapy temporarily). Prophylaxis: Posaconazole or voriconazole (if ongoing immunosuppression: HSCT, prolonged neutropenia)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for tissue biopsy if high clinical suspicion, mortality increases with delayed treatment)",
              "Voriconazole 6mg/kg IV q12h x2 doses (loading), then 4mg/kg IV q12h OR Isavuconazole 372mg IV q8h x6 doses (loading), then 372mg IV daily",
              "Monitor voriconazole trough levels (target 1-5 mcg/mL, check after 5 days, then weekly, adjust dose if subtherapeutic or supratherapeutic)",
              "Switch from IV to PO (voriconazole or isavuconazole) when able to tolerate PO",
              "Continue until clinical improvement + resolution of neutropenia (ANC >500 cells/μL) + resolution of immunosuppression (minimum 6-12 weeks)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + pulmonary infiltrates + immunocompromised host + galactomannan >0.5 index)",
              "Are antifungals started immediately? (Voriconazole 6mg/kg IV q12h x2, then 4mg/kg IV q12h OR isavuconazole 372mg IV q8h x6, then 372mg IV daily)",
              "Is CT chest performed? (Nodules with halo sign, air-crescent sign, cavitation)",
              "Is galactomannan monitored weekly? (Should decrease with treatment, goal <0.5 index)",
              "Are voriconazole trough levels monitored? (Target 1-5 mcg/mL, check after 5 days, then weekly)",
              "Is immunosuppression reduced if possible? (Taper corticosteroids, hold chemotherapy temporarily)",
              "Is surgical debridement considered? (If invasive sinusitis or CNS aspergillosis with large abscess)"
            ],
            "avoid_unnecessary_treatment": "Avoid fluconazole (no activity against Aspergillus). Avoid itraconazole (poor bioavailability, erratic absorption). Do NOT delay treatment while awaiting tissue biopsy (start empiric voriconazole if high clinical suspicion). Do NOT use echinocandins as monotherapy (inferior to voriconazole). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse). Monitor voriconazole trough levels (target 1-5 mcg/mL, adjust dose if subtherapeutic or supratherapeutic).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + pulmonary infiltrates + immunocompromised host). CT chest (nodules with halo sign, air-crescent sign, cavitation). Serum galactomannan (>0.5 index, 70-80% sensitive, 85-90% specific). BAL galactomannan (>1.0 index, 80-90% sensitive, 85-90% specific, more sensitive than serum). Tissue biopsy (gold standard) if accessible. Do NOT delay treatment while awaiting tissue biopsy if high clinical suspicion.",
            "prevention": "Primary prophylaxis: Posaconazole 300mg PO daily OR Voriconazole 200mg PO q12h (if prolonged neutropenia ANC <500 cells/μL x >10 days, HSCT with GVHD, or high-risk SOT). Secondary prophylaxis: Voriconazole 200mg PO q12h OR Posaconazole 300mg PO daily (after invasive aspergillosis until resolution of immunosuppression). Environmental control: HEPA filtration (if HSCT, prolonged neutropenia), avoid construction areas (high spore counts)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Clinical Practice Guideline for the Treatment of Aspergillosis (2016)",
              "url": "https://academic.oup.com/cid/article/63/4/e1/2566734"
            },
            {
              "label": "ECIL Guidelines for the Diagnosis and Treatment of Invasive Aspergillosis (2018)",
              "url": "https://www.ecil-leukaemia.com/en/guidelines"
            },
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "invasive-candidiasis",
      "name": "Invasive Candidiasis",
      "synonyms": [
        "Candidemia",
        "Disseminated candidiasis",
        "Esophageal candidiasis"
      ],
      "icd10": [
        "B37.7",
        "B37.1",
        "B37.81"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening invasive fungal infection requiring echinocandin IV (caspofungin, micafungin, anidulafungin) or fluconazole IV/PO (if fluconazole-susceptible Candida)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening invasive fungal infection caused by Candida species (C. albicans 40-50%, C. glabrata 20-30%, C. parapsilosis 10-15%, C. tropicalis 10-15%, C. krusei 5-10%, C. auris 1-5% emerging). Occurs in immunocompromised hosts: Candidemia (bloodstream infection, most common, 70-80%), esophageal candidiasis (HIV/AIDS CD4 <100 cells/μL, 10-15%), disseminated candidiasis (multi-organ involvement, 10-15%). Risk factors: Central venous catheter (CVC, 50-60%), broad-spectrum antibiotics (40-50%), ICU admission (30-40%), neutropenia (20-30%), solid organ transplant (SOT, 10-15%), total parenteral nutrition (TPN, 10-15%). Incidence: 8-10 cases per 100,000 population (candidemia). Mortality: 30-40% (candidemia with treatment), 50-70% (if untreated or disseminated candidiasis).",
            "clinical_presentation": "Candidemia: Fever (refractory to antibiotics, 80-90%), hypotension (30-40%, septic shock), tachycardia (>100 bpm, 50-60%). Physical exam: Fever, hypotension, tachycardia, no specific findings. Complications: Endophthalmitis (5-10%, fundoscopy shows white fluffy lesions), endocarditis (5-10%, TEE shows vegetation), osteomyelitis (5-10%), hepatosplenic candidiasis (5-10%, CT shows multiple liver/spleen abscesses). Esophageal candidiasis: Odynophagia (painful swallowing, 80-90%), dysphagia (difficulty swallowing, 60-70%), retrosternal chest pain (50-60%), endoscopy shows white plaques or ulcers.",
            "diagnostic_criteria": "Clinical diagnosis: Fever (refractory to antibiotics) + risk factors (CVC, broad-spectrum antibiotics, ICU, neutropenia, SOT, TPN). Laboratory: Positive blood cultures (Candida species, 70-80% sensitive, may require 2-3 days to grow). Beta-D-glucan (>80 pg/mL, 70-80% sensitive, 60-70% specific, not specific for Candida). Definitive diagnosis: Positive blood cultures (Candida species) OR Tissue biopsy (showing yeast and pseudohyphae).",
            "risk_factors": [
              "Central venous catheter (CVC, most important risk factor, 50-60% of candidemia)",
              "Broad-spectrum antibiotics (40-50%, disrupts normal flora, allows Candida overgrowth)",
              "ICU admission (30-40%, critical illness, multiple invasive devices)",
              "Neutropenia (ANC <500 cells/μL, 20-30%)",
              "Solid organ transplant (SOT, 10-15%, immunosuppression)",
              "Total parenteral nutrition (TPN, 10-15%, high glucose promotes Candida growth)",
              "Recent abdominal surgery (10-15%, especially GI perforation, anastomotic leak)",
              "HIV/AIDS with CD4 <100 cells/μL (esophageal candidiasis, 10-15%)"
            ],
            "red_flags": [
              "Candidemia with hypotension - septic shock (30-40%), requires ICU admission + echinocandin IV + vasopressors (norepinephrine)",
              "Endophthalmitis - vision-threatening (5-10%), requires ophthalmology consult + fundoscopy + echinocandin IV (or fluconazole if fluconazole-susceptible)",
              "Endocarditis - high mortality (50-70%), requires TEE + echinocandin IV + cardiac surgery consult (valve replacement often required)",
              "Disseminated candidiasis - multi-organ involvement (10-15%), high mortality (50-70%), requires echinocandin IV + prolonged treatment (4-6 weeks)",
              "Fluconazole-resistant Candida - C. glabrata (20-30% fluconazole-resistant), C. krusei (intrinsically fluconazole-resistant), C. auris (multi-drug resistant), requires echinocandin IV + susceptibility testing"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever (refractory to antibiotics) + risk factors (CVC, broad-spectrum antibiotics, ICU, neutropenia, SOT, TPN). Blood cultures (2-3 sets from peripheral vein + CVC if present). Beta-D-glucan (>80 pg/mL). Fundoscopy (if candidemia, rule out endophthalmitis). TEE (if candidemia + cardiac risk factors, rule out endocarditis).",
            "essential_tests": [
              "Blood cultures (2-3 sets from peripheral vein + CVC if present): Candida species (C. albicans 40-50%, C. glabrata 20-30%, C. parapsilosis 10-15%, C. tropicalis 10-15%, C. krusei 5-10%, C. auris 1-5%). Sensitivity: 70-80% (may require 2-3 days to grow, repeat if high suspicion). Turnaround: 24-48 hours (preliminary), 3-5 days (final identification + susceptibility).",
              "Beta-D-glucan: >80 pg/mL (70-80% sensitive, 60-70% specific, not specific for Candida, positive in Aspergillus, PCP). Turnaround: 1-2 days.",
              "Fundoscopy: Rule out endophthalmitis (5-10% of candidemia, white fluffy lesions on retina). Ophthalmology consult if positive. Turnaround: Same day."
            ],
            "conditional_tests": [
              "TEE (transesophageal echocardiography): Rule out endocarditis (5-10% of candidemia, vegetation on valve). Indications: Candidemia + cardiac risk factors (prosthetic valve, pacemaker, ICD, injection drug use, persistent fever >3 days despite antifungals). Turnaround: Same day.",
              "CT abdomen/pelvis: Rule out intra-abdominal abscess (if recent abdominal surgery, GI perforation, anastomotic leak). Hepatosplenic candidiasis (multiple liver/spleen abscesses, 5-10%, especially in neutropenia recovery). Turnaround: Same day.",
              "Endoscopy: Esophageal candidiasis (white plaques or ulcers, 80-90% of esophageal candidiasis). Indications: Odynophagia + dysphagia + HIV/AIDS CD4 <100 cells/μL. Turnaround: Same day.",
              "Susceptibility testing: Fluconazole MIC (C. albicans usually susceptible, C. glabrata 20-30% resistant, C. krusei intrinsically resistant, C. auris multi-drug resistant). Echinocandin MIC (C. glabrata 5-10% resistant, C. parapsilosis higher MIC). Turnaround: 3-5 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting blood cultures (start empiric echinocandin if high clinical suspicion, mortality increases with delayed treatment). Do NOT rely on negative blood cultures (sensitivity 70-80%, repeat if high suspicion). Do NOT treat asymptomatic candiduria (no benefit unless neutropenia or urologic procedure planned).",
            "turnaround_time": "Blood cultures: 24-48 hours (preliminary), 3-5 days (final identification + susceptibility). Beta-D-glucan: 1-2 days. Fundoscopy: Same day. TEE: Same day. CT abdomen/pelvis: Same day. Endoscopy: Same day. Susceptibility testing: 3-5 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Candida species: C. albicans (40-50%, most common, usually fluconazole-susceptible), C. glabrata (20-30%, 20-30% fluconazole-resistant, 5-10% echinocandin-resistant), C. parapsilosis (10-15%, higher echinocandin MIC, associated with CVC), C. tropicalis (10-15%, usually fluconazole-susceptible), C. krusei (5-10%, intrinsically fluconazole-resistant), C. auris (1-5% emerging, multi-drug resistant, 90% fluconazole-resistant, 30-40% amphotericin B-resistant, 5-10% echinocandin-resistant, infection control concern). Commensal organism (normal flora of GI tract, skin, mucous membranes). Pathogenesis: Disruption of normal flora (broad-spectrum antibiotics) + breach of mucosal barrier (CVC, surgery, neutropenia) → bloodstream invasion → dissemination (endophthalmitis, endocarditis, osteomyelitis, hepatosplenic candidiasis).",
            "pathogenesis": "Disruption of normal flora (broad-spectrum antibiotics) + breach of mucosal barrier (CVC, surgery, neutropenia) → Candida overgrowth → bloodstream invasion (candidemia) → dissemination (endophthalmitis 5-10%, endocarditis 5-10%, osteomyelitis 5-10%, hepatosplenic candidiasis 5-10%). Host immune response: Neutrophils critical for clearance (candidemia more severe if neutropenia). Complications: Septic shock (30-40%, hypotension, requires vasopressors), endophthalmitis (vision-threatening), endocarditis (high mortality 50-70%, often requires valve replacement).",
            "resistance_patterns": {
              "fluconazole_resistance": "Fluconazole resistance: C. glabrata (20-30% resistant, dose-dependent susceptibility), C. krusei (intrinsically resistant), C. auris (90% resistant). Treatment: Echinocandin (caspofungin, micafungin, anidulafungin) OR Liposomal amphotericin B 3-5mg/kg IV daily (if echinocandin-resistant).",
              "echinocandin_resistance": "Echinocandin resistance: C. glabrata (5-10% resistant, FKS mutations), C. parapsilosis (higher MIC, may require higher echinocandin doses), C. auris (5-10% resistant). Treatment: Liposomal amphotericin B 3-5mg/kg IV daily OR High-dose echinocandin (micafungin 150mg IV daily, anidulafungin 200mg IV daily).",
              "amphotericin_resistance": "Amphotericin B resistance: C. auris (30-40% resistant), C. lusitaniae (rare, intrinsically resistant). Treatment: Echinocandin (if amphotericin-resistant but echinocandin-susceptible) OR Combination therapy (echinocandin + liposomal amphotericin B)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for susceptibility testing, mortality increases with delayed treatment). Echinocandin (caspofungin 70mg IV x1, then 50mg IV daily OR micafungin 100mg IV daily OR anidulafungin 200mg IV x1, then 100mg IV daily) OR Fluconazole 800mg IV/PO x1 (loading), then 400mg IV/PO daily (if fluconazole-susceptible Candida, hemodynamically stable, no prior azole exposure). Remove CVC within 24-48 hours (reduces mortality by 20-30%, source control CRITICAL)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Echinocandin (preferred for critically ill, hemodynamically unstable, or prior azole exposure): Caspofungin 70mg IV x1 (loading), then 50mg IV daily OR Micafungin 100mg IV daily OR Anidulafungin 200mg IV x1 (loading), then 100mg IV daily. Remove CVC within 24-48 hours (source control CRITICAL, reduces mortality by 20-30%). Continue until blood cultures negative x 2 consecutive days + clinical improvement (decreased fever, hemodynamic stability) + resolution of neutropenia (if neutropenic).",
            "alternative_first_line": "Fluconazole 800mg IV/PO x1 (loading), then 400mg IV/PO daily (if fluconazole-susceptible Candida, hemodynamically stable, no prior azole exposure, no recent azole prophylaxis). Remove CVC within 24-48 hours. Switch to fluconazole after 5-7 days of echinocandin if fluconazole-susceptible Candida confirmed by susceptibility testing (step-down therapy, reduces cost, allows PO administration).",
            "candidemia_with_septic_shock": "Echinocandin (caspofungin 70mg IV x1, then 50mg IV daily OR micafungin 100mg IV daily OR anidulafungin 200mg IV x1, then 100mg IV daily) + ICU admission + vasopressors (norepinephrine) + source control (remove CVC within 24-48 hours). Do NOT use fluconazole as initial therapy (inferior to echinocandin in critically ill patients).",
            "esophageal_candidiasis": "Fluconazole 200-400mg IV/PO daily x 14-21 days (first-line, 80-90% effective). Alternative: Itraconazole 200mg PO daily x 14-21 days OR Posaconazole 400mg PO BID x 1 day, then 400mg PO daily x 14-21 days (if fluconazole-refractory). Echinocandin (caspofungin, micafungin, anidulafungin) x 14-21 days (if fluconazole-refractory or unable to tolerate PO). HIV/AIDS: Start ART if not already on ART (immune recovery prevents relapse).",
            "avoid_list": "Avoid fluconazole as initial therapy if critically ill, hemodynamically unstable, or prior azole exposure (inferior to echinocandin). Avoid voriconazole (no advantage over fluconazole for Candida, more drug interactions). Do NOT delay treatment while awaiting susceptibility testing (start empiric echinocandin, mortality increases with delayed treatment). Do NOT delay CVC removal (source control CRITICAL, reduces mortality by 20-30%)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "fluconazole_susceptible": "Fluconazole 400mg IV/PO daily (if fluconazole-susceptible C. albicans, C. tropicalis, C. parapsilosis confirmed by susceptibility testing). Step-down therapy: Switch from echinocandin to fluconazole after 5-7 days if fluconazole-susceptible + hemodynamically stable + blood cultures negative. Duration: 14 days after first negative blood culture + resolution of symptoms + resolution of neutropenia (if neutropenic). Remove CVC within 24-48 hours.",
            "fluconazole_resistant": "Echinocandin (caspofungin 50mg IV daily OR micafungin 100mg IV daily OR anidulafungin 100mg IV daily) (if fluconazole-resistant C. glabrata, C. krusei, C. auris). Duration: 14 days after first negative blood culture + resolution of symptoms + resolution of neutropenia. Remove CVC within 24-48 hours. Infectious disease consult REQUIRED (especially if C. auris, infection control measures needed).",
            "echinocandin_resistant": "Liposomal amphotericin B 3-5mg/kg IV daily (if echinocandin-resistant C. glabrata, C. auris). Alternative: High-dose echinocandin (micafungin 150mg IV daily, anidulafungin 200mg IV daily) OR Combination therapy (echinocandin + liposomal amphotericin B). Duration: 14 days after first negative blood culture + resolution of symptoms. Infectious disease consult REQUIRED.",
            "endophthalmitis": "Fluconazole 400-800mg IV/PO daily x 4-6 weeks (if fluconazole-susceptible) OR Echinocandin (if fluconazole-resistant) + Intravitreal amphotericin B 5-10 mcg per 0.1 mL (if sight-threatening or poor response to systemic therapy). Ophthalmology consult URGENT. Fundoscopy weekly (monitor for improvement). Duration: 4-6 weeks (until resolution of endophthalmitis on fundoscopy).",
            "endocarditis": "Echinocandin (caspofungin 50mg IV daily OR micafungin 100-150mg IV daily OR anidulafungin 100mg IV daily) x 6 weeks after valve replacement OR Liposomal amphotericin B 3-5mg/kg IV daily x 6 weeks after valve replacement. Cardiac surgery consult URGENT (valve replacement often required, medical therapy alone has high failure rate 50-70%). TEE weekly (monitor for vegetation resolution). Duration: 6 weeks after valve replacement OR 6 weeks after last positive blood culture if valve replacement not performed.",
            "disseminated_candidiasis": "Echinocandin (caspofungin 50mg IV daily OR micafungin 100mg IV daily OR anidulafungin 100mg IV daily) x 4-6 weeks (until resolution of all sites of infection). Hepatosplenic candidiasis: Fluconazole 400mg IV/PO daily x 3-6 months (long-term suppressive therapy until resolution of abscesses on CT). Osteomyelitis: Fluconazole 400mg PO daily x 6-12 months (after initial echinocandin x 2 weeks). Infectious disease consult REQUIRED.",
            "duration": "Candidemia (uncomplicated): 14 days after first negative blood culture + resolution of symptoms + resolution of neutropenia. Endophthalmitis: 4-6 weeks. Endocarditis: 6 weeks after valve replacement. Disseminated candidiasis: 4-6 weeks (until resolution of all sites of infection). Hepatosplenic candidiasis: 3-6 months. Osteomyelitis: 6-12 months."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Candidemia (uncomplicated): 14 days after first negative blood culture + resolution of symptoms + resolution of neutropenia (if neutropenic). Endophthalmitis: 4-6 weeks. Endocarditis: 6 weeks after valve replacement. Disseminated candidiasis: 4-6 weeks. Hepatosplenic candidiasis: 3-6 months. Osteomyelitis: 6-12 months. Esophageal candidiasis: 14-21 days. Switch from IV to PO (fluconazole) when able to tolerate PO + hemodynamically stable + fluconazole-susceptible Candida.",
            "monitoring": "Daily: Blood cultures (repeat until negative x 2 consecutive days). Temperature (monitor for defervescence, usually within 3-5 days). Hemodynamic status (blood pressure, heart rate). Every 2-3 days: CBC (monitor for resolution of neutropenia if neutropenic). Creatinine (monitor renal function). Weekly: Fundoscopy (if candidemia, monitor for endophthalmitis). TEE (if endocarditis, monitor for vegetation resolution). CT abdomen/pelvis (if hepatosplenic candidiasis, monitor for abscess resolution). Clinical improvement expected within 3-5 days (decreased fever, hemodynamic stability, negative blood cultures).",
            "stop_criteria": "Continue until blood cultures negative x 2 consecutive days + resolution of symptoms (decreased fever, hemodynamic stability) + resolution of neutropenia (if neutropenic) + 14 days after first negative blood culture (uncomplicated candidemia). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse). Remove CVC within 24-48 hours (source control CRITICAL)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "cvc_removal": "Remove CVC within 24-48 hours (source control CRITICAL, reduces mortality by 20-30%). If CVC cannot be removed (no alternative access, ongoing need for TPN or chemotherapy): Use echinocandin (NOT fluconazole, biofilm penetration poor) + consider CVC exchange over guidewire (if no tunnel infection). Monitor blood cultures daily (if persistently positive despite antifungals + CVC removal → consider metastatic infection: endophthalmitis, endocarditis, osteomyelitis).",
            "neutropenia": "Neutropenia (ANC <500 cells/μL, 20-30% of candidemia). Duration: Continue antifungals until resolution of neutropenia (ANC >500 cells/μL) + 14 days after first negative blood culture. Add G-CSF (filgrastim 5 mcg/kg SC daily) if severe neutropenia (ANC <100 cells/μL) to accelerate neutrophil recovery. Hematology consult.",
            "sot": "Solid organ transplant (SOT, 10-15% of candidemia, immunosuppression). Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult. Duration: 14 days after first negative blood culture + resolution of symptoms. Prophylaxis: Fluconazole 400mg PO daily (if high-risk SOT: liver transplant, pancreas transplant, small bowel transplant) x 3-6 months post-transplant.",
            "hiv_aids": "HIV/AIDS with CD4 <100 cells/μL (esophageal candidiasis, 10-15%). Fluconazole 200-400mg PO daily x 14-21 days. Start ART if not already on ART (immune recovery prevents relapse). Prophylaxis: Fluconazole 100-200mg PO daily (if recurrent esophageal candidiasis, CD4 <100 cells/μL) until CD4 >200 cells/μL x 3 months on ART.",
            "c_auris": "C. auris (1-5% emerging, multi-drug resistant, 90% fluconazole-resistant, 30-40% amphotericin B-resistant, 5-10% echinocandin-resistant). Infection control CRITICAL (contact precautions, dedicated equipment, environmental cleaning with chlorine-based disinfectants, patient isolation). Echinocandin (if echinocandin-susceptible) OR Liposomal amphotericin B 3-5mg/kg IV daily (if echinocandin-resistant) OR Combination therapy (echinocandin + liposomal amphotericin B). Infectious disease + infection control consult REQUIRED. Report to public health authorities.",
            "pregnancy": "Echinocandins: Limited data, use only if life-threatening candidemia (caspofungin, micafungin, anidulafungin). Fluconazole: Teratogenic at high doses (>400mg daily), avoid in first trimester if possible, use only if life-threatening candidemia. Liposomal amphotericin B: Safe in pregnancy (preferred antifungal in pregnancy). Infectious disease + obstetrics consult.",
            "counseling": "Invasive candidiasis is life-threatening (mortality 30-40% with treatment, 50-70% if untreated). Treatment duration: 14 days after first negative blood culture (uncomplicated candidemia), longer if complications (endophthalmitis 4-6 weeks, endocarditis 6 weeks, disseminated candidiasis 4-6 weeks). CVC removal CRITICAL (reduces mortality by 20-30%). Clinical improvement expected within 3-5 days (decreased fever, hemodynamic stability, negative blood cultures). Fundoscopy REQUIRED (rule out endophthalmitis). TEE if cardiac risk factors (rule out endocarditis)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for susceptibility testing, mortality increases with delayed treatment)",
              "Echinocandin (caspofungin 70mg IV x1, then 50mg IV daily OR micafungin 100mg IV daily OR anidulafungin 200mg IV x1, then 100mg IV daily) OR Fluconazole 800mg IV/PO x1, then 400mg IV/PO daily (if hemodynamically stable, no prior azole exposure)",
              "Remove CVC within 24-48 hours (source control CRITICAL, reduces mortality by 20-30%)",
              "Step-down therapy: Switch from echinocandin to fluconazole after 5-7 days if fluconazole-susceptible + hemodynamically stable + blood cultures negative",
              "Switch from IV to PO (fluconazole) when able to tolerate PO + hemodynamically stable + fluconazole-susceptible Candida",
              "Continue until blood cultures negative x 2 consecutive days + 14 days after first negative blood culture + resolution of symptoms"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + risk factors + positive blood cultures for Candida)",
              "Are antifungals started immediately? (Echinocandin OR fluconazole)",
              "Is CVC removed within 24-48 hours? (Source control CRITICAL)",
              "Are blood cultures repeated daily? (Until negative x 2 consecutive days)",
              "Is fundoscopy performed? (Rule out endophthalmitis, 5-10% of candidemia)",
              "Is TEE performed if cardiac risk factors? (Rule out endocarditis, 5-10% of candidemia)",
              "Is step-down therapy considered? (Switch from echinocandin to fluconazole after 5-7 days if fluconazole-susceptible + hemodynamically stable)",
              "Is treatment duration appropriate? (14 days after first negative blood culture + resolution of symptoms)"
            ],
            "avoid_unnecessary_treatment": "Avoid fluconazole as initial therapy if critically ill, hemodynamically unstable, or prior azole exposure (inferior to echinocandin). Avoid voriconazole (no advantage over fluconazole for Candida). Do NOT delay treatment while awaiting susceptibility testing (start empiric echinocandin). Do NOT delay CVC removal (source control CRITICAL). Do NOT treat asymptomatic candiduria (no benefit unless neutropenia or urologic procedure planned). Do NOT stop treatment early (increases relapse risk).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + risk factors + positive blood cultures for Candida). Blood cultures (2-3 sets from peripheral vein + CVC if present). Beta-D-glucan (>80 pg/mL, 70-80% sensitive, not specific for Candida). Fundoscopy (rule out endophthalmitis). TEE (if cardiac risk factors, rule out endocarditis). Susceptibility testing (fluconazole MIC, echinocandin MIC). Do NOT delay treatment while awaiting susceptibility testing.",
            "prevention": "Primary prophylaxis: Fluconazole 400mg PO daily (if high-risk SOT: liver transplant, pancreas transplant, small bowel transplant, OR high-risk ICU: recent abdominal surgery + anastomotic leak + broad-spectrum antibiotics) x 3-6 months post-transplant or until ICU discharge. Secondary prophylaxis: Fluconazole 400mg PO daily (after candidemia until resolution of immunosuppression). CVC care: Sterile insertion technique, daily assessment for removal, chlorhexidine dressing. Antibiotic stewardship: Minimize broad-spectrum antibiotics (disrupts normal flora, allows Candida overgrowth)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Clinical Practice Guideline for the Management of Candidiasis (2016)",
              "url": "https://academic.oup.com/cid/article/62/4/e1/2462830"
            },
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "CDC Candida auris Interim Clinical Guidance (2024)",
              "url": "https://www.cdc.gov/candida-auris/hcp/clinical-guidance.html"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "cryptococcal-meningitis",
      "name": "Cryptococcal Meningitis",
      "synonyms": [
        "Cryptococcosis",
        "Cryptococcal CNS infection"
      ],
      "icd10": [
        "B45.1",
        "G02.1"
      ],
      "severity": [
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening fungal meningitis requiring amphotericin B + flucytosine (induction x 14 days), then fluconazole (consolidation x 8 weeks, maintenance until immune recovery)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening fungal meningitis caused by Cryptococcus neoformans (HIV/AIDS, 90-95%) or Cryptococcus gattii (immunocompetent, 5-10%). Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <100 cells/μL, 80-90% of cryptococcal meningitis), solid organ transplant (SOT, 5-10%), prolonged corticosteroids (5-10%), advanced malignancy (5-10%). Incidence: Rare in general population, common in HIV/AIDS (5-10% lifetime risk if CD4 <100 cells/μL and no prophylaxis). Mortality: 10-20% (HIV/AIDS with treatment), 30-40% (non-HIV immunocompromised), 50-70% (if untreated or increased intracranial pressure).",
            "clinical_presentation": "Subacute onset (weeks): Headache (80-90%, most common symptom), fever (60-70%), altered mental status (50-60%), neck stiffness (30-40%, less common than bacterial meningitis), nausea/vomiting (40-50%), photophobia (20-30%), seizures (10-20%). Physical exam: Fever, altered mental status, neck stiffness (30-40%), papilledema (20-30%, suggests increased intracranial pressure). Complications: Increased intracranial pressure (ICP, 50-60%, most important predictor of mortality, requires serial lumbar punctures), hydrocephalus (10-20%, requires ventriculoperitoneal shunt), cryptococcomas (brain abscesses, 5-10%), disseminated cryptococcosis (pulmonary, skin, bone, 10-20%).",
            "diagnostic_criteria": "Clinical diagnosis: Headache + fever + altered mental status + immunocompromised host (HIV/AIDS CD4 <100 cells/μL, SOT, prolonged corticosteroids). Laboratory: Lumbar puncture (LP) showing elevated opening pressure (>25 cm H2O, 50-60%), elevated protein (>45 mg/dL, 60-70%), low glucose (<40 mg/dL, 40-50%), lymphocytic pleocytosis (WBC 20-500 cells/μL, 60-70%, may be normal in HIV/AIDS). Definitive diagnosis: Positive CSF cryptococcal antigen (CrAg, >1:1 titer, 95-99% sensitive, gold standard) OR Positive CSF India ink stain (50-70% sensitive, shows encapsulated yeast) OR Positive CSF culture (Cryptococcus neoformans or C. gattii, 90-95% sensitive).",
            "risk_factors": [
              "HIV/AIDS with CD4 <100 cells/μL (most important risk factor, 80-90% of cryptococcal meningitis)",
              "Solid organ transplant (SOT, 5-10%, immunosuppression)",
              "Prolonged corticosteroids (>0.3 mg/kg prednisone daily x >3 weeks, 5-10%)",
              "Advanced malignancy (hematologic malignancies, 5-10%)",
              "Immunosuppressive therapy (TNF-alpha inhibitors, alemtuzumab, 5-10%)",
              "Sarcoidosis (5-10%, impaired cell-mediated immunity)"
            ],
            "red_flags": [
              "Increased intracranial pressure (ICP) - opening pressure >25 cm H2O (50-60%), most important predictor of mortality, requires serial lumbar punctures (daily or every other day) to reduce ICP to <20 cm H2O",
              "Altered mental status - confusion, lethargy, coma (50-60%), suggests severe disease or increased ICP, requires ICU admission + aggressive ICP management",
              "Papilledema - suggests increased ICP (20-30%), requires ophthalmology consult + serial lumbar punctures",
              "Hydrocephalus - obstructive hydrocephalus (10-20%), requires neurosurgery consult + ventriculoperitoneal shunt",
              "IRIS (immune reconstitution inflammatory syndrome) - worsening symptoms after starting ART in HIV/AIDS (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART + continue antifungals"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Headache + fever + altered mental status + immunocompromised host (HIV/AIDS CD4 <100 cells/μL, SOT, prolonged corticosteroids). Lumbar puncture (LP) with opening pressure measurement (CRITICAL, measure ICP). CSF cryptococcal antigen (CrAg, >1:1 titer, 95-99% sensitive, gold standard). CSF India ink stain (50-70% sensitive). CSF culture (90-95% sensitive). Serum cryptococcal antigen (screening test, positive in 95-99% of cryptococcal meningitis).",
            "essential_tests": [
              "Lumbar puncture (LP) with opening pressure measurement: Opening pressure >25 cm H2O (50-60%, increased ICP, most important predictor of mortality). CSF analysis: Elevated protein (>45 mg/dL, 60-70%), low glucose (<40 mg/dL, 40-50%), lymphocytic pleocytosis (WBC 20-500 cells/μL, 60-70%, may be normal in HIV/AIDS). Turnaround: 1-2 hours.",
              "CSF cryptococcal antigen (CrAg): >1:1 titer (95-99% sensitive, gold standard). Quantitative titer (higher titer suggests higher fungal burden, >1:1024 associated with worse prognosis). Turnaround: 1-2 hours (lateral flow assay).",
              "CSF India ink stain: Positive (50-70% sensitive, shows encapsulated yeast with clear halo). Turnaround: 1 hour.",
              "CSF culture: Cryptococcus neoformans or C. gattii (90-95% sensitive). Turnaround: 3-7 days.",
              "Serum cryptococcal antigen (CrAg): >1:1 titer (95-99% sensitive, screening test). Positive in 95-99% of cryptococcal meningitis. Turnaround: 1-2 hours (lateral flow assay)."
            ],
            "conditional_tests": [
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, cryptococcal meningitis risk if CD4 <100 cells/μL).",
              "CT head (before LP): Rule out mass lesion, hydrocephalus (10-20%), cryptococcomas (5-10%). Indications: Focal neurologic deficits, papilledema, altered mental status. Turnaround: Same day.",
              "MRI brain: Cryptococcomas (brain abscesses, 5-10%, ring-enhancing lesions), hydrocephalus (10-20%), leptomeningeal enhancement (30-40%). Turnaround: Same day.",
              "Chest X-ray: Pulmonary cryptococcosis (10-20%, nodules, infiltrates, pleural effusion). Turnaround: Same day.",
              "Blood cultures: Cryptococcemia (10-20%, positive in disseminated cryptococcosis). Turnaround: 3-7 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting CSF culture (start empiric amphotericin B + flucytosine if high clinical suspicion, mortality increases with delayed treatment). Do NOT skip opening pressure measurement (ICP management CRITICAL, most important predictor of mortality). Do NOT perform LP if mass lesion or increased ICP on CT head (risk of herniation, consult neurosurgery first).",
            "turnaround_time": "LP with opening pressure: 1-2 hours. CSF CrAg: 1-2 hours (lateral flow assay). CSF India ink: 1 hour. CSF culture: 3-7 days. Serum CrAg: 1-2 hours. CT head: Same day. MRI brain: Same day. Chest X-ray: Same day. Blood cultures: 3-7 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Cryptococcus neoformans (HIV/AIDS, 90-95%) or Cryptococcus gattii (immunocompetent, 5-10%). Encapsulated yeast (polysaccharide capsule, visible on India ink stain). Environmental organism (soil, bird droppings, especially pigeon droppings). Transmission: Inhalation of airborne spores → pulmonary infection → hematogenous dissemination to CNS (meningitis, most common site). Pathogenesis: Inhalation → pulmonary infection (often asymptomatic) → hematogenous dissemination to CNS → meningitis (if CD4 <100 cells/μL or immunosuppression). Complications: Increased ICP (50-60%, most important predictor of mortality), hydrocephalus (10-20%), cryptococcomas (5-10%), disseminated cryptococcosis (pulmonary, skin, bone, 10-20%).",
            "pathogenesis": "Inhalation of Cryptococcus spores → pulmonary infection (often asymptomatic) → hematogenous dissemination to CNS (if CD4 <100 cells/μL or immunosuppression) → meningitis (polysaccharide capsule inhibits phagocytosis, allows CNS invasion). Host immune response: CD4 T-cells critical for clearance (cryptococcal meningitis occurs when CD4 <100 cells/μL). Complications: Increased ICP (50-60%, polysaccharide capsule blocks CSF reabsorption, most important predictor of mortality, requires serial lumbar punctures), hydrocephalus (10-20%, obstructive, requires ventriculoperitoneal shunt), cryptococcomas (brain abscesses, 5-10%), IRIS (10-30% in HIV/AIDS after starting ART).",
            "resistance_patterns": {
              "fluconazole_resistance": "Fluconazole resistance: Rare (<5%). Acquired resistance (after prolonged fluconazole exposure, especially if subtherapeutic doses or poor adherence). Treatment: Amphotericin B 0.7-1 mg/kg IV daily + Flucytosine 25mg/kg PO QID (if fluconazole-resistant).",
              "amphotericin_resistance": "Amphotericin B resistance: Very rare (<1%). Treatment: High-dose amphotericin B (liposomal amphotericin B 5-6 mg/kg IV daily) + Flucytosine 25mg/kg PO QID.",
              "flucytosine_resistance": "Flucytosine resistance: Rare (5-10%). Acquired resistance (if flucytosine monotherapy, always use in combination with amphotericin B). Treatment: Amphotericin B 0.7-1 mg/kg IV daily (without flucytosine) OR Liposomal amphotericin B 3-4 mg/kg IV daily + Fluconazole 800mg IV/PO daily."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for CSF culture, mortality increases with delayed treatment). Induction: Amphotericin B liposomal 3-4 mg/kg IV daily + Flucytosine 25mg/kg PO QID x 14 days (HIV/AIDS) or x 14-28 days (non-HIV). Consolidation: Fluconazole 400mg PO daily x 8 weeks. Maintenance: Fluconazole 200mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS). ICP management: Serial lumbar punctures (daily or every other day) if opening pressure >25 cm H2O (reduce ICP to <20 cm H2O, most important intervention to reduce mortality)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "induction": "Amphotericin B liposomal 3-4 mg/kg IV daily + Flucytosine 25mg/kg PO QID x 14 days (HIV/AIDS) or x 14-28 days (non-HIV). Liposomal amphotericin B preferred over conventional amphotericin B (less nephrotoxic). Monitor flucytosine levels (target peak 50-100 mcg/mL, check after 3-5 days, adjust dose if renal impairment). ICP management: Serial lumbar punctures (daily or every other day) if opening pressure >25 cm H2O (remove 10-30 mL CSF to reduce ICP to <20 cm H2O, most important intervention to reduce mortality).",
            "consolidation": "Fluconazole 400mg PO daily x 8 weeks (after completing induction therapy). Start consolidation after 14 days of induction (HIV/AIDS) or 14-28 days (non-HIV). Continue until clinical improvement (decreased headache, fever, altered mental status) + negative CSF culture (repeat LP at 2 weeks to confirm sterilization).",
            "maintenance": "Fluconazole 200mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS). Start maintenance after completing consolidation (8 weeks). HIV/AIDS: Start ART after 2-6 weeks of induction therapy (reduces IRIS risk, earlier ART if CD4 <50 cells/μL). Discontinue maintenance when CD4 >200 cells/μL x 3 months on ART.",
            "icp_management": "Serial lumbar punctures (daily or every other day) if opening pressure >25 cm H2O (remove 10-30 mL CSF to reduce ICP to <20 cm H2O, most important intervention to reduce mortality). Continue serial LPs until opening pressure <20 cm H2O x 2 consecutive LPs. If opening pressure persistently elevated despite serial LPs: Consider temporary lumbar drain OR Ventriculoperitoneal shunt (if hydrocephalus). Avoid acetazolamide, mannitol, corticosteroids (NOT effective for cryptococcal ICP, may worsen outcomes).",
            "avoid_list": "Avoid fluconazole monotherapy for induction (inferior to amphotericin B + flucytosine, higher mortality). Avoid flucytosine monotherapy (rapid resistance development, always use in combination with amphotericin B). Avoid corticosteroids for ICP management (NOT effective, may worsen outcomes). Do NOT delay treatment while awaiting CSF culture (mortality increases with delayed treatment). Do NOT skip opening pressure measurement (ICP management CRITICAL)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_cryptococcal_meningitis": "Induction: Amphotericin B liposomal 3-4 mg/kg IV daily + Flucytosine 25mg/kg PO QID x 14 days (HIV/AIDS) or x 14-28 days (non-HIV). Consolidation: Fluconazole 400mg PO daily x 8 weeks. Maintenance: Fluconazole 200mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS). ICP management: Serial lumbar punctures if opening pressure >25 cm H2O.",
            "hiv_aids_specific": "Induction: 14 days (shorter duration acceptable if clinical improvement + negative CSF culture at 2 weeks). Start ART after 2-6 weeks of induction therapy (reduces IRIS risk, earlier ART if CD4 <50 cells/μL). Maintenance: Fluconazole 200mg PO daily (until CD4 >200 cells/μL x 3 months on ART). Discontinue maintenance when CD4 >200 cells/μL x 3 months on ART. IRIS: Worsening symptoms after starting ART (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids (prednisone 40mg PO daily, then taper over 4-6 weeks) + continue ART + continue antifungals.",
            "non_hiv_specific": "Induction: 14-28 days (longer duration if slow clinical improvement or persistently positive CSF culture). Consolidation: Fluconazole 400mg PO daily x 8 weeks. Maintenance: Fluconazole 200mg PO daily x 6-12 months (until resolution of immunosuppression). Reduce immunosuppression if possible (taper corticosteroids, reduce tacrolimus). Infectious disease consult.",
            "treatment_response": "Clinical improvement expected within 7-14 days (decreased headache, fever, altered mental status). Repeat LP at 2 weeks (confirm CSF sterilization, negative CSF culture). If no improvement after 14 days: Check flucytosine levels (target peak 50-100 mcg/mL, adjust dose if subtherapeutic). Repeat LP (assess ICP, CSF culture, CSF CrAg titer). Consider alternative diagnosis (bacterial meningitis, viral meningitis, other fungal meningitis) OR Increase amphotericin B dose (liposomal amphotericin B 5-6 mg/kg IV daily) OR Extend induction duration (14-28 days).",
            "cryptococcomas": "Amphotericin B liposomal 3-4 mg/kg IV daily + Flucytosine 25mg/kg PO QID x 14-28 days (induction), then fluconazole 400-800mg PO daily x 6-12 months (consolidation + maintenance). Neurosurgery consult (consider surgical excision if large cryptococcoma >2 cm or mass effect). MRI brain every 4-6 weeks (monitor for resolution).",
            "duration": "Induction: 14 days (HIV/AIDS) or 14-28 days (non-HIV). Consolidation: 8 weeks. Maintenance: Until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or 6-12 months (non-HIV). Total duration: Minimum 10-14 months (HIV/AIDS), 6-12 months (non-HIV)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Induction: 14 days (HIV/AIDS) or 14-28 days (non-HIV). Consolidation: 8 weeks. Maintenance: Until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or 6-12 months (non-HIV). Total duration: Minimum 10-14 months (HIV/AIDS), 6-12 months (non-HIV). ICP management: Serial lumbar punctures (daily or every other day) until opening pressure <20 cm H2O x 2 consecutive LPs.",
            "monitoring": "Daily (during induction): Opening pressure (if >25 cm H2O, serial LPs daily or every other day). Temperature (monitor for defervescence, usually within 7-14 days). Mental status (monitor for improvement). Creatinine (monitor for amphotericin B nephrotoxicity, maintain CrCl >50 mL/min with saline hydration). Electrolytes (monitor for hypokalemia, hypomagnesemia, supplement if low). Weekly (during induction): Flucytosine levels (target peak 50-100 mcg/mL, check after 3-5 days, then weekly). CBC (monitor for flucytosine toxicity: leukopenia, thrombocytopenia, anemia). At 2 weeks: Repeat LP (confirm CSF sterilization, negative CSF culture, decreased CSF CrAg titer). At 8 weeks: Repeat LP (confirm CSF sterilization before discontinuing consolidation).",
            "stop_criteria": "Discontinue induction after 14 days (HIV/AIDS) or 14-28 days (non-HIV) + clinical improvement + negative CSF culture at 2 weeks. Discontinue consolidation after 8 weeks + clinical improvement + negative CSF culture. Discontinue maintenance when immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or after 6-12 months (non-HIV). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "icp_management": "Increased ICP (opening pressure >25 cm H2O, 50-60%, most important predictor of mortality). Serial lumbar punctures (daily or every other day, remove 10-30 mL CSF to reduce ICP to <20 cm H2O, most important intervention to reduce mortality). Continue serial LPs until opening pressure <20 cm H2O x 2 consecutive LPs. If opening pressure persistently elevated despite serial LPs: Consider temporary lumbar drain OR Ventriculoperitoneal shunt (if hydrocephalus). Avoid acetazolamide, mannitol, corticosteroids (NOT effective for cryptococcal ICP, may worsen outcomes).",
            "hiv_aids": "CD4 <100 cells/μL (most important risk factor, 80-90% of cryptococcal meningitis). Induction: 14 days. Start ART after 2-6 weeks of induction therapy (reduces IRIS risk, earlier ART if CD4 <50 cells/μL). Maintenance: Fluconazole 200mg PO daily (until CD4 >200 cells/μL x 3 months on ART). IRIS: Worsening symptoms after starting ART (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids (prednisone 40mg PO daily, then taper over 4-6 weeks) + continue ART + continue antifungals.",
            "sot": "Solid organ transplant (SOT, 5-10% of cryptococcal meningitis, immunosuppression). Induction: 14-28 days (longer duration if slow clinical improvement). Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult. Maintenance: Fluconazole 200mg PO daily x 6-12 months (until resolution of immunosuppression).",
            "flucytosine_toxicity": "Leukopenia (WBC <3,000, 20-30%), thrombocytopenia (platelets <50,000, 10-20%), anemia (Hgb <8 g/dL, 10-20%). Management: Monitor flucytosine levels (target peak 50-100 mcg/mL, toxicity if >100 mcg/mL). Reduce flucytosine dose if renal impairment (CrCl <50 mL/min). Monitor CBC weekly. If severe toxicity (WBC <1,000, platelets <25,000): Discontinue flucytosine, continue amphotericin B monotherapy.",
            "amphotericin_toxicity": "Nephrotoxicity (30-40%, maintain CrCl >50 mL/min with saline hydration 1 L NS before + 1 L NS after each dose, monitor creatinine daily). Electrolyte abnormalities: Hypokalemia (50-60%, monitor potassium daily, supplement if <3.5 mEq/L), hypomagnesemia (30-40%, monitor magnesium weekly, supplement if <1.5 mg/dL). Infusion-related reactions (fever, chills, rigors, 50-60%, premedicate with acetaminophen 650mg PO + diphenhydramine 25-50mg PO + hydrocortisone 50mg IV 30 minutes before infusion).",
            "pregnancy": "Amphotericin B: Safe in pregnancy (preferred antifungal in pregnancy). Flucytosine: Teratogenic in animals, avoid in first trimester if possible (use only if life-threatening cryptococcal meningitis). Fluconazole: Teratogenic at high doses (>400mg daily), avoid in first trimester if possible. Infectious disease + obstetrics consult.",
            "counseling": "Cryptococcal meningitis is life-threatening (mortality 10-20% with treatment, 50-70% if untreated or increased ICP). Treatment duration: Induction 14 days (HIV/AIDS) or 14-28 days (non-HIV), consolidation 8 weeks, maintenance until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or 6-12 months (non-HIV). Total duration: Minimum 10-14 months. ICP management CRITICAL (serial lumbar punctures if opening pressure >25 cm H2O, most important intervention to reduce mortality). HIV/AIDS: Start ART after 2-6 weeks of induction therapy (immune recovery prevents relapse). Clinical improvement expected within 7-14 days."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for CSF culture, mortality increases with delayed treatment)",
              "Induction: Amphotericin B liposomal 3-4 mg/kg IV daily + Flucytosine 25mg/kg PO QID x 14 days (HIV/AIDS) or x 14-28 days (non-HIV)",
              "ICP management: Serial lumbar punctures (daily or every other day) if opening pressure >25 cm H2O (remove 10-30 mL CSF to reduce ICP to <20 cm H2O, most important intervention to reduce mortality)",
              "Consolidation: Fluconazole 400mg PO daily x 8 weeks (after completing induction)",
              "Maintenance: Fluconazole 200mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Headache + fever + altered mental status + immunocompromised host + positive CSF CrAg)",
              "Are antifungals started immediately? (Amphotericin B liposomal 3-4 mg/kg IV daily + Flucytosine 25mg/kg PO QID)",
              "Is opening pressure measured? (CRITICAL, ICP management most important predictor of mortality)",
              "Are serial lumbar punctures performed if opening pressure >25 cm H2O? (Daily or every other day, remove 10-30 mL CSF to reduce ICP to <20 cm H2O)",
              "Are flucytosine levels monitored? (Target peak 50-100 mcg/mL, check after 3-5 days, then weekly)",
              "Is repeat LP performed at 2 weeks? (Confirm CSF sterilization, negative CSF culture)",
              "Is ART started appropriately? (HIV/AIDS: Start ART after 2-6 weeks of induction therapy, reduces IRIS risk)"
            ],
            "avoid_unnecessary_treatment": "Avoid fluconazole monotherapy for induction (inferior to amphotericin B + flucytosine, higher mortality). Avoid flucytosine monotherapy (rapid resistance development). Avoid corticosteroids for ICP management (NOT effective, may worsen outcomes). Do NOT delay treatment while awaiting CSF culture. Do NOT skip opening pressure measurement (ICP management CRITICAL). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse).",
            "diagnostic_stewardship": "Clinical diagnosis (headache + fever + altered mental status + immunocompromised host). Lumbar puncture with opening pressure measurement (CRITICAL). CSF CrAg (>1:1 titer, 95-99% sensitive, gold standard). CSF India ink stain (50-70% sensitive). CSF culture (90-95% sensitive). Serum CrAg (screening test, positive in 95-99% of cryptococcal meningitis). Do NOT delay treatment while awaiting CSF culture.",
            "prevention": "Primary prophylaxis: Fluconazole 200mg PO daily (if HIV/AIDS CD4 <100 cells/μL + positive serum CrAg) until CD4 >200 cells/μL x 3 months on ART. Secondary prophylaxis: Fluconazole 200mg PO daily (after cryptococcal meningitis until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS). Screening: Serum CrAg (if HIV/AIDS CD4 <100 cells/μL, screen for asymptomatic cryptococcal antigenemia, treat with fluconazole 800mg PO daily x 2 weeks, then 400mg PO daily x 8 weeks, then 200mg PO daily until CD4 >200 cells/μL x 3 months on ART)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Clinical Practice Guideline for the Management of Cryptococcal Disease (2010, Reaffirmed 2020)",
              "url": "https://academic.oup.com/cid/article/50/3/291/424230"
            },
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "WHO Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children (2018)",
              "url": "https://www.who.int/publications/i/item/978-92-4-155029-1"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "toxoplasma-encephalitis",
      "name": "Toxoplasma Encephalitis",
      "synonyms": [
        "Cerebral toxoplasmosis",
        "CNS toxoplasmosis"
      ],
      "icd10": [
        "B58.2",
        "G05.2"
      ],
      "severity": [
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening opportunistic parasitic infection requiring pyrimethamine + sulfadiazine + leucovorin x 6 weeks (acute), then secondary prophylaxis until immune recovery",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening opportunistic parasitic infection caused by Toxoplasma gondii. Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <100 cells/μL, 90-95% of toxoplasma encephalitis), solid organ transplant (SOT, 5-10%, especially heart transplant), hematopoietic stem cell transplant (HSCT, rare <1%). Seroprevalence: 10-30% of US adults (latent infection, reactivates when immunocompromised). Incidence: Rare in general population, common in HIV/AIDS (10-15% lifetime risk if CD4 <100 cells/μL and no prophylaxis). Mortality: 10-20% (with treatment), 50-70% (if untreated or delayed treatment).",
            "clinical_presentation": "Subacute onset (days to weeks): Headache (50-60%), altered mental status (confusion, lethargy, 40-50%), focal neurologic deficits (hemiparesis, aphasia, ataxia, 60-70%), seizures (30-40%), fever (40-50%). Physical exam: Altered mental status, focal neurologic deficits (hemiparesis, aphasia, cranial nerve palsies), seizures. MRI brain: Multiple ring-enhancing lesions (80-90%, typically in basal ganglia, corticomedullary junction), mass effect (30-40%), edema (50-60%). Complications: Seizures (30-40%), herniation (10-20%, if large lesions with mass effect), IRIS (10-20% in HIV/AIDS after starting ART).",
            "diagnostic_criteria": "Clinical diagnosis: Headache + altered mental status + focal neurologic deficits + immunocompromised host (HIV/AIDS CD4 <100 cells/μL, SOT, HSCT) + MRI brain showing multiple ring-enhancing lesions. Laboratory: Positive serum Toxoplasma IgG (90-95% of toxoplasma encephalitis, indicates prior exposure, reactivation of latent infection). Negative serum Toxoplasma IgG makes toxoplasma encephalitis unlikely (<5%). Definitive diagnosis: Brain biopsy (gold standard, rarely performed due to high risk) showing Toxoplasma tachyzoites or cysts OR Positive Toxoplasma PCR in CSF (50-70% sensitive, 95-99% specific).",
            "risk_factors": [
              "HIV/AIDS with CD4 <100 cells/μL (most important risk factor, 90-95% of toxoplasma encephalitis)",
              "Positive serum Toxoplasma IgG (indicates prior exposure, reactivation of latent infection, 90-95% of toxoplasma encephalitis)",
              "Solid organ transplant (SOT, 5-10%, especially heart transplant, D+/R- highest risk)",
              "Hematopoietic stem cell transplant (HSCT, rare <1%)",
              "Prolonged immunosuppression (high-dose corticosteroids, T-cell depleting agents)"
            ],
            "red_flags": [
              "Seizures - focal or generalized seizures (30-40%), requires antiepileptic drugs (levetiracetam, phenytoin) + pyrimethamine + sulfadiazine",
              "Mass effect with herniation risk - large lesions with mass effect (10-20%), requires neurosurgery consult + corticosteroids (dexamethasone 4mg IV q6h) + pyrimethamine + sulfadiazine",
              "Altered mental status - confusion, lethargy, coma (40-50%), suggests severe disease, requires ICU admission",
              "IRIS (immune reconstitution inflammatory syndrome) - worsening symptoms after starting ART in HIV/AIDS (10-20%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART + continue anti-Toxoplasma therapy",
              "Treatment failure - no improvement after 10-14 days of pyrimethamine + sulfadiazine, consider alternative diagnosis (CNS lymphoma, progressive multifocal leukoencephalopathy, other opportunistic infections) OR brain biopsy"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Headache + altered mental status + focal neurologic deficits + immunocompromised host (HIV/AIDS CD4 <100 cells/μL, SOT, HSCT). MRI brain (multiple ring-enhancing lesions, 80-90%). Serum Toxoplasma IgG (positive in 90-95% of toxoplasma encephalitis, negative makes toxoplasma encephalitis unlikely). Toxoplasma PCR in CSF (50-70% sensitive, 95-99% specific). Brain biopsy (gold standard, rarely performed due to high risk).",
            "essential_tests": [
              "MRI brain (with contrast): Multiple ring-enhancing lesions (80-90%, typically in basal ganglia, corticomedullary junction), mass effect (30-40%), edema (50-60%). More sensitive than CT brain. Turnaround: Same day.",
              "Serum Toxoplasma IgG: Positive (90-95% of toxoplasma encephalitis, indicates prior exposure, reactivation of latent infection). Negative serum Toxoplasma IgG makes toxoplasma encephalitis unlikely (<5%). Turnaround: 1-2 days.",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, toxoplasma encephalitis risk if CD4 <100 cells/μL). Turnaround: 1-2 days."
            ],
            "conditional_tests": [
              "Toxoplasma PCR in CSF: Positive (50-70% sensitive, 95-99% specific). Requires lumbar puncture. Turnaround: 1-2 days.",
              "Brain biopsy: Toxoplasma tachyzoites or cysts (gold standard, rarely performed due to high risk: bleeding, infection, neurologic deficits). Indications: Atypical presentation, treatment failure after 10-14 days, negative serum Toxoplasma IgG, single lesion (CNS lymphoma more likely). Turnaround: 2-3 days (histology), 1-2 days (PCR).",
              "CT brain (with contrast): Ring-enhancing lesions (less sensitive than MRI, 60-70%). Use if MRI not available. Turnaround: Same day.",
              "Lumbar puncture: CSF analysis usually non-specific (elevated protein, lymphocytic pleocytosis). Toxoplasma PCR in CSF (50-70% sensitive, 95-99% specific). Turnaround: 1-2 days.",
              "Serum Toxoplasma IgM: Usually negative (reactivation of latent infection, not primary infection). Not useful for diagnosis. Turnaround: 1-2 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting brain biopsy if high clinical suspicion (start empiric pyrimethamine + sulfadiazine + leucovorin, mortality increases with delayed treatment). Do NOT perform lumbar puncture if mass effect on MRI (risk of herniation, consult neurosurgery first). Do NOT rely on negative serum Toxoplasma IgG to rule out toxoplasma encephalitis (5% of toxoplasma encephalitis have negative IgG, especially if severe immunosuppression).",
            "turnaround_time": "MRI brain: Same day. Serum Toxoplasma IgG: 1-2 days. Toxoplasma PCR in CSF: 1-2 days. Brain biopsy: 2-3 days (histology), 1-2 days (PCR). CT brain: Same day. HIV testing: 1-2 days. CD4 count: 1-2 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Toxoplasma gondii. Obligate intracellular protozoan parasite. Definitive host: Cats (oocysts shed in feces). Intermediate hosts: Humans, birds, mammals. Transmission: Ingestion of oocysts (contaminated food, water, soil) OR Ingestion of tissue cysts (undercooked meat, especially pork, lamb) OR Congenital (transplacental transmission). Seroprevalence: 10-30% of US adults (latent infection, tissue cysts in brain, muscle, reactivates when immunocompromised). Pathogenesis: Primary infection (usually asymptomatic in immunocompetent) → latency (tissue cysts in brain, muscle) → reactivation (when CD4 <100 cells/μL or immunosuppression) → encephalitis (tachyzoites proliferate, cause necrosis, inflammation, ring-enhancing lesions).",
            "pathogenesis": "Reactivation of latent Toxoplasma tissue cysts (when CD4 <100 cells/μL or immunosuppression) → tachyzoites proliferate → brain parenchyma invasion → necrosis, inflammation, edema → ring-enhancing lesions (typically in basal ganglia, corticomedullary junction) → focal neurologic deficits, seizures, altered mental status. Host immune response: CD4 T-cells critical for control of latent infection (toxoplasma encephalitis occurs when CD4 <100 cells/μL). Complications: Seizures (30-40%), mass effect with herniation (10-20%), IRIS (10-20% in HIV/AIDS after starting ART).",
            "resistance_patterns": {
              "pyrimethamine_resistance": "Pyrimethamine resistance: Rare (<5%). Acquired resistance (after prolonged pyrimethamine exposure, especially if subtherapeutic doses or poor adherence). Treatment: Increase pyrimethamine dose (100mg PO daily) OR Switch to alternative therapy (TMP-SMX, clindamycin + pyrimethamine, atovaquone).",
              "sulfadiazine_resistance": "Sulfadiazine resistance: Rare (<5%). Treatment: Switch to alternative therapy (clindamycin 600mg PO/IV q6h + pyrimethamine + leucovorin OR TMP-SMX DS 2 tabs PO BID OR atovaquone 1500mg PO BID + pyrimethamine + leucovorin).",
              "tmp_smx_resistance": "TMP-SMX resistance: Rare (<5%). Treatment: Pyrimethamine + sulfadiazine + leucovorin (first-line) OR Clindamycin + pyrimethamine + leucovorin OR Atovaquone + pyrimethamine + leucovorin."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for brain biopsy if high clinical suspicion, mortality increases with delayed treatment). Acute therapy: Pyrimethamine 200mg PO x1 (loading), then 50-75mg PO daily + Sulfadiazine 1-1.5g PO QID + Leucovorin 10-25mg PO daily x 6 weeks. Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily (divided BID-QID) + Leucovorin 10-25mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Pyrimethamine 200mg PO x1 (loading), then 50-75mg PO daily (if weight <60 kg: 50mg daily, if weight ≥60 kg: 75mg daily) + Sulfadiazine 1-1.5g PO QID (if weight <60 kg: 1g QID, if weight ≥60 kg: 1.5g QID) + Leucovorin 10-25mg PO daily x 6 weeks (acute therapy). Leucovorin REQUIRED (prevents pyrimethamine-induced bone marrow suppression). Monitor CBC weekly (pyrimethamine toxicity: leukopenia, thrombocytopenia, anemia).",
            "alternative_first_line": "TMP-SMX DS (160/800mg) 2 tabs PO BID x 6 weeks (if pyrimethamine or sulfadiazine intolerance). Less effective than pyrimethamine + sulfadiazine (observational data suggest higher relapse rate). Alternative: Clindamycin 600mg PO/IV q6h + Pyrimethamine 200mg PO x1, then 50-75mg PO daily + Leucovorin 10-25mg PO daily x 6 weeks (if sulfadiazine intolerance). Alternative: Atovaquone 1500mg PO BID + Pyrimethamine 200mg PO x1, then 50-75mg PO daily + Leucovorin 10-25mg PO daily x 6 weeks (if sulfadiazine intolerance).",
            "adjunctive_therapy": "Antiepileptic drugs (if seizures, 30-40%): Levetiracetam 500-1000mg PO BID OR Phenytoin 300mg PO daily (avoid phenytoin if possible, drug interactions with pyrimethamine). Corticosteroids (if mass effect with herniation risk, 10-20%): Dexamethasone 4mg IV q6h (taper over 2-4 weeks as lesions improve). Avoid corticosteroids if no mass effect (may impair immune response, delay diagnosis).",
            "secondary_prophylaxis": "Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily (divided BID-QID) + Leucovorin 10-25mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS). Start secondary prophylaxis after completing 6 weeks of acute therapy. Alternative: TMP-SMX DS 1 tab PO daily (if pyrimethamine or sulfadiazine intolerance). Discontinue secondary prophylaxis when CD4 >200 cells/μL x 3 months on ART.",
            "avoid_list": "Avoid azithromycin monotherapy (ineffective for acute toxoplasma encephalitis, use only for primary prophylaxis). Avoid atovaquone monotherapy (less effective than pyrimethamine + sulfadiazine, use only in combination with pyrimethamine). Do NOT delay treatment while awaiting brain biopsy (mortality increases with delayed treatment). Do NOT use corticosteroids if no mass effect (may impair immune response, delay diagnosis)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_toxoplasma_encephalitis": "Acute therapy: Pyrimethamine 200mg PO x1 (loading), then 50-75mg PO daily + Sulfadiazine 1-1.5g PO QID + Leucovorin 10-25mg PO daily x 6 weeks. Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily (divided BID-QID) + Leucovorin 10-25mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS).",
            "hiv_aids_specific": "Acute therapy: 6 weeks. Start ART after 2 weeks of acute therapy (reduces IRIS risk). Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily + Leucovorin 10-25mg PO daily (until CD4 >200 cells/μL x 3 months on ART). Discontinue secondary prophylaxis when CD4 >200 cells/μL x 3 months on ART. IRIS: Worsening symptoms after starting ART (10-20%, usually 2-4 weeks after starting ART), requires corticosteroids (dexamethasone 4mg IV q6h, then taper over 4-6 weeks) + continue ART + continue anti-Toxoplasma therapy.",
            "sot_hsct_specific": "Acute therapy: 6 weeks. Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult. Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily + Leucovorin 10-25mg PO daily x 6-12 months (until resolution of immunosuppression).",
            "treatment_response": "Clinical improvement expected within 7-14 days (decreased headache, improved mental status, improved focal neurologic deficits). Repeat MRI brain at 2-4 weeks (decreased size of lesions, decreased mass effect, decreased enhancement). If no improvement after 10-14 days: Consider alternative diagnosis (CNS lymphoma, progressive multifocal leukoencephalopathy, other opportunistic infections) OR Brain biopsy (gold standard) OR Switch to alternative therapy (clindamycin + pyrimethamine + leucovorin, atovaquone + pyrimethamine + leucovorin).",
            "duration": "Acute therapy: 6 weeks. Secondary prophylaxis: Until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or 6-12 months (non-HIV). Total duration: Minimum 6-12 months (HIV/AIDS), 6-12 months (non-HIV)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Acute therapy: 6 weeks. Secondary prophylaxis: Until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or 6-12 months (non-HIV). Total duration: Minimum 6-12 months (HIV/AIDS), 6-12 months (non-HIV).",
            "monitoring": "Weekly: CBC (monitor for pyrimethamine toxicity: leukopenia WBC <3,000, thrombocytopenia platelets <50,000, anemia Hgb <8 g/dL). Clinical status (headache, mental status, focal neurologic deficits, seizures). At 2-4 weeks: Repeat MRI brain (assess for improvement: decreased size of lesions, decreased mass effect, decreased enhancement). At 6 weeks: Repeat MRI brain (confirm resolution or improvement before transitioning to secondary prophylaxis). Clinical improvement expected within 7-14 days (decreased headache, improved mental status, improved focal neurologic deficits).",
            "stop_criteria": "Discontinue acute therapy after 6 weeks + clinical improvement + MRI brain showing decreased lesions. Start secondary prophylaxis after completing acute therapy. Discontinue secondary prophylaxis when immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or after 6-12 months (non-HIV). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <100 cells/μL (most important risk factor, 90-95% of toxoplasma encephalitis). Acute therapy: 6 weeks. Start ART after 2 weeks of acute therapy (reduces IRIS risk). Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily + Leucovorin 10-25mg PO daily (until CD4 >200 cells/μL x 3 months on ART). IRIS: Worsening symptoms after starting ART (10-20%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART + continue anti-Toxoplasma therapy.",
            "sot_hsct": "Solid organ transplant (SOT, 5-10%, especially heart transplant, D+/R- highest risk). HSCT (rare <1%). Acute therapy: 6 weeks. Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult. Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily + Leucovorin 10-25mg PO daily x 6-12 months (until resolution of immunosuppression).",
            "pyrimethamine_toxicity": "Leukopenia (WBC <3,000, 20-30%), thrombocytopenia (platelets <50,000, 10-20%), anemia (Hgb <8 g/dL, 10-20%). Management: Leucovorin 10-25mg PO daily (REQUIRED, prevents bone marrow suppression). Monitor CBC weekly. If severe toxicity (WBC <1,000, platelets <25,000): Increase leucovorin dose (50mg PO daily) OR Reduce pyrimethamine dose (25mg PO daily) OR Switch to alternative therapy (TMP-SMX, clindamycin + pyrimethamine, atovaquone).",
            "sulfadiazine_intolerance": "Sulfadiazine intolerance (rash, fever, GI upset, 20-30%). Management: Switch to alternative therapy (clindamycin 600mg PO/IV q6h + pyrimethamine + leucovorin OR TMP-SMX DS 2 tabs PO BID OR atovaquone 1500mg PO BID + pyrimethamine + leucovorin).",
            "pregnancy": "Pyrimethamine: Teratogenic (folic acid antagonist), avoid in first trimester if possible (use only if life-threatening toxoplasma encephalitis). Sulfadiazine: Avoid in third trimester (risk of kernicterus in newborn). Spiramycin: Safe in pregnancy (use for primary prophylaxis in pregnancy, NOT for acute toxoplasma encephalitis). Infectious disease + obstetrics consult.",
            "counseling": "Toxoplasma encephalitis is life-threatening (mortality 10-20% with treatment, 50-70% if untreated). Treatment duration: Acute therapy 6 weeks, secondary prophylaxis until immune recovery (CD4 >200 cells/μL x 3 months on ART for HIV/AIDS) or 6-12 months (non-HIV). Total duration: Minimum 6-12 months. Clinical improvement expected within 7-14 days. Leucovorin REQUIRED (prevents pyrimethamine-induced bone marrow suppression). HIV/AIDS: Start ART after 2 weeks of acute therapy (immune recovery prevents relapse). Future: Lifelong ART + secondary prophylaxis until CD4 >200 cells/μL x 3 months."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for brain biopsy if high clinical suspicion, mortality increases with delayed treatment)",
              "Acute therapy: Pyrimethamine 200mg PO x1 (loading), then 50-75mg PO daily + Sulfadiazine 1-1.5g PO QID + Leucovorin 10-25mg PO daily x 6 weeks",
              "Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily + Leucovorin 10-25mg PO daily (until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS)",
              "Discontinue secondary prophylaxis when CD4 >200 cells/μL x 3 months on ART"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Headache + altered mental status + focal neurologic deficits + immunocompromised host + MRI brain showing multiple ring-enhancing lesions + positive serum Toxoplasma IgG)",
              "Are anti-Toxoplasma drugs started immediately? (Pyrimethamine + sulfadiazine + leucovorin)",
              "Is leucovorin prescribed? (REQUIRED, prevents pyrimethamine-induced bone marrow suppression)",
              "Is CBC monitored weekly? (Pyrimethamine toxicity: leukopenia, thrombocytopenia, anemia)",
              "Is repeat MRI brain performed at 2-4 weeks? (Assess for improvement: decreased size of lesions, decreased mass effect)",
              "Is ART started appropriately? (HIV/AIDS: Start ART after 2 weeks of acute therapy, reduces IRIS risk)",
              "Is secondary prophylaxis started after completing acute therapy? (Pyrimethamine + sulfadiazine + leucovorin until immune recovery)"
            ],
            "avoid_unnecessary_treatment": "Avoid azithromycin monotherapy (ineffective for acute toxoplasma encephalitis). Avoid atovaquone monotherapy (less effective than pyrimethamine + sulfadiazine). Do NOT delay treatment while awaiting brain biopsy. Do NOT use corticosteroids if no mass effect (may impair immune response). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse). Do NOT forget leucovorin (REQUIRED, prevents pyrimethamine-induced bone marrow suppression).",
            "diagnostic_stewardship": "Clinical diagnosis (headache + altered mental status + focal neurologic deficits + immunocompromised host + MRI brain showing multiple ring-enhancing lesions + positive serum Toxoplasma IgG). Serum Toxoplasma IgG (positive in 90-95% of toxoplasma encephalitis, negative makes toxoplasma encephalitis unlikely). Toxoplasma PCR in CSF (50-70% sensitive, 95-99% specific). Brain biopsy (gold standard, rarely performed due to high risk). Do NOT delay treatment while awaiting brain biopsy if high clinical suspicion.",
            "prevention": "Primary prophylaxis: TMP-SMX DS 1 tab PO daily (if HIV/AIDS CD4 <100 cells/μL + positive serum Toxoplasma IgG) until CD4 >200 cells/μL x 3 months on ART. Alternative: Dapsone 50mg PO daily + Pyrimethamine 50mg PO weekly + Leucovorin 25mg PO weekly OR Atovaquone 1500mg PO daily. Secondary prophylaxis: Pyrimethamine 25-50mg PO daily + Sulfadiazine 2-4g PO daily + Leucovorin 10-25mg PO daily (after toxoplasma encephalitis until immune recovery: CD4 >200 cells/μL x 3 months on ART for HIV/AIDS)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection (2009, Reaffirmed 2018)",
              "url": "https://academic.oup.com/cid/article/49/1/1/316441"
            },
            {
              "label": "WHO Guidelines on the Treatment of Toxoplasmosis (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "mycobacterium-avium-complex",
      "name": "Mycobacterium avium Complex (MAC)",
      "synonyms": [
        "MAC infection",
        "Disseminated MAC",
        "MAI"
      ],
      "icd10": [
        "A31.0",
        "A31.2"
      ],
      "severity": [
        "moderate",
        "severe"
      ],
      "shortDescription": "Disseminated opportunistic mycobacterial infection requiring azithromycin + ethambutol + rifabutin x 12 months (until immune recovery)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Disseminated opportunistic mycobacterial infection caused by Mycobacterium avium complex (MAC, includes M. avium and M. intracellulare). Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <50 cells/μL, 90-95% of disseminated MAC). Environmental organism (soil, water, food). Incidence: Rare in general population, common in HIV/AIDS (10-20% lifetime risk if CD4 <50 cells/μL and no prophylaxis). Mortality: 10-20% (with treatment + ART), 50-70% (if untreated).",
            "clinical_presentation": "Subacute onset (weeks to months): Fever (80-90%, persistent, high-grade), night sweats (60-70%), weight loss (50-60%), diarrhea (40-50%), abdominal pain (30-40%), hepatosplenomegaly (30-40%). Physical exam: Fever, cachexia, hepatosplenomegaly, lymphadenopathy (20-30%). Laboratory: Anemia (Hgb <10 g/dL, 70-80%), elevated alkaline phosphatase (60-70%), elevated LDH (50-60%). Complications: Bacteremia (90-95%, positive blood cultures), lymphadenitis (20-30%), hepatitis (10-20%), osteomyelitis (5-10%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + night sweats + weight loss + diarrhea + immunocompromised host (HIV/AIDS CD4 <50 cells/μL). Laboratory: Positive blood cultures (MAC, 90-95% sensitive, gold standard, requires 7-14 days to grow on mycobacterial culture). Definitive diagnosis: Positive blood cultures (MAC) OR Tissue biopsy (lymph node, bone marrow, liver) showing acid-fast bacilli (AFB) + positive MAC culture.",
            "risk_factors": [
              "HIV/AIDS with CD4 <50 cells/μL (most important risk factor, 90-95% of disseminated MAC)",
              "No MAC prophylaxis (azithromycin or clarithromycin, reduces MAC incidence by 70-80%)",
              "No ART (antiretroviral therapy, immune recovery prevents MAC)",
              "Advanced HIV/AIDS (CD4 <10 cells/μL, highest risk)"
            ],
            "red_flags": [
              "Severe anemia - Hgb <8 g/dL (30-40%), requires transfusion + azithromycin + ethambutol + rifabutin",
              "IRIS (immune reconstitution inflammatory syndrome) - worsening symptoms after starting ART (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART + continue MAC therapy",
              "Treatment failure - persistent fever despite MAC therapy x 4-8 weeks, consider drug resistance (macrolide resistance, rifamycin resistance) OR alternative diagnosis (tuberculosis, other opportunistic infections)",
              "Drug interactions - rifabutin interacts with protease inhibitors, NNRTIs (reduce rifabutin dose to 150mg daily or 3x weekly if on protease inhibitors)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + night sweats + weight loss + diarrhea + immunocompromised host (HIV/AIDS CD4 <50 cells/μL). Blood cultures for AFB (mycobacterial blood culture, 90-95% sensitive, gold standard, requires 7-14 days to grow). Tissue biopsy (lymph node, bone marrow, liver) if blood cultures negative.",
            "essential_tests": [
              "Blood cultures for AFB (mycobacterial blood culture): MAC (90-95% sensitive, gold standard). Requires 7-14 days to grow on mycobacterial culture. Turnaround: 7-14 days (preliminary), 14-21 days (final identification + susceptibility).",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, MAC risk if CD4 <50 cells/μL). Turnaround: 1-2 days.",
              "CBC: Anemia (Hgb <10 g/dL, 70-80%). Turnaround: 1-2 hours.",
              "Alkaline phosphatase: Elevated (60-70%). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "Tissue biopsy (lymph node, bone marrow, liver): Acid-fast bacilli (AFB) on stain + positive MAC culture. Indications: Negative blood cultures + high clinical suspicion. Turnaround: 7-14 days (culture), 1-2 days (AFB stain).",
              "Chest X-ray: Pulmonary MAC (rare in HIV/AIDS, more common in non-HIV immunocompromised or structural lung disease). Nodules, infiltrates, cavitation. Turnaround: Same day.",
              "CT abdomen/pelvis: Hepatosplenomegaly (30-40%), lymphadenopathy (20-30%), mesenteric lymphadenopathy (10-20%). Turnaround: Same day.",
              "Susceptibility testing: Macrolide MIC (azithromycin, clarithromycin), rifamycin MIC (rifabutin). Turnaround: 14-21 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting blood cultures if high clinical suspicion (start empiric azithromycin + ethambutol + rifabutin, mortality increases with delayed treatment). Do NOT confuse MAC with tuberculosis (MAC does NOT require respiratory isolation, NOT transmitted person-to-person).",
            "turnaround_time": "Blood cultures for AFB: 7-14 days (preliminary), 14-21 days (final identification + susceptibility). HIV testing: 1-2 days. CD4 count: 1-2 days. CBC: 1-2 hours. Alkaline phosphatase: 1-2 hours. Tissue biopsy: 7-14 days (culture), 1-2 days (AFB stain). Susceptibility testing: 14-21 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Mycobacterium avium complex (MAC, includes M. avium and M. intracellulare). Non-tuberculous mycobacteria (NTM). Environmental organism (soil, water, food, biofilms). Transmission: Ingestion or inhalation (NOT transmitted person-to-person, NO respiratory isolation required). Pathogenesis: Ingestion/inhalation → GI tract colonization → dissemination (if CD4 <50 cells/μL) → bacteremia, hepatosplenomegaly, lymphadenitis. Host immune response: CD4 T-cells critical for control (disseminated MAC occurs when CD4 <50 cells/μL). Complications: Bacteremia (90-95%), lymphadenitis (20-30%), hepatitis (10-20%), osteomyelitis (5-10%), IRIS (10-30% after starting ART).",
            "pathogenesis": "Ingestion or inhalation of MAC → GI tract colonization → dissemination (if CD4 <50 cells/μL) → bacteremia (90-95%, positive blood cultures) → hepatosplenomegaly (30-40%), lymphadenitis (20-30%), hepatitis (10-20%), osteomyelitis (5-10%). Host immune response: CD4 T-cells critical for control (disseminated MAC occurs when CD4 <50 cells/μL). Complications: Severe anemia (Hgb <8 g/dL, 30-40%), IRIS (10-30% after starting ART, worsening symptoms, requires corticosteroids).",
            "resistance_patterns": {
              "macrolide_resistance": "Macrolide resistance (azithromycin, clarithromycin): Acquired resistance (after prolonged macrolide monotherapy, 10-20%). Risk factors: Macrolide monotherapy (always use combination therapy), subtherapeutic levels, poor adherence. Treatment: Amikacin 10-15mg/kg IV daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily + Moxifloxacin 400mg PO daily (if macrolide-resistant MAC). Infectious disease consult REQUIRED.",
              "rifamycin_resistance": "Rifamycin resistance (rifabutin): Rare (<5%). Treatment: Azithromycin 500mg PO daily + Ethambutol 15mg/kg PO daily + Moxifloxacin 400mg PO daily (if rifabutin-resistant MAC).",
              "ethambutol_resistance": "Ethambutol resistance: Rare (<5%). Treatment: Azithromycin 500mg PO daily + Rifabutin 300mg PO daily + Moxifloxacin 400mg PO daily (if ethambutol-resistant MAC)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for susceptibility testing, mortality increases with delayed treatment). Azithromycin 500mg PO daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily x 12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART). Start ART after 2 weeks of MAC therapy (reduces IRIS risk). Continue MAC therapy until immune recovery (CD4 >100 cells/μL x 6 months on ART) + negative blood cultures x 12 months."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Azithromycin 500mg PO daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily x 12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months). Start ART after 2 weeks of MAC therapy (reduces IRIS risk). Monitor for drug interactions (rifabutin interacts with protease inhibitors, NNRTIs, reduce rifabutin dose to 150mg daily or 3x weekly if on protease inhibitors).",
            "alternative_first_line": "Clarithromycin 500mg PO BID + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily x 12 months (if azithromycin intolerance). Clarithromycin has more drug interactions than azithromycin (CYP3A4 inhibitor). Monitor for QTc prolongation (clarithromycin).",
            "severe_disease": "Azithromycin 500mg PO daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily + Amikacin 10-15mg/kg IV daily (if severe disease: CD4 <10 cells/μL, high mycobacterial load >2 log CFU/mL, severe symptoms). Continue amikacin x 4-8 weeks (until clinical improvement), then continue azithromycin + ethambutol + rifabutin x 12 months. Monitor for amikacin toxicity (nephrotoxicity, ototoxicity, check creatinine and audiometry weekly).",
            "secondary_prophylaxis": "Azithromycin 500mg PO daily (after completing 12 months of MAC therapy, continue until immune recovery: CD4 >100 cells/μL x 6 months on ART). Discontinue secondary prophylaxis when CD4 >100 cells/μL x 6 months on ART.",
            "avoid_list": "Avoid macrolide monotherapy (rapid resistance development, always use combination therapy). Avoid rifampin (less active than rifabutin against MAC, more drug interactions). Do NOT delay treatment while awaiting susceptibility testing (mortality increases with delayed treatment). Do NOT confuse MAC with tuberculosis (MAC does NOT require respiratory isolation)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_mac": "Azithromycin 500mg PO daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily x 12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months). Start ART after 2 weeks of MAC therapy (reduces IRIS risk). Continue MAC therapy until immune recovery + negative blood cultures x 12 months.",
            "hiv_aids_specific": "Start ART after 2 weeks of MAC therapy (reduces IRIS risk). Continue MAC therapy until immune recovery (CD4 >100 cells/μL x 6 months on ART) + negative blood cultures x 12 months. Secondary prophylaxis: Azithromycin 500mg PO daily (after completing 12 months of MAC therapy, continue until CD4 >100 cells/μL x 6 months on ART). IRIS: Worsening symptoms after starting ART (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids (prednisone 20-40mg PO daily, then taper over 4-6 weeks) + continue ART + continue MAC therapy.",
            "macrolide_resistant_mac": "Amikacin 10-15mg/kg IV daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily + Moxifloxacin 400mg PO daily x 12 months (if macrolide-resistant MAC confirmed by susceptibility testing). Infectious disease consult REQUIRED. Monitor for amikacin toxicity (nephrotoxicity, ototoxicity, check creatinine and audiometry weekly).",
            "treatment_response": "Clinical improvement expected within 4-8 weeks (decreased fever, weight gain, improved symptoms). Repeat blood cultures at 4-8 weeks (should be negative, if persistently positive → consider drug resistance or alternative diagnosis). If no improvement after 4-8 weeks: Check susceptibility testing (macrolide MIC, rifamycin MIC). Consider alternative diagnosis (tuberculosis, other opportunistic infections). Infectious disease consult.",
            "duration": "12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months). Secondary prophylaxis: Azithromycin 500mg PO daily (after completing 12 months of MAC therapy, continue until CD4 >100 cells/μL x 6 months on ART)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months). Secondary prophylaxis: Azithromycin 500mg PO daily (after completing 12 months of MAC therapy, continue until CD4 >100 cells/μL x 6 months on ART). Total duration: Minimum 12-18 months.",
            "monitoring": "Monthly: Blood cultures for AFB (should be negative after 4-8 weeks of therapy, if persistently positive → consider drug resistance). CBC (monitor for anemia, should improve with treatment). Alkaline phosphatase (should decrease with treatment). Clinical status (fever, weight, symptoms). Every 3 months: CD4 count (monitor for immune recovery, goal CD4 >100 cells/μL x 6 months on ART). Weekly (if on amikacin): Creatinine (monitor for nephrotoxicity). Audiometry (monitor for ototoxicity). Clinical improvement expected within 4-8 weeks (decreased fever, weight gain, improved symptoms).",
            "stop_criteria": "Discontinue MAC therapy after 12 months + immune recovery (CD4 >100 cells/μL x 6 months on ART) + negative blood cultures x 12 months. Start secondary prophylaxis (azithromycin 500mg PO daily) after completing MAC therapy. Discontinue secondary prophylaxis when CD4 >100 cells/μL x 6 months on ART. Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <50 cells/μL (most important risk factor, 90-95% of disseminated MAC). Start ART after 2 weeks of MAC therapy (reduces IRIS risk). Continue MAC therapy until immune recovery (CD4 >100 cells/μL x 6 months on ART) + negative blood cultures x 12 months. IRIS: Worsening symptoms after starting ART (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids (prednisone 20-40mg PO daily, then taper over 4-6 weeks) + continue ART + continue MAC therapy.",
            "drug_interactions": "Rifabutin interacts with protease inhibitors, NNRTIs (CYP3A4 inducer). Reduce rifabutin dose to 150mg PO daily or 3x weekly if on protease inhibitors (ritonavir, atazanavir, darunavir). Increase rifabutin dose to 450-600mg PO daily if on efavirenz (NNRTI, CYP3A4 inducer). Monitor for rifabutin toxicity (uveitis, arthralgia, leukopenia). Clarithromycin interacts with protease inhibitors (CYP3A4 inhibitor), prefer azithromycin (no CYP3A4 interaction).",
            "ethambutol_toxicity": "Optic neuritis (1-2%, dose-dependent, reversible if caught early). Monitor visual acuity and color vision monthly (Ishihara color plates). Discontinue ethambutol if visual changes (blurred vision, decreased color vision, scotomas). Alternative: Moxifloxacin 400mg PO daily (if ethambutol toxicity).",
            "rifabutin_toxicity": "Uveitis (1-2%, dose-dependent, reversible). Arthralgia (5-10%). Leukopenia (10-20%). Monitor CBC monthly. Discontinue rifabutin if severe toxicity (uveitis, severe leukopenia WBC <1,000). Alternative: Moxifloxacin 400mg PO daily (if rifabutin toxicity).",
            "pregnancy": "Azithromycin: Safe in pregnancy. Ethambutol: Safe in pregnancy. Rifabutin: Limited data, use only if life-threatening MAC. Clarithromycin: Avoid in pregnancy (teratogenic in animals). Infectious disease + obstetrics consult.",
            "counseling": "Disseminated MAC is life-threatening (mortality 10-20% with treatment + ART, 50-70% if untreated). Treatment duration: 12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months). Clinical improvement expected within 4-8 weeks (decreased fever, weight gain). HIV/AIDS: Start ART after 2 weeks of MAC therapy (immune recovery prevents relapse). Future: Lifelong ART + secondary prophylaxis (azithromycin 500mg PO daily) until CD4 >100 cells/μL x 6 months on ART. MAC is NOT contagious (NO respiratory isolation required)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for susceptibility testing, mortality increases with delayed treatment)",
              "Azithromycin 500mg PO daily + Ethambutol 15mg/kg PO daily + Rifabutin 300mg PO daily x 12 months (until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months)",
              "Start ART after 2 weeks of MAC therapy (reduces IRIS risk)",
              "Secondary prophylaxis: Azithromycin 500mg PO daily (after completing 12 months of MAC therapy, continue until CD4 >100 cells/μL x 6 months on ART)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + night sweats + weight loss + diarrhea + immunocompromised host + positive blood cultures for MAC)",
              "Are MAC drugs started immediately? (Azithromycin + ethambutol + rifabutin)",
              "Are blood cultures repeated at 4-8 weeks? (Should be negative, if persistently positive → consider drug resistance)",
              "Is ART started appropriately? (HIV/AIDS: Start ART after 2 weeks of MAC therapy, reduces IRIS risk)",
              "Are drug interactions monitored? (Rifabutin interacts with protease inhibitors, NNRTIs, adjust dose)",
              "Is visual acuity monitored monthly? (Ethambutol toxicity: optic neuritis)",
              "Is treatment duration appropriate? (12 months until immune recovery: CD4 >100 cells/μL x 6 months on ART + negative blood cultures x 12 months)"
            ],
            "avoid_unnecessary_treatment": "Avoid macrolide monotherapy (rapid resistance development, always use combination therapy). Avoid rifampin (less active than rifabutin against MAC). Do NOT delay treatment while awaiting susceptibility testing. Do NOT confuse MAC with tuberculosis (MAC does NOT require respiratory isolation, NOT transmitted person-to-person). Do NOT stop treatment early (increases relapse risk, mortality 50-70% if relapse).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + night sweats + weight loss + diarrhea + immunocompromised host). Blood cultures for AFB (mycobacterial blood culture, 90-95% sensitive, gold standard, requires 7-14 days to grow). Tissue biopsy (lymph node, bone marrow, liver) if blood cultures negative. Do NOT delay treatment while awaiting blood cultures if high clinical suspicion.",
            "prevention": "Primary prophylaxis: Azithromycin 1200mg PO weekly OR Clarithromycin 500mg PO BID (if HIV/AIDS CD4 <50 cells/μL) until CD4 >100 cells/μL x 3 months on ART. Secondary prophylaxis: Azithromycin 500mg PO daily (after disseminated MAC until immune recovery: CD4 >100 cells/μL x 6 months on ART). Discontinue prophylaxis when CD4 >100 cells/μL x 6 months on ART."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases (2007, Reaffirmed 2020)",
              "url": "https://www.atsjournals.org/doi/full/10.1164/rccm.200604-571ST"
            },
            {
              "label": "WHO Guidelines on the Treatment of Mycobacterium avium Complex (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "nocardiosis",
      "name": "Nocardiosis",
      "synonyms": [
        "Nocardia infection",
        "Disseminated nocardiosis"
      ],
      "icd10": [
        "A43.9",
        "A43.0",
        "A43.1"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Opportunistic bacterial infection requiring TMP-SMX DS 2-3 tabs PO TID x 6-12 months, often with CNS involvement",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Opportunistic bacterial infection caused by Nocardia species (N. asteroides, N. brasiliensis, N. farcinica). Aerobic, gram-positive, weakly acid-fast, filamentous bacteria. Environmental organism (soil, water, decaying vegetation). Transmission: Inhalation (pulmonary nocardiosis, 70-80%) OR Direct inoculation (cutaneous nocardiosis, 10-20%). Occurs in immunocompromised hosts: Solid organ transplant (SOT, 40-50%), prolonged corticosteroids (30-40%), HIV/AIDS (10-20%), malignancy (10-20%). Incidence: Rare (0.5-1 per 100,000 per year). Mortality: 20-40% (with treatment), 50-70% (if CNS involvement or delayed treatment).",
            "clinical_presentation": "Pulmonary nocardiosis (70-80%): Subacute onset (weeks to months), cough (60-70%), fever (50-60%), dyspnea (40-50%), chest pain (30-40%), weight loss (30-40%). Chest X-ray: Nodules (50-60%), infiltrates (40-50%), cavitation (20-30%), pleural effusion (10-20%). CNS nocardiosis (30-40%, often with pulmonary nocardiosis): Headache (50-60%), altered mental status (40-50%), focal neurologic deficits (30-40%), seizures (20-30%). MRI brain: Ring-enhancing lesions (abscesses, 80-90%), multiple lesions (50-60%). Cutaneous nocardiosis (10-20%): Cellulitis, abscess, lymphocutaneous syndrome (sporotrichoid pattern). Disseminated nocardiosis (20-30%): Multiple organ involvement (lungs + CNS + skin).",
            "diagnostic_criteria": "Clinical diagnosis: Cough + fever + dyspnea + immunocompromised host + chest X-ray showing nodules/infiltrates/cavitation. Laboratory: Positive sputum culture (Nocardia, 50-70% sensitive) OR Positive blood culture (Nocardia, 10-20% sensitive, indicates disseminated disease) OR Positive tissue culture (lung biopsy, brain biopsy, skin biopsy, 80-90% sensitive, gold standard). Definitive diagnosis: Positive culture (Nocardia) from any site.",
            "risk_factors": [
              "Solid organ transplant (SOT, 40-50%, most important risk factor)",
              "Prolonged corticosteroids (>10mg prednisone daily x >1 month, 30-40%)",
              "HIV/AIDS (CD4 <200 cells/μL, 10-20%)",
              "Malignancy (especially hematologic malignancies, 10-20%)",
              "Chronic lung disease (COPD, bronchiectasis, 10-20%)"
            ],
            "red_flags": [
              "CNS involvement - brain abscesses (30-40%, often with pulmonary nocardiosis), requires MRI brain + TMP-SMX DS 2-3 tabs PO TID x 12 months (longer duration than pulmonary nocardiosis alone)",
              "Disseminated disease - multiple organ involvement (lungs + CNS + skin, 20-30%), requires TMP-SMX DS 2-3 tabs PO TID + imipenem OR amikacin x 4-6 weeks, then TMP-SMX x 12 months",
              "Treatment failure - persistent fever despite TMP-SMX x 4-8 weeks, consider drug resistance (TMP-SMX resistance 10-20%) OR alternative diagnosis (tuberculosis, fungal infection)",
              "TMP-SMX intolerance - rash, fever, GI upset (20-30%), requires alternative therapy (imipenem, amikacin, linezolid, ceftriaxone)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Cough + fever + dyspnea + immunocompromised host + chest X-ray showing nodules/infiltrates/cavitation. Sputum culture (Nocardia, 50-70% sensitive). Blood culture (Nocardia, 10-20% sensitive). Tissue culture (lung biopsy, brain biopsy, skin biopsy, 80-90% sensitive, gold standard). MRI brain (if headache, altered mental status, focal neurologic deficits, seizures, rule out CNS involvement).",
            "essential_tests": [
              "Chest X-ray: Nodules (50-60%), infiltrates (40-50%), cavitation (20-30%), pleural effusion (10-20%). Turnaround: Same day.",
              "Sputum culture (bacterial culture + AFB culture): Nocardia (50-70% sensitive, requires 3-7 days to grow, weakly acid-fast on AFB stain). Turnaround: 3-7 days (preliminary), 7-14 days (final identification + susceptibility).",
              "Blood culture: Nocardia (10-20% sensitive, indicates disseminated disease). Turnaround: 3-7 days (preliminary), 7-14 days (final identification)."
            ],
            "conditional_tests": [
              "CT chest: Nodules (50-60%), infiltrates (40-50%), cavitation (20-30%), pleural effusion (10-20%). More sensitive than chest X-ray. Turnaround: Same day.",
              "MRI brain (with contrast): Ring-enhancing lesions (abscesses, 80-90%), multiple lesions (50-60%). Indications: Headache, altered mental status, focal neurologic deficits, seizures (rule out CNS involvement, 30-40% of nocardiosis). Turnaround: Same day.",
              "Tissue biopsy (lung biopsy, brain biopsy, skin biopsy): Nocardia on culture (80-90% sensitive, gold standard). Gram stain: Gram-positive, filamentous, branching bacteria. AFB stain: Weakly acid-fast. Turnaround: 3-7 days (culture), 1-2 days (stain).",
              "Susceptibility testing: TMP-SMX MIC, imipenem MIC, amikacin MIC, linezolid MIC, ceftriaxone MIC. Turnaround: 7-14 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting culture if high clinical suspicion (start empiric TMP-SMX DS 2-3 tabs PO TID, mortality increases with delayed treatment). Do NOT confuse Nocardia with tuberculosis (Nocardia is weakly acid-fast, but NOT Mycobacterium tuberculosis, requires different treatment).",
            "turnaround_time": "Chest X-ray: Same day. Sputum culture: 3-7 days (preliminary), 7-14 days (final identification + susceptibility). Blood culture: 3-7 days (preliminary), 7-14 days (final identification). CT chest: Same day. MRI brain: Same day. Tissue biopsy: 3-7 days (culture), 1-2 days (stain). Susceptibility testing: 7-14 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Nocardia species (N. asteroides complex 50-60%, N. brasiliensis 10-20%, N. farcinica 10-20%, N. nova 5-10%). Aerobic, gram-positive, weakly acid-fast, filamentous, branching bacteria. Environmental organism (soil, water, decaying vegetation). Transmission: Inhalation (pulmonary nocardiosis, 70-80%) OR Direct inoculation (cutaneous nocardiosis, 10-20%). Pathogenesis: Inhalation → pulmonary infection (nodules, infiltrates, cavitation) → hematogenous dissemination (if immunocompromised) → CNS (brain abscesses, 30-40%), skin (cellulitis, abscess, 10-20%), other organs (kidney, liver, spleen, 5-10%). Host immune response: Cell-mediated immunity critical for control (nocardiosis occurs in immunocompromised hosts).",
            "pathogenesis": "Inhalation of Nocardia → pulmonary infection (nodules, infiltrates, cavitation, 70-80%) → hematogenous dissemination (if immunocompromised) → CNS (brain abscesses, 30-40%, often with pulmonary nocardiosis), skin (cellulitis, abscess, 10-20%), other organs (kidney, liver, spleen, 5-10%). Host immune response: Cell-mediated immunity critical for control (nocardiosis occurs in immunocompromised hosts: SOT, prolonged corticosteroids, HIV/AIDS, malignancy). Complications: CNS abscesses (30-40%, mortality 40-60%), disseminated disease (20-30%, mortality 50-70%).",
            "resistance_patterns": {
              "tmp_smx_resistance": "TMP-SMX resistance: 10-20% (varies by species, N. farcinica 30-40% resistant). Treatment: Imipenem 500mg IV q6h + Amikacin 15mg/kg IV daily x 4-6 weeks, then Linezolid 600mg PO BID x 6-12 months (if TMP-SMX-resistant Nocardia). Infectious disease consult REQUIRED.",
              "imipenem_resistance": "Imipenem resistance: 5-10%. Treatment: Amikacin 15mg/kg IV daily + Linezolid 600mg PO BID x 4-6 weeks, then Linezolid 600mg PO BID x 6-12 months (if imipenem-resistant Nocardia).",
              "multidrug_resistance": "Multidrug-resistant Nocardia (resistant to TMP-SMX + imipenem + amikacin): Rare (<5%). Treatment: Linezolid 600mg PO BID + Ceftriaxone 2g IV daily x 4-6 weeks, then Linezolid 600mg PO BID x 6-12 months. Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for susceptibility testing, mortality increases with delayed treatment). TMP-SMX DS 2-3 tabs PO TID x 6-12 months (pulmonary nocardiosis without CNS involvement) OR x 12 months (CNS involvement or disseminated disease). Screen for CNS involvement (MRI brain) in all patients with nocardiosis (30-40% have CNS involvement, often asymptomatic initially)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "TMP-SMX DS (160/800mg) 2-3 tabs PO TID (high-dose, 10-15mg/kg/day TMP component) x 6-12 months (pulmonary nocardiosis without CNS involvement) OR x 12 months (CNS involvement or disseminated disease). Screen for CNS involvement (MRI brain) in all patients with nocardiosis (30-40% have CNS involvement, often asymptomatic initially). Monitor for TMP-SMX toxicity (rash, fever, GI upset, hyperkalemia, bone marrow suppression, check CBC and electrolytes weekly).",
            "severe_disease": "TMP-SMX DS 2-3 tabs PO TID + Imipenem 500mg IV q6h OR Amikacin 15mg/kg IV daily x 4-6 weeks (if severe disease: CNS involvement, disseminated disease, critically ill), then TMP-SMX DS 2-3 tabs PO TID x 12 months. Monitor for imipenem toxicity (seizures, especially if CNS involvement or renal impairment). Monitor for amikacin toxicity (nephrotoxicity, ototoxicity, check creatinine and audiometry weekly).",
            "alternative_first_line": "Imipenem 500mg IV q6h + Amikacin 15mg/kg IV daily x 4-6 weeks, then Linezolid 600mg PO BID x 6-12 months (if TMP-SMX intolerance or TMP-SMX-resistant Nocardia). Alternative: Ceftriaxone 2g IV daily + Amikacin 15mg/kg IV daily x 4-6 weeks, then Linezolid 600mg PO BID x 6-12 months. Monitor for linezolid toxicity (bone marrow suppression, peripheral neuropathy, optic neuritis, check CBC weekly, monitor visual acuity monthly).",
            "cns_involvement": "TMP-SMX DS 2-3 tabs PO TID + Imipenem 500mg IV q6h OR Amikacin 15mg/kg IV daily x 4-6 weeks (induction), then TMP-SMX DS 2-3 tabs PO TID x 12 months (consolidation). Duration: 12 months (CNS involvement requires longer duration than pulmonary nocardiosis alone). Neurosurgery consult (consider surgical drainage if large abscess >2 cm or mass effect). Repeat MRI brain at 4-6 weeks (assess for improvement).",
            "avoid_list": "Avoid monotherapy (always use combination therapy for severe disease: CNS involvement, disseminated disease). Avoid short duration (<6 months, increases relapse risk 30-40%). Do NOT delay treatment while awaiting susceptibility testing (mortality increases with delayed treatment). Do NOT skip MRI brain (30-40% have CNS involvement, often asymptomatic initially)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_nocardiosis": "TMP-SMX DS 2-3 tabs PO TID x 6-12 months (pulmonary nocardiosis without CNS involvement) OR x 12 months (CNS involvement or disseminated disease). Adjust based on susceptibility testing (TMP-SMX MIC, imipenem MIC, amikacin MIC, linezolid MIC). Screen for CNS involvement (MRI brain) in all patients with nocardiosis.",
            "pulmonary_nocardiosis": "TMP-SMX DS 2-3 tabs PO TID x 6-12 months (if no CNS involvement). Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms). Repeat chest X-ray at 4-6 weeks (assess for improvement: decreased nodules, infiltrates). Duration: 6-12 months (minimum 6 months, extend to 12 months if slow response or severe disease).",
            "cns_nocardiosis": "TMP-SMX DS 2-3 tabs PO TID + Imipenem 500mg IV q6h OR Amikacin 15mg/kg IV daily x 4-6 weeks (induction), then TMP-SMX DS 2-3 tabs PO TID x 12 months (consolidation). Duration: 12 months (CNS involvement requires longer duration). Neurosurgery consult (consider surgical drainage if large abscess >2 cm or mass effect). Repeat MRI brain at 4-6 weeks (assess for improvement: decreased size of abscesses, decreased enhancement).",
            "tmp_smx_resistant_nocardiosis": "Imipenem 500mg IV q6h + Amikacin 15mg/kg IV daily x 4-6 weeks, then Linezolid 600mg PO BID x 6-12 months (if TMP-SMX-resistant Nocardia confirmed by susceptibility testing). Infectious disease consult REQUIRED. Monitor for linezolid toxicity (bone marrow suppression, peripheral neuropathy, optic neuritis, check CBC weekly, monitor visual acuity monthly).",
            "treatment_response": "Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms). Repeat chest X-ray at 4-6 weeks (assess for improvement: decreased nodules, infiltrates). Repeat MRI brain at 4-6 weeks (if CNS involvement, assess for improvement: decreased size of abscesses). If no improvement after 4-8 weeks: Check susceptibility testing (TMP-SMX MIC, imipenem MIC, amikacin MIC, linezolid MIC). Consider alternative diagnosis (tuberculosis, fungal infection). Infectious disease consult.",
            "duration": "Pulmonary nocardiosis (no CNS involvement): 6-12 months. CNS nocardiosis or disseminated disease: 12 months. Minimum duration: 6 months (pulmonary), 12 months (CNS or disseminated). Extend duration if slow response or severe disease."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Pulmonary nocardiosis (no CNS involvement): 6-12 months. CNS nocardiosis or disseminated disease: 12 months. Minimum duration: 6 months (pulmonary), 12 months (CNS or disseminated). Extend duration if slow response or severe disease.",
            "monitoring": "Weekly (first 4-8 weeks): CBC (monitor for TMP-SMX toxicity: leukopenia, thrombocytopenia, anemia). Electrolytes (monitor for hyperkalemia, TMP-SMX inhibits potassium excretion). Creatinine (monitor for nephrotoxicity if on amikacin). Clinical status (fever, symptoms). At 4-6 weeks: Repeat chest X-ray (assess for improvement: decreased nodules, infiltrates). Repeat MRI brain (if CNS involvement, assess for improvement: decreased size of abscesses). Monthly: CBC (monitor for TMP-SMX toxicity or linezolid toxicity). Visual acuity (if on linezolid, monitor for optic neuritis). Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms).",
            "stop_criteria": "Discontinue treatment after 6-12 months (pulmonary nocardiosis) or 12 months (CNS or disseminated disease) + clinical improvement + radiologic improvement (chest X-ray, MRI brain). Do NOT stop treatment early (increases relapse risk 30-40%, mortality 50-70% if relapse). Extend duration if slow response or severe disease."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "cns_involvement": "Brain abscesses (30-40%, often with pulmonary nocardiosis, often asymptomatic initially). Screen for CNS involvement (MRI brain) in all patients with nocardiosis. Treatment: TMP-SMX DS 2-3 tabs PO TID + Imipenem 500mg IV q6h OR Amikacin 15mg/kg IV daily x 4-6 weeks, then TMP-SMX DS 2-3 tabs PO TID x 12 months. Duration: 12 months (CNS involvement requires longer duration). Neurosurgery consult (consider surgical drainage if large abscess >2 cm or mass effect). Repeat MRI brain at 4-6 weeks (assess for improvement).",
            "sot": "Solid organ transplant (SOT, 40-50%, most important risk factor). Reduce immunosuppression if possible (taper tacrolimus, mycophenolate). Infectious disease + transplant consult. Treatment: TMP-SMX DS 2-3 tabs PO TID x 6-12 months (pulmonary) or x 12 months (CNS or disseminated). Screen for CNS involvement (MRI brain) in all SOT patients with nocardiosis.",
            "tmp_smx_toxicity": "Rash (20-30%), fever (10-20%), GI upset (nausea, vomiting, 20-30%), hyperkalemia (10-20%, TMP-SMX inhibits potassium excretion), bone marrow suppression (leukopenia, thrombocytopenia, anemia, 10-20%). Management: Monitor CBC and electrolytes weekly. If severe toxicity (WBC <1,000, platelets <25,000, K >6 mEq/L): Switch to alternative therapy (imipenem + amikacin, then linezolid).",
            "linezolid_toxicity": "Bone marrow suppression (leukopenia, thrombocytopenia, anemia, 20-30%, dose-dependent, duration-dependent). Peripheral neuropathy (10-20%, duration-dependent, may be irreversible). Optic neuritis (1-2%, duration-dependent, reversible if caught early). Management: Monitor CBC weekly. Monitor visual acuity monthly (Ishihara color plates). Discontinue linezolid if severe toxicity (WBC <1,000, platelets <25,000, visual changes). Alternative: Ceftriaxone 2g IV daily.",
            "pregnancy": "TMP-SMX: Avoid in first trimester (folic acid antagonist, teratogenic) and third trimester (risk of kernicterus in newborn). Use only if life-threatening nocardiosis. Imipenem: Limited data, use only if life-threatening nocardiosis. Amikacin: Avoid in pregnancy (ototoxic to fetus). Linezolid: Limited data, use only if life-threatening nocardiosis. Infectious disease + obstetrics consult.",
            "counseling": "Nocardiosis is life-threatening (mortality 20-40% with treatment, 50-70% if CNS involvement or delayed treatment). Treatment duration: 6-12 months (pulmonary nocardiosis) or 12 months (CNS or disseminated disease). Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms). Screen for CNS involvement (MRI brain) in all patients with nocardiosis (30-40% have CNS involvement, often asymptomatic initially). Do NOT stop treatment early (increases relapse risk 30-40%). Future: Reduce immunosuppression if possible (taper corticosteroids, reduce tacrolimus)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for susceptibility testing, mortality increases with delayed treatment)",
              "TMP-SMX DS 2-3 tabs PO TID x 6-12 months (pulmonary nocardiosis without CNS involvement) OR x 12 months (CNS involvement or disseminated disease)",
              "Screen for CNS involvement (MRI brain) in all patients with nocardiosis (30-40% have CNS involvement, often asymptomatic initially)",
              "Adjust based on susceptibility testing (TMP-SMX MIC, imipenem MIC, amikacin MIC, linezolid MIC)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Cough + fever + dyspnea + immunocompromised host + chest X-ray showing nodules/infiltrates/cavitation + positive culture for Nocardia)",
              "Is TMP-SMX started immediately? (TMP-SMX DS 2-3 tabs PO TID, high-dose)",
              "Is MRI brain performed? (Screen for CNS involvement in all patients with nocardiosis, 30-40% have CNS involvement)",
              "Is CBC and electrolytes monitored weekly? (TMP-SMX toxicity: leukopenia, thrombocytopenia, hyperkalemia)",
              "Is repeat chest X-ray performed at 4-6 weeks? (Assess for improvement: decreased nodules, infiltrates)",
              "Is repeat MRI brain performed at 4-6 weeks? (If CNS involvement, assess for improvement: decreased size of abscesses)",
              "Is treatment duration appropriate? (6-12 months for pulmonary, 12 months for CNS or disseminated)"
            ],
            "avoid_unnecessary_treatment": "Avoid monotherapy (always use combination therapy for severe disease: CNS involvement, disseminated disease). Avoid short duration (<6 months, increases relapse risk 30-40%). Do NOT delay treatment while awaiting susceptibility testing. Do NOT skip MRI brain (30-40% have CNS involvement, often asymptomatic initially). Do NOT stop treatment early (increases relapse risk 30-40%, mortality 50-70% if relapse).",
            "diagnostic_stewardship": "Clinical diagnosis (cough + fever + dyspnea + immunocompromised host + chest X-ray showing nodules/infiltrates/cavitation). Sputum culture (Nocardia, 50-70% sensitive). Blood culture (Nocardia, 10-20% sensitive). Tissue culture (lung biopsy, brain biopsy, skin biopsy, 80-90% sensitive, gold standard). MRI brain (screen for CNS involvement in all patients with nocardiosis). Do NOT delay treatment while awaiting culture if high clinical suspicion.",
            "prevention": "No specific prophylaxis. Reduce immunosuppression if possible (taper corticosteroids, reduce tacrolimus). Avoid exposure to soil, water, decaying vegetation (if severely immunocompromised)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections (2023)",
              "url": "https://www.cdc.gov/hai/organisms/nocardia.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Nocardiosis (2021)",
              "url": "https://academic.oup.com/cid/article/72/11/e913/6131384"
            },
            {
              "label": "AST Consensus Conference on the Treatment of Nocardiosis in Solid Organ Transplant Recipients (2019)",
              "url": "https://www.astjournals.com/doi/10.1111/ajt.15309"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "bk-virus-nephropathy",
      "name": "BK Virus Nephropathy",
      "synonyms": [
        "BK polyomavirus nephropathy",
        "BKVN"
      ],
      "icd10": [
        "N15.9",
        "B34.1"
      ],
      "severity": [
        "moderate",
        "severe"
      ],
      "shortDescription": "Opportunistic viral infection in kidney transplant recipients requiring reduction of immunosuppression, no proven antiviral therapy",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Opportunistic viral infection caused by BK polyomavirus (BKV). Occurs almost exclusively in kidney transplant recipients (80-90% of BK virus nephropathy). Seroprevalence: 80-90% of adults (latent infection in kidney, reactivates when immunosuppressed). Incidence: 1-10% of kidney transplant recipients develop BK virus nephropathy (usually 3-12 months post-transplant). Mortality: Rare (<5%), but graft loss 30-50% (if BK virus nephropathy progresses to advanced fibrosis).",
            "clinical_presentation": "Often asymptomatic (detected by screening). Rising creatinine (30-40%, graft dysfunction). Decreased urine output (20-30%). Fever (10-20%, rare). Physical exam: Usually normal. Laboratory: Elevated creatinine (30-40%), positive BK viremia (plasma BK viral load >10,000 copies/mL, 90-95% sensitive for BK virus nephropathy), positive BK viruria (urine BK viral load >10^7 copies/mL, 80-90% sensitive but less specific). Kidney biopsy: Tubular epithelial cells with intranuclear viral inclusions (SV40 immunohistochemistry positive, gold standard). Complications: Graft dysfunction (30-40%), graft loss (30-50% if advanced fibrosis), ureteral stenosis (5-10%).",
            "diagnostic_criteria": "Clinical diagnosis: Rising creatinine + kidney transplant recipient + positive BK viremia (plasma BK viral load >10,000 copies/mL). Definitive diagnosis: Kidney biopsy showing tubular epithelial cells with intranuclear viral inclusions (SV40 immunohistochemistry positive, gold standard) + positive BK viremia.",
            "risk_factors": [
              "Kidney transplant (most important risk factor, 80-90% of BK virus nephropathy)",
              "High-dose immunosuppression (tacrolimus + mycophenolate + prednisone, 3-drug regimen)",
              "Acute rejection treatment (high-dose corticosteroids, T-cell depleting agents)",
              "Time post-transplant (usually 3-12 months post-transplant, peak incidence 6 months)"
            ],
            "red_flags": [
              "Graft dysfunction - rising creatinine (30-40%), requires reduction of immunosuppression (reduce tacrolimus, reduce or discontinue mycophenolate)",
              "High BK viremia - plasma BK viral load >10,000 copies/mL (90-95% sensitive for BK virus nephropathy), requires reduction of immunosuppression",
              "Graft loss - advanced fibrosis on kidney biopsy (30-50% if BK virus nephropathy progresses), may require return to dialysis or re-transplantation",
              "Ureteral stenosis - hydronephrosis (5-10%), requires urology consult + ureteral stent or nephrostomy tube"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Rising creatinine + kidney transplant recipient. Screening: Plasma BK viral load (every 1-3 months for first 2 years post-transplant, then every 3-6 months thereafter). Urine BK viral load (every 1-3 months for first 2 years post-transplant). Kidney biopsy (if BK viremia >10,000 copies/mL + rising creatinine, gold standard for diagnosis).",
            "essential_tests": [
              "Plasma BK viral load (quantitative PCR): >10,000 copies/mL (90-95% sensitive for BK virus nephropathy). <1,000 copies/mL (low risk). 1,000-10,000 copies/mL (intermediate risk, monitor closely). >10,000 copies/mL (high risk, presumptive BK virus nephropathy, reduce immunosuppression). Turnaround: 1-3 days.",
              "Creatinine: Elevated (30-40%, graft dysfunction). Turnaround: 1-2 hours.",
              "Kidney transplant history: Time post-transplant (usually 3-12 months post-transplant, peak incidence 6 months). Immunosuppression regimen (tacrolimus + mycophenolate + prednisone)."
            ],
            "conditional_tests": [
              "Urine BK viral load (quantitative PCR): >10^7 copies/mL (80-90% sensitive for BK virus nephropathy, but less specific than plasma BK viral load). Turnaround: 1-3 days.",
              "Kidney biopsy: Tubular epithelial cells with intranuclear viral inclusions (SV40 immunohistochemistry positive, gold standard). Indications: BK viremia >10,000 copies/mL + rising creatinine (confirm diagnosis, rule out acute rejection). Turnaround: 2-3 days (histology), 1-2 days (SV40 immunohistochemistry).",
              "Urine cytology (decoy cells): Tubular epithelial cells with intranuclear viral inclusions (50-70% sensitive, less specific than BK viral load). Turnaround: 1-2 days.",
              "Renal ultrasound: Hydronephrosis (if ureteral stenosis, 5-10%). Turnaround: Same day."
            ],
            "when_not_to_test": "Do NOT delay reduction of immunosuppression while awaiting kidney biopsy if high clinical suspicion (BK viremia >10,000 copies/mL + rising creatinine, graft loss risk increases with delayed treatment). Do NOT confuse BK virus nephropathy with acute rejection (both cause rising creatinine, but treatment is opposite: BK virus nephropathy requires reduction of immunosuppression, acute rejection requires increase of immunosuppression).",
            "turnaround_time": "Plasma BK viral load: 1-3 days. Creatinine: 1-2 hours. Urine BK viral load: 1-3 days. Kidney biopsy: 2-3 days (histology), 1-2 days (SV40 immunohistochemistry). Urine cytology: 1-2 days. Renal ultrasound: Same day."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "BK polyomavirus (BKV). Non-enveloped, double-stranded DNA virus. Polyomaviridae family. Seroprevalence: 80-90% of adults (latent infection in kidney, reactivates when immunosuppressed). Transmission: Primary infection in childhood (asymptomatic or mild respiratory illness) → latency in kidney → reactivation (when immunosuppressed, especially kidney transplant recipients). Pathogenesis: Reactivation of latent BKV in kidney (when immunosuppressed) → viral replication in tubular epithelial cells → tubular injury, inflammation, fibrosis → graft dysfunction (rising creatinine) → graft loss (30-50% if advanced fibrosis). Host immune response: Cell-mediated immunity critical for control (BK virus nephropathy occurs when immunosuppressed).",
            "pathogenesis": "Reactivation of latent BKV in kidney (when immunosuppressed, especially kidney transplant recipients) → viral replication in tubular epithelial cells → tubular injury (intranuclear viral inclusions, tubular atrophy), inflammation (interstitial nephritis), fibrosis (if chronic) → graft dysfunction (rising creatinine, 30-40%) → graft loss (30-50% if advanced fibrosis). Host immune response: Cell-mediated immunity critical for control (BK virus nephropathy occurs when immunosuppressed, reduction of immunosuppression allows immune recovery and viral clearance). Complications: Graft dysfunction (30-40%), graft loss (30-50% if advanced fibrosis), ureteral stenosis (5-10%).",
            "resistance_patterns": {
              "no_proven_antiviral": "No proven antiviral therapy for BK virus nephropathy. Cidofovir: Controversial (nephrotoxic, limited efficacy, observational data only, NOT recommended by AST guidelines). Leflunomide: Controversial (limited efficacy, observational data only, NOT recommended by AST guidelines). Fluoroquinolones (ciprofloxacin, levofloxacin): Controversial (limited efficacy, observational data only, NOT recommended by AST guidelines). IVIG: Controversial (limited efficacy, observational data only, NOT recommended by AST guidelines).",
              "primary_treatment": "Reduction of immunosuppression (most important intervention, allows immune recovery and viral clearance). Reduce tacrolimus (target trough 4-6 ng/mL, lower than standard 6-10 ng/mL). Reduce or discontinue mycophenolate (reduce dose by 25-50% OR discontinue). Switch from tacrolimus to cyclosporine (some observational data suggest lower BK virus nephropathy risk with cyclosporine). Switch from mycophenolate to mTOR inhibitor (sirolimus, everolimus, some observational data suggest lower BK virus nephropathy risk with mTOR inhibitors)."
            },
            "timing_critical": "Start reduction of immunosuppression immediately upon diagnosis (BK viremia >10,000 copies/mL + rising creatinine, graft loss risk increases with delayed treatment). Monitor plasma BK viral load every 2-4 weeks (goal: decrease to <1,000 copies/mL, viral clearance). Monitor creatinine every 1-2 weeks (goal: stabilization or improvement). Balance: Reduce immunosuppression enough to clear BK virus, but NOT too much (risk of acute rejection 10-30%)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Reduction of immunosuppression (most important intervention, allows immune recovery and viral clearance). Reduce tacrolimus (target trough 4-6 ng/mL, lower than standard 6-10 ng/mL). Reduce mycophenolate dose by 25-50% OR Discontinue mycophenolate. Monitor plasma BK viral load every 2-4 weeks (goal: decrease to <1,000 copies/mL, viral clearance). Monitor creatinine every 1-2 weeks (goal: stabilization or improvement). Transplant nephrology consult REQUIRED.",
            "alternative_strategies": "Switch from tacrolimus to cyclosporine (some observational data suggest lower BK virus nephropathy risk with cyclosporine, target trough 100-150 ng/mL). Switch from mycophenolate to mTOR inhibitor (sirolimus 2-5 ng/mL OR everolimus 3-8 ng/mL, some observational data suggest lower BK virus nephropathy risk with mTOR inhibitors). Transplant nephrology consult REQUIRED.",
            "controversial_antivirals": "Cidofovir 0.25-1 mg/kg IV weekly x 2, then every 2 weeks (controversial, nephrotoxic, limited efficacy, observational data only, NOT recommended by AST guidelines). Leflunomide 100mg PO daily x 5 days (loading), then 20-40mg PO daily (controversial, limited efficacy, observational data only, NOT recommended by AST guidelines). Fluoroquinolones (ciprofloxacin 500mg PO BID OR levofloxacin 500mg PO daily, controversial, limited efficacy, observational data only, NOT recommended by AST guidelines). IVIG 2g/kg IV x 1 dose (controversial, limited efficacy, observational data only, NOT recommended by AST guidelines).",
            "monitoring_acute_rejection": "Monitor for acute rejection (10-30% risk after reduction of immunosuppression). Signs: Rising creatinine, decreased urine output, fever. Kidney biopsy (if rising creatinine despite reduction of immunosuppression, rule out acute rejection). Treatment: Increase immunosuppression (high-dose corticosteroids, T-cell depleting agents) + balance with BK virus nephropathy risk (difficult, transplant nephrology consult REQUIRED).",
            "avoid_list": "Avoid high-dose immunosuppression (increases BK virus nephropathy risk). Avoid cidofovir (nephrotoxic, limited efficacy, NOT recommended by AST guidelines). Do NOT delay reduction of immunosuppression while awaiting kidney biopsy (graft loss risk increases with delayed treatment). Do NOT confuse BK virus nephropathy with acute rejection (treatment is opposite)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_bk_virus_nephropathy": "Reduction of immunosuppression (most important intervention). Reduce tacrolimus (target trough 4-6 ng/mL). Reduce mycophenolate dose by 25-50% OR Discontinue mycophenolate. Monitor plasma BK viral load every 2-4 weeks (goal: decrease to <1,000 copies/mL, viral clearance). Monitor creatinine every 1-2 weeks (goal: stabilization or improvement). Transplant nephrology consult REQUIRED.",
            "treatment_response": "Viral clearance expected within 3-6 months (plasma BK viral load <1,000 copies/mL, 60-70% of patients). Creatinine stabilization or improvement expected within 4-8 weeks (50-60% of patients). If no improvement after 3-6 months: Consider alternative strategies (switch from tacrolimus to cyclosporine, switch from mycophenolate to mTOR inhibitor). Kidney biopsy (assess for advanced fibrosis, if advanced fibrosis → poor prognosis, graft loss 30-50%). Transplant nephrology consult.",
            "viral_clearance": "Plasma BK viral load <1,000 copies/mL (goal, 60-70% of patients achieve viral clearance within 3-6 months). Continue reduced immunosuppression until viral clearance (plasma BK viral load <1,000 copies/mL x 2 consecutive measurements 2-4 weeks apart). After viral clearance: Gradually increase immunosuppression (increase tacrolimus trough to 6-8 ng/mL, restart mycophenolate at low dose). Monitor plasma BK viral load every 1-3 months (watch for recurrence, 10-20% recurrence rate).",
            "graft_loss": "Advanced fibrosis on kidney biopsy (30-50% if BK virus nephropathy progresses). Graft loss (return to dialysis or re-transplantation). Transplant nephrology consult. Consider re-transplantation (after viral clearance, wait 6-12 months after viral clearance before re-transplantation).",
            "duration": "Continue reduced immunosuppression until viral clearance (plasma BK viral load <1,000 copies/mL x 2 consecutive measurements 2-4 weeks apart, usually 3-6 months). After viral clearance: Gradually increase immunosuppression. Monitor plasma BK viral load every 1-3 months (watch for recurrence)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Continue reduced immunosuppression until viral clearance (plasma BK viral load <1,000 copies/mL x 2 consecutive measurements 2-4 weeks apart, usually 3-6 months). After viral clearance: Gradually increase immunosuppression (increase tacrolimus trough to 6-8 ng/mL, restart mycophenolate at low dose). Monitor plasma BK viral load every 1-3 months (watch for recurrence, 10-20% recurrence rate).",
            "monitoring": "Every 2-4 weeks: Plasma BK viral load (goal: decrease to <1,000 copies/mL, viral clearance). Creatinine (goal: stabilization or improvement). Tacrolimus trough (target 4-6 ng/mL during treatment, increase to 6-8 ng/mL after viral clearance). Every 1-3 months (after viral clearance): Plasma BK viral load (watch for recurrence, 10-20% recurrence rate). Creatinine (monitor graft function). Kidney biopsy (if rising creatinine, rule out acute rejection or recurrent BK virus nephropathy). Viral clearance expected within 3-6 months (plasma BK viral load <1,000 copies/mL, 60-70% of patients).",
            "stop_criteria": "Discontinue reduced immunosuppression after viral clearance (plasma BK viral load <1,000 copies/mL x 2 consecutive measurements 2-4 weeks apart). Gradually increase immunosuppression (increase tacrolimus trough to 6-8 ng/mL, restart mycophenolate at low dose). Monitor plasma BK viral load every 1-3 months (watch for recurrence). Do NOT increase immunosuppression too quickly (risk of BK virus nephropathy recurrence 10-20%)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "kidney_transplant": "Kidney transplant (most important risk factor, 80-90% of BK virus nephropathy). Time post-transplant (usually 3-12 months post-transplant, peak incidence 6 months). High-dose immunosuppression (tacrolimus + mycophenolate + prednisone, 3-drug regimen). Reduction of immunosuppression (most important intervention, allows immune recovery and viral clearance). Transplant nephrology consult REQUIRED.",
            "acute_rejection_risk": "Acute rejection (10-30% risk after reduction of immunosuppression). Monitor for acute rejection (rising creatinine, decreased urine output, fever). Kidney biopsy (if rising creatinine despite reduction of immunosuppression, rule out acute rejection). Treatment: Increase immunosuppression (high-dose corticosteroids, T-cell depleting agents) + balance with BK virus nephropathy risk (difficult, transplant nephrology consult REQUIRED).",
            "ureteral_stenosis": "Ureteral stenosis (5-10%, BK virus replication in ureteral epithelium → fibrosis → obstruction). Hydronephrosis on renal ultrasound. Urology consult (ureteral stent or nephrostomy tube). May require surgical reconstruction (ureteroneocystostomy).",
            "screening": "Screening: Plasma BK viral load (every 1-3 months for first 2 years post-transplant, then every 3-6 months thereafter). Urine BK viral load (every 1-3 months for first 2 years post-transplant). Early detection allows early reduction of immunosuppression (prevents progression to advanced fibrosis, reduces graft loss risk).",
            "pregnancy": "BK virus nephropathy in pregnancy: Rare (pregnancy is relative contraindication in first 1-2 years post-transplant). Reduction of immunosuppression (most important intervention). Transplant nephrology + obstetrics consult. Monitor plasma BK viral load every 2-4 weeks. Monitor creatinine every 1-2 weeks.",
            "counseling": "BK virus nephropathy is life-threatening to the kidney graft (graft loss 30-50% if advanced fibrosis). Treatment: Reduction of immunosuppression (most important intervention, allows immune recovery and viral clearance). Viral clearance expected within 3-6 months (plasma BK viral load <1,000 copies/mL, 60-70% of patients). Risk: Acute rejection (10-30% after reduction of immunosuppression). Screening: Plasma BK viral load every 1-3 months for first 2 years post-transplant (early detection prevents graft loss). Future: Lifelong immunosuppression + lifelong monitoring for BK virus nephropathy recurrence."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start reduction of immunosuppression immediately upon diagnosis (BK viremia >10,000 copies/mL + rising creatinine, graft loss risk increases with delayed treatment)",
              "Reduce tacrolimus (target trough 4-6 ng/mL, lower than standard 6-10 ng/mL)",
              "Reduce mycophenolate dose by 25-50% OR Discontinue mycophenolate",
              "Monitor plasma BK viral load every 2-4 weeks (goal: decrease to <1,000 copies/mL, viral clearance)",
              "Transplant nephrology consult REQUIRED"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Rising creatinine + kidney transplant recipient + BK viremia >10,000 copies/mL)",
              "Is immunosuppression reduced immediately? (Reduce tacrolimus, reduce or discontinue mycophenolate)",
              "Is plasma BK viral load monitored every 2-4 weeks? (Goal: decrease to <1,000 copies/mL, viral clearance)",
              "Is creatinine monitored every 1-2 weeks? (Goal: stabilization or improvement)",
              "Is acute rejection monitored? (10-30% risk after reduction of immunosuppression, kidney biopsy if rising creatinine)",
              "Is transplant nephrology consulted? (REQUIRED for management of BK virus nephropathy)"
            ],
            "avoid_unnecessary_treatment": "Avoid high-dose immunosuppression (increases BK virus nephropathy risk). Avoid cidofovir (nephrotoxic, limited efficacy, NOT recommended by AST guidelines). Avoid leflunomide (limited efficacy, NOT recommended by AST guidelines). Avoid fluoroquinolones (limited efficacy, NOT recommended by AST guidelines). Avoid IVIG (limited efficacy, NOT recommended by AST guidelines). Do NOT delay reduction of immunosuppression while awaiting kidney biopsy. Do NOT confuse BK virus nephropathy with acute rejection (treatment is opposite).",
            "diagnostic_stewardship": "Clinical diagnosis (rising creatinine + kidney transplant recipient + BK viremia >10,000 copies/mL). Kidney biopsy (gold standard, tubular epithelial cells with intranuclear viral inclusions, SV40 immunohistochemistry positive). Screening: Plasma BK viral load (every 1-3 months for first 2 years post-transplant, then every 3-6 months thereafter). Early detection allows early reduction of immunosuppression (prevents progression to advanced fibrosis, reduces graft loss risk). Do NOT delay reduction of immunosuppression while awaiting kidney biopsy if high clinical suspicion.",
            "prevention": "Screening: Plasma BK viral load (every 1-3 months for first 2 years post-transplant, then every 3-6 months thereafter). Early detection allows early reduction of immunosuppression (prevents progression to advanced fibrosis, reduces graft loss risk). Avoid excessive immunosuppression (use lowest effective dose of tacrolimus and mycophenolate). Avoid T-cell depleting agents (if possible, increases BK virus nephropathy risk)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "AST Infectious Diseases Community of Practice Guidelines: BK Polyomavirus in Solid Organ Transplantation (2019)",
              "url": "https://www.astjournals.com/doi/10.1111/ajt.15192"
            },
            {
              "label": "KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients (2009, Reaffirmed 2020)",
              "url": "https://kdigo.org/guidelines/transplant-recipient/"
            },
            {
              "label": "CDC Guidelines for BK Virus in Transplant Recipients (2023)",
              "url": "https://www.cdc.gov/hai/transplant/bk-virus.html"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "progressive-multifocal-leukoencephalopathy",
      "name": "Progressive Multifocal Leukoencephalopathy (PML)",
      "synonyms": [
        "PML",
        "JC virus encephalopathy"
      ],
      "icd10": [
        "A81.2"
      ],
      "severity": [
        "severe",
        "critical"
      ],
      "shortDescription": "Fatal opportunistic viral infection requiring immune reconstitution (start/optimize ART), no proven antiviral therapy",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Fatal opportunistic viral infection caused by JC polyomavirus (JCV). Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <200 cells/μL, 80-90% of PML), natalizumab therapy (multiple sclerosis, Crohn disease, 5-10%), other immunosuppression (SOT, HSCT, rituximab, <5%). Seroprevalence: 50-80% of adults (latent infection, reactivates when immunocompromised). Incidence: Rare in general population, 1-5% lifetime risk in HIV/AIDS (if CD4 <200 cells/μL and no ART). Mortality: 30-50% (with ART), 90-100% (if untreated or no immune reconstitution).",
            "clinical_presentation": "Subacute onset (weeks to months): Altered mental status (confusion, dementia, 50-60%), focal neurologic deficits (hemiparesis, aphasia, ataxia, 60-70%), visual deficits (hemianopsia, cortical blindness, 30-40%), seizures (10-20%). Physical exam: Altered mental status, focal neurologic deficits (hemiparesis, aphasia, ataxia, cranial nerve palsies), visual field deficits. MRI brain: Multiple asymmetric white matter lesions (subcortical, periventricular, 90-95%), no mass effect (unlike toxoplasma encephalitis or CNS lymphoma), no enhancement (unlike toxoplasma encephalitis). Complications: Progressive neurologic decline (50-60%), death (30-50% with ART, 90-100% if untreated), IRIS (10-30% in HIV/AIDS after starting ART).",
            "diagnostic_criteria": "Clinical diagnosis: Altered mental status + focal neurologic deficits + immunocompromised host (HIV/AIDS CD4 <200 cells/μL, natalizumab therapy, other immunosuppression) + MRI brain showing multiple asymmetric white matter lesions (no mass effect, no enhancement). Laboratory: Positive JCV PCR in CSF (70-90% sensitive, 95-99% specific). Definitive diagnosis: Brain biopsy (gold standard, rarely performed due to high risk) showing demyelination + bizarre astrocytes + JCV-infected oligodendrocytes (JCV immunohistochemistry positive).",
            "risk_factors": [
              "HIV/AIDS with CD4 <200 cells/μL (most important risk factor, 80-90% of PML)",
              "Natalizumab therapy (multiple sclerosis, Crohn disease, 5-10%, risk increases with duration >2 years + positive JCV antibody + prior immunosuppression)",
              "Other immunosuppression (SOT, HSCT, rituximab, chronic lymphocytic leukemia, lymphoma, <5%)",
              "No ART (antiretroviral therapy, immune reconstitution prevents PML)"
            ],
            "red_flags": [
              "Progressive neurologic decline - altered mental status, focal neurologic deficits (50-60%), suggests poor prognosis, mortality 30-50% with ART",
              "IRIS (immune reconstitution inflammatory syndrome) - worsening symptoms after starting ART in HIV/AIDS (10-30%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART (no proven antiviral therapy)",
              "Natalizumab-associated PML - discontinue natalizumab immediately + plasma exchange (remove natalizumab, accelerate immune reconstitution) + monitor for IRIS",
              "No immune reconstitution - if unable to start ART (HIV/AIDS) or unable to reduce immunosuppression (SOT, HSCT), prognosis is poor, mortality 90-100%"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Altered mental status + focal neurologic deficits + immunocompromised host (HIV/AIDS CD4 <200 cells/μL, natalizumab therapy, other immunosuppression). MRI brain (multiple asymmetric white matter lesions, no mass effect, no enhancement, 90-95%). JCV PCR in CSF (70-90% sensitive, 95-99% specific). Brain biopsy (gold standard, rarely performed due to high risk).",
            "essential_tests": [
              "MRI brain (with contrast): Multiple asymmetric white matter lesions (subcortical, periventricular, 90-95%), no mass effect (unlike toxoplasma encephalitis or CNS lymphoma), no enhancement (unlike toxoplasma encephalitis). More sensitive than CT brain. Turnaround: Same day.",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, PML risk if CD4 <200 cells/μL). Turnaround: 1-2 days.",
              "Lumbar puncture: JCV PCR in CSF (70-90% sensitive, 95-99% specific). CSF analysis usually normal or mildly elevated protein. Turnaround: 1-3 days (JCV PCR)."
            ],
            "conditional_tests": [
              "JCV PCR in CSF (quantitative): Positive (70-90% sensitive, 95-99% specific). Higher viral load (>1,000 copies/mL) suggests worse prognosis. Turnaround: 1-3 days.",
              "Brain biopsy: Demyelination + bizarre astrocytes + JCV-infected oligodendrocytes (JCV immunohistochemistry positive, gold standard, rarely performed due to high risk: bleeding, infection, neurologic deficits). Indications: Atypical presentation, negative JCV PCR in CSF, diagnostic uncertainty. Turnaround: 2-3 days (histology), 1-2 days (JCV immunohistochemistry).",
              "CT brain (with contrast): White matter lesions (less sensitive than MRI, 60-70%). Use if MRI not available. Turnaround: Same day.",
              "JCV antibody (serum): Positive (50-80% of adults, indicates prior exposure, NOT diagnostic of PML). Used for risk stratification in natalizumab therapy (positive JCV antibody + natalizumab >2 years + prior immunosuppression → high PML risk). Turnaround: 1-2 days."
            ],
            "when_not_to_test": "Do NOT delay immune reconstitution while awaiting brain biopsy if high clinical suspicion (start ART immediately in HIV/AIDS, mortality increases with delayed treatment). Do NOT perform lumbar puncture if mass effect on MRI (risk of herniation, but PML typically has NO mass effect). Do NOT rely on negative JCV PCR in CSF to rule out PML (70-90% sensitive, 10-30% false negative rate).",
            "turnaround_time": "MRI brain: Same day. HIV testing: 1-2 days. CD4 count: 1-2 days. JCV PCR in CSF: 1-3 days. Brain biopsy: 2-3 days (histology), 1-2 days (JCV immunohistochemistry). CT brain: Same day. JCV antibody: 1-2 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "JC polyomavirus (JCV). Non-enveloped, double-stranded DNA virus. Polyomaviridae family. Seroprevalence: 50-80% of adults (latent infection in kidney, bone marrow, reactivates when immunocompromised). Transmission: Primary infection in childhood (asymptomatic or mild respiratory illness) → latency in kidney, bone marrow → reactivation (when CD4 <200 cells/μL or immunosuppression) → hematogenous dissemination to brain → infection of oligodendrocytes → demyelination → PML. Pathogenesis: Reactivation of latent JCV (when CD4 <200 cells/μL or immunosuppression) → hematogenous dissemination to brain → infection of oligodendrocytes (myelin-producing cells) → lytic infection → demyelination (white matter lesions) → progressive neurologic decline → death (30-50% with ART, 90-100% if untreated). Host immune response: CD4 T-cells critical for control of latent infection (PML occurs when CD4 <200 cells/μL or immunosuppression).",
            "pathogenesis": "Reactivation of latent JCV (when CD4 <200 cells/μL or immunosuppression) → hematogenous dissemination to brain → infection of oligodendrocytes (myelin-producing cells) → lytic infection → demyelination (white matter lesions, subcortical, periventricular) → progressive neurologic decline (altered mental status, focal neurologic deficits, visual deficits) → death (30-50% with ART, 90-100% if untreated). Host immune response: CD4 T-cells critical for control (PML occurs when CD4 <200 cells/μL or immunosuppression, immune reconstitution is the ONLY effective treatment). Complications: Progressive neurologic decline (50-60%), death (30-50% with ART, 90-100% if untreated), IRIS (10-30% in HIV/AIDS after starting ART, paradoxical worsening).",
            "resistance_patterns": {
              "no_proven_antiviral": "No proven antiviral therapy for PML. Cidofovir: Ineffective (multiple RCTs showed no benefit). Cytarabine: Ineffective (multiple RCTs showed no benefit). Mefloquine: Ineffective (observational data only, no RCTs). Mirtazapine: Ineffective (observational data only, no RCTs). Interferon-alpha: Ineffective (observational data only, no RCTs).",
              "primary_treatment": "Immune reconstitution (ONLY effective treatment). HIV/AIDS: Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%). Natalizumab-associated PML: Discontinue natalizumab immediately + Plasma exchange (remove natalizumab, accelerate immune reconstitution, 3-5 sessions over 1-2 weeks). Other immunosuppression (SOT, HSCT, rituximab): Reduce immunosuppression if possible (taper tacrolimus, mycophenolate, corticosteroids). If unable to reduce immunosuppression → prognosis is poor, mortality 90-100%."
            },
            "timing_critical": "Start immune reconstitution immediately upon diagnosis (do NOT delay for brain biopsy if high clinical suspicion, mortality increases with delayed treatment). HIV/AIDS: Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%). Natalizumab-associated PML: Discontinue natalizumab immediately + Plasma exchange (remove natalizumab, accelerate immune reconstitution). Monitor for IRIS (10-30% in HIV/AIDS after starting ART, worsening symptoms, requires corticosteroids + continue ART)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line_hiv_aids": "Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%). Use standard ART regimen (integrase inhibitor + 2 NRTIs, e.g., bictegravir/emtricitabine/tenofovir alafenamide). Monitor for IRIS (10-30%, usually 2-4 weeks after starting ART, worsening symptoms, requires corticosteroids + continue ART). Infectious disease consult REQUIRED.",
            "first_line_natalizumab": "Discontinue natalizumab immediately + Plasma exchange (remove natalizumab, accelerate immune reconstitution, 3-5 sessions over 1-2 weeks). Monitor for IRIS (30-50% in natalizumab-associated PML, worsening symptoms after plasma exchange, requires corticosteroids). Neurology consult REQUIRED. Do NOT restart natalizumab (lifelong contraindication after PML).",
            "first_line_other_immunosuppression": "Reduce immunosuppression if possible (taper tacrolimus, mycophenolate, corticosteroids). Infectious disease + transplant consult (if SOT). Hematology/oncology consult (if HSCT, rituximab, lymphoma). If unable to reduce immunosuppression → prognosis is poor, mortality 90-100%.",
            "iris_management": "IRIS (immune reconstitution inflammatory syndrome): Worsening symptoms after starting ART (HIV/AIDS, 10-30%) or after plasma exchange (natalizumab-associated PML, 30-50%), usually 2-4 weeks after immune reconstitution. Symptoms: Worsening altered mental status, focal neurologic deficits, seizures, headache. MRI brain: Increased size of lesions, new enhancement, edema, mass effect. Treatment: Corticosteroids (dexamethasone 4-8mg IV q6h OR prednisone 1mg/kg PO daily, then taper over 4-6 weeks) + Continue ART (do NOT stop ART, immune reconstitution is the ONLY effective treatment for PML). Monitor closely (ICU admission if severe IRIS).",
            "avoid_list": "Avoid cidofovir (ineffective, multiple RCTs showed no benefit). Avoid cytarabine (ineffective, multiple RCTs showed no benefit). Avoid mefloquine (ineffective, observational data only). Avoid mirtazapine (ineffective, observational data only). Do NOT delay immune reconstitution while awaiting brain biopsy (mortality increases with delayed treatment). Do NOT stop ART if IRIS occurs (immune reconstitution is the ONLY effective treatment for PML, use corticosteroids to manage IRIS)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_pml": "Immune reconstitution (ONLY effective treatment). HIV/AIDS: Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%). Natalizumab-associated PML: Discontinue natalizumab immediately + Plasma exchange. Other immunosuppression: Reduce immunosuppression if possible. Monitor for IRIS (10-30% in HIV/AIDS, 30-50% in natalizumab-associated PML).",
            "hiv_aids_specific": "Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%). Use standard ART regimen (integrase inhibitor + 2 NRTIs). Monitor for IRIS (10-30%, usually 2-4 weeks after starting ART, worsening symptoms, requires corticosteroids + continue ART). Infectious disease consult REQUIRED. Prognosis: Mortality 30-50% (with ART), 90-100% (if untreated). Survivors often have residual neurologic deficits (50-60%).",
            "natalizumab_specific": "Discontinue natalizumab immediately + Plasma exchange (remove natalizumab, accelerate immune reconstitution, 3-5 sessions over 1-2 weeks). Monitor for IRIS (30-50%, worsening symptoms after plasma exchange, requires corticosteroids). Neurology consult REQUIRED. Do NOT restart natalizumab (lifelong contraindication after PML). Prognosis: Mortality 20-30% (with plasma exchange), 50-70% (if natalizumab not removed). Survivors often have residual neurologic deficits (60-70%).",
            "treatment_response": "Clinical stabilization or improvement expected within 3-6 months (decreased progression of neurologic deficits, 50-60% of patients). Repeat MRI brain at 3-6 months (assess for stabilization or improvement: no new lesions, decreased size of lesions). If progressive neurologic decline despite immune reconstitution: Poor prognosis, mortality 50-70%. Supportive care (physical therapy, occupational therapy, speech therapy). Palliative care consult (if progressive decline).",
            "duration": "Continue ART lifelong (HIV/AIDS, immune recovery prevents PML recurrence). Continue reduced immunosuppression (other immunosuppression, if possible). Monitor for PML recurrence (rare <5%, repeat MRI brain if new neurologic symptoms). Prognosis: Mortality 30-50% (HIV/AIDS with ART), 20-30% (natalizumab-associated PML with plasma exchange), 90-100% (if no immune reconstitution). Survivors often have residual neurologic deficits (50-70%)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Continue ART lifelong (HIV/AIDS, immune recovery prevents PML recurrence). Continue reduced immunosuppression (other immunosuppression, if possible). Monitor for PML recurrence (rare <5%, repeat MRI brain if new neurologic symptoms). Prognosis: Mortality 30-50% (HIV/AIDS with ART), 20-30% (natalizumab-associated PML with plasma exchange), 90-100% (if no immune reconstitution).",
            "monitoring": "Every 3-6 months: MRI brain (assess for stabilization or improvement: no new lesions, decreased size of lesions). Clinical status (altered mental status, focal neurologic deficits, visual deficits). CD4 count (if HIV/AIDS, monitor for immune recovery, goal CD4 >200 cells/μL). HIV viral load (if HIV/AIDS, monitor for virologic suppression, goal <50 copies/mL). Clinical stabilization or improvement expected within 3-6 months (decreased progression of neurologic deficits, 50-60% of patients). Survivors often have residual neurologic deficits (50-70%, hemiparesis, aphasia, ataxia, visual deficits).",
            "stop_criteria": "No specific stop criteria (no proven antiviral therapy). Continue ART lifelong (HIV/AIDS). Continue reduced immunosuppression (other immunosuppression, if possible). Monitor for PML recurrence (rare <5%, repeat MRI brain if new neurologic symptoms). Supportive care (physical therapy, occupational therapy, speech therapy). Palliative care consult (if progressive decline despite immune reconstitution)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <200 cells/μL (most important risk factor, 80-90% of PML). Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%). Monitor for IRIS (10-30%, usually 2-4 weeks after starting ART, worsening symptoms, requires corticosteroids + continue ART). Prognosis: Mortality 30-50% (with ART), 90-100% (if untreated). Survivors often have residual neurologic deficits (50-60%).",
            "natalizumab": "Natalizumab therapy (multiple sclerosis, Crohn disease, 5-10% of PML). Risk increases with duration >2 years + positive JCV antibody + prior immunosuppression. Discontinue natalizumab immediately + Plasma exchange (remove natalizumab, accelerate immune reconstitution, 3-5 sessions over 1-2 weeks). Monitor for IRIS (30-50%, worsening symptoms after plasma exchange, requires corticosteroids). Do NOT restart natalizumab (lifelong contraindication after PML). Prognosis: Mortality 20-30% (with plasma exchange), 50-70% (if natalizumab not removed).",
            "iris": "IRIS (immune reconstitution inflammatory syndrome): Worsening symptoms after starting ART (HIV/AIDS, 10-30%) or after plasma exchange (natalizumab-associated PML, 30-50%), usually 2-4 weeks after immune reconstitution. Symptoms: Worsening altered mental status, focal neurologic deficits, seizures, headache. MRI brain: Increased size of lesions, new enhancement, edema, mass effect. Treatment: Corticosteroids (dexamethasone 4-8mg IV q6h OR prednisone 1mg/kg PO daily, then taper over 4-6 weeks) + Continue ART (do NOT stop ART, immune reconstitution is the ONLY effective treatment for PML).",
            "prognosis": "Mortality: 30-50% (HIV/AIDS with ART), 20-30% (natalizumab-associated PML with plasma exchange), 90-100% (if no immune reconstitution). Survivors often have residual neurologic deficits (50-70%, hemiparesis, aphasia, ataxia, visual deficits). Supportive care (physical therapy, occupational therapy, speech therapy). Palliative care consult (if progressive decline despite immune reconstitution).",
            "pregnancy": "PML in pregnancy: Rare (pregnancy is relative contraindication in advanced HIV/AIDS). Start ART immediately (immune recovery allows JCV clearance). Infectious disease + obstetrics consult. Monitor for IRIS. Prognosis: Mortality 30-50% (with ART).",
            "counseling": "PML is life-threatening (mortality 30-50% with ART, 90-100% if untreated). Treatment: Immune reconstitution (ONLY effective treatment). HIV/AIDS: Start ART immediately (immune recovery allows JCV clearance). Natalizumab-associated PML: Discontinue natalizumab immediately + Plasma exchange. No proven antiviral therapy (cidofovir, cytarabine, mefloquine, mirtazapine are ineffective). Clinical stabilization or improvement expected within 3-6 months (50-60% of patients). Survivors often have residual neurologic deficits (50-70%, hemiparesis, aphasia, ataxia, visual deficits). Future: Lifelong ART (HIV/AIDS) + lifelong monitoring for PML recurrence."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start immune reconstitution immediately upon diagnosis (do NOT delay for brain biopsy if high clinical suspicion, mortality increases with delayed treatment)",
              "HIV/AIDS: Start ART immediately (immune recovery allows JCV clearance, reduces mortality from 90-100% to 30-50%)",
              "Natalizumab-associated PML: Discontinue natalizumab immediately + Plasma exchange (remove natalizumab, accelerate immune reconstitution)",
              "Monitor for IRIS (10-30% in HIV/AIDS, 30-50% in natalizumab-associated PML, worsening symptoms, requires corticosteroids + continue ART)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Altered mental status + focal neurologic deficits + immunocompromised host + MRI brain showing multiple asymmetric white matter lesions + positive JCV PCR in CSF)",
              "Is immune reconstitution started immediately? (HIV/AIDS: Start ART immediately, Natalizumab: Discontinue + plasma exchange)",
              "Is IRIS monitored? (10-30% in HIV/AIDS, 30-50% in natalizumab-associated PML, worsening symptoms after immune reconstitution)",
              "Is repeat MRI brain performed at 3-6 months? (Assess for stabilization or improvement: no new lesions, decreased size of lesions)",
              "Is supportive care provided? (Physical therapy, occupational therapy, speech therapy for residual neurologic deficits)"
            ],
            "avoid_unnecessary_treatment": "Avoid cidofovir (ineffective, multiple RCTs showed no benefit). Avoid cytarabine (ineffective, multiple RCTs showed no benefit). Avoid mefloquine (ineffective, observational data only). Avoid mirtazapine (ineffective, observational data only). Do NOT delay immune reconstitution while awaiting brain biopsy. Do NOT stop ART if IRIS occurs (immune reconstitution is the ONLY effective treatment for PML, use corticosteroids to manage IRIS).",
            "diagnostic_stewardship": "Clinical diagnosis (altered mental status + focal neurologic deficits + immunocompromised host + MRI brain showing multiple asymmetric white matter lesions, no mass effect, no enhancement). JCV PCR in CSF (70-90% sensitive, 95-99% specific). Brain biopsy (gold standard, rarely performed due to high risk). Do NOT delay immune reconstitution while awaiting brain biopsy if high clinical suspicion.",
            "prevention": "Primary prevention: ART (HIV/AIDS, immune recovery prevents PML). Avoid natalizumab (if positive JCV antibody + prior immunosuppression, high PML risk). JCV antibody screening (before starting natalizumab, if positive → high PML risk, consider alternative therapy). Secondary prevention: Lifelong ART (HIV/AIDS, immune recovery prevents PML recurrence). Do NOT restart natalizumab (lifelong contraindication after PML)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "AAN Practice Guideline: Evaluation and Management of Progressive Multifocal Leukoencephalopathy (2018)",
              "url": "https://www.aan.com/Guidelines/home/GuidelineDetail/900"
            },
            {
              "label": "WHO Guidelines on the Treatment of Progressive Multifocal Leukoencephalopathy (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "mucormycosis",
      "name": "Mucormycosis",
      "synonyms": [
        "Zygomycosis",
        "Invasive mucormycosis"
      ],
      "icd10": [
        "B46.0",
        "B46.1",
        "B46.2",
        "B46.3"
      ],
      "severity": [
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening invasive fungal infection requiring amphotericin B liposomal 5-10mg/kg IV daily + surgical debridement (REQUIRED)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening invasive fungal infection caused by Mucorales (Rhizopus, Mucor, Rhizomucor, Lichtheimia). Occurs in severely immunocompromised or metabolically compromised hosts: Uncontrolled diabetes mellitus with ketoacidosis (40-50%), hematologic malignancies (20-30%), SOT (10-20%), prolonged neutropenia (10-20%), iron overload (deferoxamine therapy, 5-10%). Environmental organism (soil, decaying vegetation). Incidence: Rare (0.5-1 per 100,000 per year). Mortality: 40-80% (with treatment + surgery), 90-100% (if no surgery or delayed treatment).",
            "clinical_presentation": "Rhinocerebral mucormycosis (40-50%, most common in diabetic ketoacidosis): Acute onset (days), facial pain (60-70%), nasal congestion (50-60%), black necrotic eschar (nasal turbinates, palate, 40-50%), proptosis (30-40%), ophthalmoplegia (20-30%), altered mental status (if CNS extension, 10-20%). Pulmonary mucormycosis (30-40%, most common in hematologic malignancies): Fever (70-80%), cough (60-70%), hemoptysis (30-40%), dyspnea (50-60%). Chest X-ray: Nodules (50-60%), infiltrates (40-50%), cavitation (20-30%), pleural effusion (10-20%). Cutaneous mucormycosis (10-20%): Cellulitis, necrotic ulcers, black eschar. Disseminated mucormycosis (10-20%): Multiple organ involvement. Complications: CNS extension (rhinocerebral, 10-20%, mortality 80-90%), pulmonary hemorrhage (pulmonary, 20-30%), dissemination (10-20%, mortality 90-100%).",
            "diagnostic_criteria": "Clinical diagnosis: Facial pain + black necrotic eschar + immunocompromised host (uncontrolled diabetes with ketoacidosis, hematologic malignancies, SOT, prolonged neutropenia). Laboratory: Positive tissue culture (Mucorales, 50-70% sensitive) OR Positive tissue histology (broad, non-septate, ribbon-like hyphae with right-angle branching, 80-90% sensitive, gold standard). Definitive diagnosis: Positive tissue culture (Mucorales) OR Positive tissue histology (broad, non-septate hyphae).",
            "risk_factors": [
              "Uncontrolled diabetes mellitus with ketoacidosis (40-50%, most important risk factor for rhinocerebral mucormycosis)",
              "Hematologic malignancies (acute leukemia, lymphoma, 20-30%, most important risk factor for pulmonary mucormycosis)",
              "Solid organ transplant (SOT, 10-20%)",
              "Prolonged neutropenia (ANC <500 cells/μL x >10 days, 10-20%)",
              "Iron overload (deferoxamine therapy, 5-10%, deferoxamine is a siderophore that enhances Mucorales growth)"
            ],
            "red_flags": [
              "Black necrotic eschar - nasal turbinates, palate (40-50%), pathognomonic for rhinocerebral mucormycosis, requires immediate ENT consult + surgical debridement + amphotericin B liposomal 5-10mg/kg IV daily",
              "CNS extension - altered mental status, cranial nerve palsies (10-20%), mortality 80-90%, requires neurosurgery consult + aggressive surgical debridement + amphotericin B liposomal 10mg/kg IV daily",
              "Pulmonary hemorrhage - hemoptysis (20-30%), life-threatening, requires ICU admission + amphotericin B liposomal 5-10mg/kg IV daily + surgical resection if localized",
              "Disseminated disease - multiple organ involvement (10-20%), mortality 90-100%, requires amphotericin B liposomal 10mg/kg IV daily + surgical debridement of all accessible sites"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Facial pain + black necrotic eschar + immunocompromised host (uncontrolled diabetes with ketoacidosis, hematologic malignancies, SOT, prolonged neutropenia). Tissue biopsy (nasal turbinates, palate, lung, skin, gold standard). Tissue culture (Mucorales, 50-70% sensitive). Tissue histology (broad, non-septate, ribbon-like hyphae with right-angle branching, 80-90% sensitive). CT sinuses (rhinocerebral, bone erosion, soft tissue invasion). MRI brain (if CNS extension). CT chest (pulmonary, nodules, infiltrates, cavitation).",
            "essential_tests": [
              "Tissue biopsy (nasal turbinates, palate, lung, skin): Broad, non-septate, ribbon-like hyphae with right-angle branching (80-90% sensitive, gold standard). Tissue culture (Mucorales, 50-70% sensitive, requires 3-7 days to grow). Turnaround: 1-2 days (histology), 3-7 days (culture).",
              "CT sinuses (with contrast): Bone erosion (40-50%), soft tissue invasion (50-60%), sinus opacification (70-80%). Indications: Rhinocerebral mucormycosis. Turnaround: Same day.",
              "Blood glucose: Elevated (if diabetic ketoacidosis, 40-50% of rhinocerebral mucormycosis). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "MRI brain (with contrast): CNS extension (meningitis, cerebritis, abscess, cavernous sinus thrombosis, 10-20%). Indications: Altered mental status, cranial nerve palsies. Turnaround: Same day.",
              "CT chest (with contrast): Nodules (50-60%), infiltrates (40-50%), cavitation (20-30%), pleural effusion (10-20%), reverse halo sign (10-20%, suggestive of mucormycosis). Indications: Pulmonary mucormycosis. Turnaround: Same day.",
              "Serum (1,3)-β-D-glucan: Negative (Mucorales do NOT produce (1,3)-β-D-glucan, unlike Aspergillus and Candida). Negative (1,3)-β-D-glucan in a patient with invasive mold infection suggests mucormycosis. Turnaround: 1-2 days.",
              "Serum galactomannan: Negative (Mucorales do NOT produce galactomannan, unlike Aspergillus). Negative galactomannan in a patient with invasive mold infection suggests mucormycosis. Turnaround: 1-2 days.",
              "Mucorales PCR (blood, tissue): Positive (experimental, not widely available, 60-70% sensitive). Turnaround: 1-3 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting tissue culture if high clinical suspicion (start empiric amphotericin B liposomal 5-10mg/kg IV daily + surgical debridement, mortality increases with delayed treatment). Do NOT rely on blood cultures (Mucorales rarely grow in blood cultures, <5% sensitive). Do NOT rely on serum (1,3)-β-D-glucan or galactomannan (Mucorales do NOT produce these biomarkers, negative results suggest mucormycosis).",
            "turnaround_time": "Tissue biopsy: 1-2 days (histology), 3-7 days (culture). CT sinuses: Same day. Blood glucose: 1-2 hours. MRI brain: Same day. CT chest: Same day. Serum (1,3)-β-D-glucan: 1-2 days. Serum galactomannan: 1-2 days. Mucorales PCR: 1-3 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Mucorales (Rhizopus 60-70%, Mucor 10-20%, Rhizomucor 5-10%, Lichtheimia 5-10%). Filamentous fungi. Environmental organism (soil, decaying vegetation, bread mold). Transmission: Inhalation of spores (pulmonary, rhinocerebral) OR Direct inoculation (cutaneous, trauma, burns). Pathogenesis: Inhalation of spores → germination (if immunocompromised or metabolically compromised) → angioinvasion (Mucorales have tropism for blood vessels) → thrombosis, tissue necrosis, infarction → black necrotic eschar (rhinocerebral), pulmonary hemorrhage (pulmonary), dissemination (hematogenous spread). Host immune response: Neutrophils and macrophages critical for control (mucormycosis occurs in neutropenia, hematologic malignancies). Metabolic factors: Acidosis (diabetic ketoacidosis) and iron overload (deferoxamine) enhance Mucorales growth.",
            "pathogenesis": "Inhalation of spores → germination (if immunocompromised or metabolically compromised) → angioinvasion (Mucorales have tropism for blood vessels, invade arteries) → thrombosis (vascular occlusion), tissue necrosis, infarction → black necrotic eschar (rhinocerebral, 40-50%), pulmonary hemorrhage (pulmonary, 20-30%), dissemination (hematogenous spread, 10-20%). Host immune response: Neutrophils and macrophages critical for control (mucormycosis occurs in neutropenia, hematologic malignancies). Metabolic factors: Acidosis (diabetic ketoacidosis, 40-50% of rhinocerebral mucormycosis) and iron overload (deferoxamine, 5-10%) enhance Mucorales growth. Complications: CNS extension (rhinocerebral, 10-20%, mortality 80-90%), pulmonary hemorrhage (pulmonary, 20-30%), dissemination (10-20%, mortality 90-100%).",
            "resistance_patterns": {
              "intrinsic_resistance": "Intrinsic resistance to voriconazole, fluconazole, echinocandins (Mucorales lack ergosterol biosynthesis pathway targets). Do NOT use voriconazole, fluconazole, or echinocandins for mucormycosis (ineffective, may worsen outcomes). Amphotericin B: First-line (liposomal amphotericin B 5-10mg/kg IV daily, higher doses than for other fungal infections). Posaconazole: Second-line (salvage therapy, 300mg IV/PO BID x 1 day, then 300mg IV/PO daily). Isavuconazole: Second-line (salvage therapy, 372mg IV q8h x 6 doses, then 372mg IV daily).",
              "acquired_resistance": "Acquired resistance to amphotericin B: Rare (<5%). Treatment: Increase amphotericin B dose (liposomal amphotericin B 10mg/kg IV daily) + Posaconazole 300mg IV/PO daily (combination therapy). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for tissue culture if high clinical suspicion, mortality increases with delayed treatment). Amphotericin B liposomal 5-10mg/kg IV daily (higher doses than for other fungal infections) + Surgical debridement (REQUIRED, remove all necrotic tissue, mortality 90-100% if no surgery). Control underlying condition (correct diabetic ketoacidosis, discontinue deferoxamine, reverse neutropenia with G-CSF). Surgical debridement within 24-48 hours (mortality increases with delayed surgery)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Amphotericin B liposomal 5-10mg/kg IV daily (higher doses than for other fungal infections, use 10mg/kg IV daily if CNS extension or disseminated disease) + Surgical debridement (REQUIRED, remove all necrotic tissue, mortality 90-100% if no surgery). ENT consult (rhinocerebral, surgical debridement of nasal turbinates, palate, sinuses). Thoracic surgery consult (pulmonary, surgical resection if localized). Neurosurgery consult (CNS extension, aggressive surgical debridement). Control underlying condition (correct diabetic ketoacidosis, discontinue deferoxamine, reverse neutropenia with G-CSF). Infectious disease consult REQUIRED.",
            "surgical_debridement": "Surgical debridement (REQUIRED, remove all necrotic tissue, mortality 90-100% if no surgery). Rhinocerebral: ENT consult, surgical debridement of nasal turbinates, palate, sinuses, orbit (if orbital involvement), repeat debridement every 24-48 hours until all necrotic tissue removed. Pulmonary: Thoracic surgery consult, surgical resection if localized (lobectomy, pneumonectomy), reduces mortality by 30-40%. Cutaneous: Surgical debridement of necrotic skin and soft tissue. Disseminated: Surgical debridement of all accessible sites. Timing: Surgical debridement within 24-48 hours (mortality increases with delayed surgery).",
            "control_underlying_condition": "Correct diabetic ketoacidosis (insulin, fluids, electrolytes, correct acidosis, 40-50% of rhinocerebral mucormycosis). Discontinue deferoxamine (if iron overload, deferoxamine is a siderophore that enhances Mucorales growth, 5-10%). Reverse neutropenia (G-CSF 5mcg/kg SC daily, if prolonged neutropenia, 10-20%). Reduce immunosuppression (if SOT, taper tacrolimus, mycophenolate, 10-20%). Infectious disease + endocrinology consult (diabetic ketoacidosis). Infectious disease + transplant consult (SOT).",
            "salvage_therapy": "Posaconazole 300mg IV/PO BID x 1 day (loading), then 300mg IV/PO daily (if amphotericin B intolerance or refractory disease). Isavuconazole 372mg IV q8h x 6 doses (loading, 48 hours), then 372mg IV daily (if amphotericin B intolerance or refractory disease). Combination therapy: Amphotericin B liposomal 5-10mg/kg IV daily + Posaconazole 300mg IV/PO daily (if refractory disease, observational data suggest improved outcomes, no RCTs). Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid voriconazole (intrinsic resistance, ineffective, may worsen outcomes). Avoid fluconazole (intrinsic resistance, ineffective). Avoid echinocandins (intrinsic resistance, ineffective). Do NOT delay treatment while awaiting tissue culture (mortality increases with delayed treatment). Do NOT delay surgical debridement (mortality 90-100% if no surgery, surgical debridement within 24-48 hours)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_mucormycosis": "Amphotericin B liposomal 5-10mg/kg IV daily (use 10mg/kg IV daily if CNS extension or disseminated disease) + Surgical debridement (REQUIRED, remove all necrotic tissue, repeat debridement every 24-48 hours until all necrotic tissue removed). Control underlying condition (correct diabetic ketoacidosis, discontinue deferoxamine, reverse neutropenia with G-CSF). Duration: Minimum 4-6 weeks (IV amphotericin B), then step down to posaconazole 300mg PO daily x 6-12 months (total duration 6-12 months).",
            "rhinocerebral_mucormycosis": "Amphotericin B liposomal 5-10mg/kg IV daily (use 10mg/kg IV daily if CNS extension) + ENT surgical debridement (remove all necrotic tissue: nasal turbinates, palate, sinuses, orbit if involved, repeat debridement every 24-48 hours until all necrotic tissue removed). Correct diabetic ketoacidosis (insulin, fluids, electrolytes, 40-50% of rhinocerebral mucormycosis). Neurosurgery consult (if CNS extension, 10-20%, mortality 80-90%). Duration: Minimum 4-6 weeks (IV amphotericin B), then posaconazole 300mg PO daily x 6-12 months.",
            "pulmonary_mucormycosis": "Amphotericin B liposomal 5-10mg/kg IV daily + Thoracic surgery consult (surgical resection if localized: lobectomy, pneumonectomy, reduces mortality by 30-40%). Reverse neutropenia (G-CSF 5mcg/kg SC daily, if prolonged neutropenia, 10-20%). Reduce immunosuppression (if SOT, taper tacrolimus, mycophenolate, 10-20%). Duration: Minimum 4-6 weeks (IV amphotericin B), then posaconazole 300mg PO daily x 6-12 months.",
            "treatment_response": "Clinical improvement expected within 7-14 days (decreased fever, decreased pain, improved symptoms). Repeat CT sinuses (rhinocerebral) or CT chest (pulmonary) at 2-4 weeks (assess for improvement: decreased soft tissue invasion, decreased nodules/infiltrates). If no improvement after 2-4 weeks: Increase amphotericin B dose (liposomal amphotericin B 10mg/kg IV daily). Add posaconazole 300mg IV/PO daily (combination therapy). Repeat surgical debridement (remove all necrotic tissue). Infectious disease consult.",
            "duration": "Minimum 4-6 weeks (IV amphotericin B), then step down to posaconazole 300mg PO daily x 6-12 months (total duration 6-12 months). Continue until clinical improvement + radiologic improvement (CT sinuses, CT chest) + resolution of immunosuppression. Extend duration if slow response or severe disease (CNS extension, disseminated disease)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Minimum 4-6 weeks (IV amphotericin B), then step down to posaconazole 300mg PO daily x 6-12 months (total duration 6-12 months). Continue until clinical improvement + radiologic improvement (CT sinuses, CT chest) + resolution of immunosuppression. Extend duration if slow response or severe disease (CNS extension, disseminated disease).",
            "monitoring": "Daily (during IV amphotericin B): Creatinine (monitor for nephrotoxicity, maintain CrCl >50 mL/min with saline hydration 1 L NS before + 1 L NS after each dose). Electrolytes (monitor for hypokalemia, hypomagnesemia, supplement if low). Clinical status (fever, pain, symptoms). Weekly: CBC (monitor for neutropenia, if prolonged neutropenia → G-CSF 5mcg/kg SC daily). At 2-4 weeks: Repeat CT sinuses (rhinocerebral) or CT chest (pulmonary) (assess for improvement: decreased soft tissue invasion, decreased nodules/infiltrates). Monthly: Repeat CT sinuses or CT chest (monitor for resolution). Clinical improvement expected within 7-14 days (decreased fever, decreased pain, improved symptoms).",
            "stop_criteria": "Discontinue IV amphotericin B after 4-6 weeks + clinical improvement + radiologic improvement. Step down to posaconazole 300mg PO daily x 6-12 months. Discontinue posaconazole after 6-12 months + clinical improvement + radiologic improvement + resolution of immunosuppression. Do NOT stop treatment early (increases relapse risk 30-40%, mortality 80-90% if relapse)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "diabetic_ketoacidosis": "Diabetic ketoacidosis (40-50% of rhinocerebral mucormycosis, most important risk factor). Correct diabetic ketoacidosis (insulin, fluids, electrolytes, correct acidosis, CRITICAL for treatment success). Acidosis enhances Mucorales growth (low pH favors fungal germination and angioinvasion). Endocrinology consult. Monitor blood glucose every 1-2 hours (target 140-180 mg/dL). Amphotericin B liposomal 5-10mg/kg IV daily + ENT surgical debridement.",
            "hematologic_malignancies": "Hematologic malignancies (acute leukemia, lymphoma, 20-30%, most important risk factor for pulmonary mucormycosis). Prolonged neutropenia (ANC <500 cells/μL x >10 days, 10-20%). Reverse neutropenia (G-CSF 5mcg/kg SC daily, CRITICAL for treatment success). Hematology/oncology consult. Amphotericin B liposomal 5-10mg/kg IV daily + Thoracic surgery consult (surgical resection if localized).",
            "deferoxamine": "Deferoxamine (iron chelator, 5-10% of mucormycosis). Deferoxamine is a siderophore that enhances Mucorales growth (provides iron to fungus). Discontinue deferoxamine immediately (CRITICAL for treatment success). Alternative iron chelator: Deferasirox (does NOT enhance Mucorales growth). Amphotericin B liposomal 5-10mg/kg IV daily + Surgical debridement.",
            "amphotericin_toxicity": "Nephrotoxicity (30-40%, maintain CrCl >50 mL/min with saline hydration 1 L NS before + 1 L NS after each dose, monitor creatinine daily). Electrolyte abnormalities: Hypokalemia (50-60%, monitor potassium daily, supplement if <3.5 mEq/L), hypomagnesemia (30-40%, monitor magnesium weekly, supplement if <1.5 mg/dL). Infusion-related reactions (fever, chills, rigors, 50-60%, premedicate with acetaminophen 650mg PO + diphenhydramine 25-50mg PO + hydrocortisone 50mg IV 30 minutes before infusion).",
            "pregnancy": "Mucormycosis in pregnancy: Rare (pregnancy is relative contraindication in advanced immunosuppression). Amphotericin B: Safe in pregnancy (preferred antifungal in pregnancy). Posaconazole: Avoid in pregnancy (teratogenic in animals). Infectious disease + obstetrics consult. Amphotericin B liposomal 5-10mg/kg IV daily + Surgical debridement.",
            "counseling": "Mucormycosis is life-threatening (mortality 40-80% with treatment + surgery, 90-100% if no surgery or delayed treatment). Treatment: Amphotericin B liposomal 5-10mg/kg IV daily + Surgical debridement (REQUIRED, remove all necrotic tissue, mortality 90-100% if no surgery). Control underlying condition (correct diabetic ketoacidosis, discontinue deferoxamine, reverse neutropenia with G-CSF). Duration: Minimum 4-6 weeks (IV amphotericin B), then posaconazole 300mg PO daily x 6-12 months (total duration 6-12 months). Clinical improvement expected within 7-14 days. Surgical debridement within 24-48 hours (mortality increases with delayed surgery)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for tissue culture if high clinical suspicion, mortality increases with delayed treatment)",
              "Amphotericin B liposomal 5-10mg/kg IV daily (higher doses than for other fungal infections, use 10mg/kg IV daily if CNS extension or disseminated disease)",
              "Surgical debridement (REQUIRED, remove all necrotic tissue, mortality 90-100% if no surgery, surgical debridement within 24-48 hours)",
              "Control underlying condition (correct diabetic ketoacidosis, discontinue deferoxamine, reverse neutropenia with G-CSF)",
              "Step down to posaconazole 300mg PO daily after 4-6 weeks of IV amphotericin B (total duration 6-12 months)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Facial pain + black necrotic eschar + immunocompromised host + tissue histology showing broad, non-septate hyphae)",
              "Is amphotericin B started immediately? (Amphotericin B liposomal 5-10mg/kg IV daily, higher doses than for other fungal infections)",
              "Is surgical debridement performed within 24-48 hours? (REQUIRED, remove all necrotic tissue, mortality 90-100% if no surgery)",
              "Is underlying condition controlled? (Correct diabetic ketoacidosis, discontinue deferoxamine, reverse neutropenia with G-CSF)",
              "Is repeat surgical debridement performed? (Every 24-48 hours until all necrotic tissue removed)",
              "Is repeat CT performed at 2-4 weeks? (Assess for improvement: decreased soft tissue invasion, decreased nodules/infiltrates)"
            ],
            "avoid_unnecessary_treatment": "Avoid voriconazole (intrinsic resistance, ineffective, may worsen outcomes). Avoid fluconazole (intrinsic resistance, ineffective). Avoid echinocandins (intrinsic resistance, ineffective). Do NOT delay treatment while awaiting tissue culture. Do NOT delay surgical debridement (mortality 90-100% if no surgery, surgical debridement within 24-48 hours). Do NOT stop treatment early (increases relapse risk 30-40%, mortality 80-90% if relapse).",
            "diagnostic_stewardship": "Clinical diagnosis (facial pain + black necrotic eschar + immunocompromised host). Tissue biopsy (nasal turbinates, palate, lung, skin, gold standard). Tissue histology (broad, non-septate, ribbon-like hyphae with right-angle branching, 80-90% sensitive). Tissue culture (Mucorales, 50-70% sensitive). Negative serum (1,3)-β-D-glucan and galactomannan (Mucorales do NOT produce these biomarkers, negative results suggest mucormycosis). Do NOT delay treatment while awaiting tissue culture if high clinical suspicion.",
            "prevention": "Control underlying conditions (tight glycemic control in diabetes, avoid deferoxamine if possible, reverse neutropenia with G-CSF). Avoid environmental exposure (soil, decaying vegetation, construction sites) if severely immunocompromised. No specific prophylaxis (posaconazole prophylaxis may reduce mucormycosis risk in high-risk patients: prolonged neutropenia, hematologic malignancies, observational data only)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "ECMM/ISHAM Consensus Definitions of Invasive Fungal Diseases: Mucormycosis (2020)",
              "url": "https://academic.oup.com/cid/article/71/6/1367/5810200"
            },
            {
              "label": "IDSA Clinical Practice Guideline for the Management of Mucormycosis (2022)",
              "url": "https://academic.oup.com/cid/article/75/5/e1-e27/6517968"
            },
            {
              "label": "CDC Guidelines for Mucormycosis (2023)",
              "url": "https://www.cdc.gov/fungal/diseases/mucormycosis/index.html"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "histoplasmosis-disseminated",
      "name": "Histoplasmosis (Disseminated)",
      "synonyms": [
        "Disseminated histoplasmosis",
        "Progressive disseminated histoplasmosis"
      ],
      "icd10": [
        "B39.3",
        "B39.4",
        "B39.5"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Opportunistic fungal infection requiring amphotericin B liposomal 3mg/kg IV daily x 14 days, then itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Opportunistic fungal infection caused by Histoplasma capsulatum. Occurs in severely immunocompromised hosts: HIV/AIDS (CD4 <150 cells/μL, 80-90% of disseminated histoplasmosis), SOT (5-10%), HSCT (rare <5%), TNF-alpha inhibitors (rare <5%). Endemic organism (Ohio and Mississippi River valleys, Central America, South America). Transmission: Inhalation of spores (soil contaminated with bird or bat droppings). Incidence: Rare in general population, 5-10% lifetime risk in HIV/AIDS (if CD4 <150 cells/μL and living in endemic area, no prophylaxis). Mortality: 10-20% (with treatment + ART), 80-90% (if untreated).",
            "clinical_presentation": "Subacute onset (weeks to months): Fever (80-90%, persistent, high-grade), weight loss (60-70%), hepatosplenomegaly (50-60%), lymphadenopathy (40-50%), cough (30-40%), dyspnea (20-30%). Physical exam: Fever, cachexia, hepatosplenomegaly, lymphadenopathy, oral ulcers (10-20%). Laboratory: Anemia (Hgb <10 g/dL, 60-70%), thrombocytopenia (platelets <100,000, 40-50%), elevated alkaline phosphatase (50-60%), elevated LDH (40-50%). Chest X-ray: Diffuse infiltrates (40-50%), nodules (20-30%), normal (30-40%). Complications: Septic shock (10-20%, mortality 50-70%), adrenal insufficiency (5-10%), CNS histoplasmosis (meningitis, 5-10%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + weight loss + hepatosplenomegaly + immunocompromised host (HIV/AIDS CD4 <150 cells/μL) + living in endemic area. Laboratory: Positive Histoplasma antigen (urine or serum, 90-95% sensitive for disseminated histoplasmosis, gold standard) OR Positive blood culture (Histoplasma, 50-70% sensitive, requires 7-14 days to grow on fungal culture) OR Positive tissue biopsy (bone marrow, liver, lymph node, 80-90% sensitive). Definitive diagnosis: Positive Histoplasma antigen OR Positive culture (Histoplasma) OR Positive tissue biopsy.",
            "risk_factors": [
              "HIV/AIDS with CD4 <150 cells/μL (most important risk factor, 80-90% of disseminated histoplasmosis)",
              "Living in endemic area (Ohio and Mississippi River valleys, Central America, South America)",
              "Exposure to bird or bat droppings (soil contaminated with droppings, caves, old buildings, chicken coops)",
              "Solid organ transplant (SOT, 5-10%)",
              "TNF-alpha inhibitors (infliximab, adalimumab, rare <5%)"
            ],
            "red_flags": [
              "Septic shock - hypotension, tachycardia, altered mental status (10-20%, mortality 50-70%), requires ICU admission + amphotericin B liposomal 3mg/kg IV daily + vasopressors",
              "Adrenal insufficiency - hypotension, hyponatremia, hyperkalemia (5-10%), requires hydrocortisone 100mg IV q8h + amphotericin B liposomal 3mg/kg IV daily",
              "CNS histoplasmosis - meningitis, altered mental status, headache (5-10%), requires amphotericin B liposomal 5mg/kg IV daily x 4-6 weeks, then itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months",
              "IRIS (immune reconstitution inflammatory syndrome) - worsening symptoms after starting ART in HIV/AIDS (10-20%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART + continue antifungals"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + weight loss + hepatosplenomegaly + immunocompromised host (HIV/AIDS CD4 <150 cells/μL) + living in endemic area. Histoplasma antigen (urine or serum, 90-95% sensitive for disseminated histoplasmosis, gold standard). Blood culture (Histoplasma, 50-70% sensitive, requires 7-14 days to grow on fungal culture). Tissue biopsy (bone marrow, liver, lymph node, 80-90% sensitive).",
            "essential_tests": [
              "Histoplasma antigen (urine or serum): Positive (90-95% sensitive for disseminated histoplasmosis, gold standard). Quantitative (higher levels suggest more severe disease). Turnaround: 1-2 days.",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, disseminated histoplasmosis risk if CD4 <150 cells/μL). Turnaround: 1-2 days.",
              "CBC: Anemia (Hgb <10 g/dL, 60-70%), thrombocytopenia (platelets <100,000, 40-50%). Turnaround: 1-2 hours.",
              "Alkaline phosphatase: Elevated (50-60%). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "Blood culture (fungal culture): Histoplasma (50-70% sensitive, requires 7-14 days to grow on fungal culture, lysis-centrifugation method preferred). Turnaround: 7-14 days (preliminary), 14-21 days (final identification).",
              "Tissue biopsy (bone marrow, liver, lymph node): Histoplasma on culture (80-90% sensitive) OR Histoplasma on histology (small intracellular yeast, 2-4 microns, GMS stain positive). Turnaround: 7-14 days (culture), 1-2 days (histology).",
              "Chest X-ray: Diffuse infiltrates (40-50%), nodules (20-30%), normal (30-40%). Turnaround: Same day.",
              "Lumbar puncture: CSF Histoplasma antigen (if CNS symptoms: altered mental status, headache, 5-10%). CSF culture (Histoplasma). Turnaround: 1-2 days (antigen), 7-14 days (culture)."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting blood culture if high clinical suspicion (start empiric amphotericin B liposomal 3mg/kg IV daily, mortality increases with delayed treatment). Do NOT rely on serology (Histoplasma antibody, 70-80% sensitive, slower turnaround, less useful for acute diagnosis). Do NOT confuse with tuberculosis (both cause fever, weight loss, hepatosplenomegaly, but Histoplasma antigen is specific).",
            "turnaround_time": "Histoplasma antigen: 1-2 days. HIV testing: 1-2 days. CD4 count: 1-2 days. CBC: 1-2 hours. Alkaline phosphatase: 1-2 hours. Blood culture: 7-14 days (preliminary), 14-21 days (final identification). Tissue biopsy: 7-14 days (culture), 1-2 days (histology). Chest X-ray: Same day. Lumbar puncture: 1-2 days (antigen), 7-14 days (culture)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Histoplasma capsulatum. Dimorphic fungus (mold in environment, yeast in tissue). Endemic organism (Ohio and Mississippi River valleys, Central America, South America). Transmission: Inhalation of spores (soil contaminated with bird or bat droppings, caves, old buildings, chicken coops). Pathogenesis: Inhalation of spores → germination in lungs → conversion to yeast form → phagocytosis by macrophages → intracellular replication (if immunocompromised) → hematogenous dissemination → reticuloendothelial system (liver, spleen, bone marrow, lymph nodes) → disseminated histoplasmosis. Host immune response: Cell-mediated immunity critical for control (disseminated histoplasmosis occurs when CD4 <150 cells/μL or immunosuppression).",
            "pathogenesis": "Inhalation of spores → germination in lungs → conversion to yeast form → phagocytosis by macrophages → intracellular replication (if immunocompromised) → hematogenous dissemination → reticuloendothelial system (liver, spleen, bone marrow, lymph nodes) → disseminated histoplasmosis (fever, weight loss, hepatosplenomegaly, lymphadenopathy, anemia, thrombocytopenia). Host immune response: Cell-mediated immunity critical for control (disseminated histoplasmosis occurs when CD4 <150 cells/μL or immunosuppression). Complications: Septic shock (10-20%, mortality 50-70%), adrenal insufficiency (5-10%), CNS histoplasmosis (meningitis, 5-10%), IRIS (10-20% in HIV/AIDS after starting ART).",
            "resistance_patterns": {
              "itraconazole_resistance": "Itraconazole resistance: Rare (<5%). Treatment: Posaconazole 300mg PO BID x 1 day, then 300mg PO daily OR Voriconazole 6mg/kg IV q12h x2, then 4mg/kg IV q12h (if itraconazole-resistant Histoplasma). Infectious disease consult REQUIRED.",
              "amphotericin_resistance": "Amphotericin B resistance: Rare (<5%). Treatment: Increase amphotericin B dose (liposomal amphotericin B 5mg/kg IV daily) OR Switch to posaconazole 300mg PO daily (if amphotericin B-resistant Histoplasma). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for blood culture if high clinical suspicion, mortality increases with delayed treatment). Amphotericin B liposomal 3mg/kg IV daily x 14 days (induction), then Itraconazole 200mg PO TID x 3 days (loading), then 200mg PO BID x 12 months (consolidation + maintenance). Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). Continue antifungals until immune recovery (CD4 >150 cells/μL x 6 months on ART) + negative Histoplasma antigen."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": "Amphotericin B liposomal 3mg/kg IV daily x 14 days (induction), then Itraconazole 200mg PO TID x 3 days (loading), then 200mg PO BID x 12 months (consolidation + maintenance). Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). Monitor itraconazole levels (target trough >1 mcg/mL, check after 2 weeks, then every 3 months). Infectious disease consult REQUIRED.",
            "severe_disease": "Amphotericin B liposomal 3mg/kg IV daily x 14 days (if septic shock, ICU admission, adrenal insufficiency, CNS histoplasmosis). If CNS histoplasmosis: Amphotericin B liposomal 5mg/kg IV daily x 4-6 weeks (higher dose, longer duration), then Itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months. If adrenal insufficiency: Hydrocortisone 100mg IV q8h + Amphotericin B liposomal 3mg/kg IV daily. If septic shock: Vasopressors + Amphotericin B liposomal 3mg/kg IV daily.",
            "alternative_first_line": "Itraconazole 200mg PO TID x 3 days (loading), then 200mg PO BID x 12 months (if mild-moderate disease, no septic shock, no CNS involvement, hemodynamically stable). Monitor itraconazole levels (target trough >1 mcg/mL, check after 2 weeks, then every 3 months). Less effective than amphotericin B for severe disease (use amphotericin B if severe disease).",
            "secondary_prophylaxis": "Itraconazole 200mg PO daily (after completing 12 months of treatment, continue until immune recovery: CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen). Discontinue secondary prophylaxis when CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen.",
            "avoid_list": "Avoid fluconazole (less active than itraconazole against Histoplasma, use only if itraconazole intolerance). Do NOT delay treatment while awaiting blood culture (mortality increases with delayed treatment). Do NOT skip itraconazole loading dose (200mg PO TID x 3 days, achieves therapeutic levels faster). Do NOT forget to monitor itraconazole levels (target trough >1 mcg/mL, subtherapeutic levels increase relapse risk)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_disseminated_histoplasmosis": "Amphotericin B liposomal 3mg/kg IV daily x 14 days (induction), then Itraconazole 200mg PO TID x 3 days (loading), then 200mg PO BID x 12 months (consolidation + maintenance). Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). Continue antifungals until immune recovery (CD4 >150 cells/μL x 6 months on ART) + negative Histoplasma antigen.",
            "hiv_aids_specific": "Induction: Amphotericin B liposomal 3mg/kg IV daily x 14 days. Consolidation + maintenance: Itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months. Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). Secondary prophylaxis: Itraconazole 200mg PO daily (after completing 12 months of treatment, continue until CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen). IRIS: Worsening symptoms after starting ART (10-20%, usually 2-4 weeks after starting ART), requires corticosteroids (prednisone 20-40mg PO daily, then taper over 4-6 weeks) + continue ART + continue antifungals.",
            "cns_histoplasmosis": "Amphotericin B liposomal 5mg/kg IV daily x 4-6 weeks (higher dose, longer duration), then Itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months. Repeat lumbar puncture at 4-6 weeks (confirm CSF sterilization, negative CSF Histoplasma antigen). Duration: 12 months (CNS histoplasmosis requires longer duration). Infectious disease + neurology consult.",
            "treatment_response": "Clinical improvement expected within 7-14 days (decreased fever, weight gain, improved symptoms). Repeat Histoplasma antigen at 4-8 weeks (should decrease by >50%, if not → consider treatment failure). If no improvement after 4-8 weeks: Check itraconazole levels (target trough >1 mcg/mL, adjust dose if subtherapeutic). Consider alternative diagnosis (tuberculosis, other opportunistic infections). Infectious disease consult.",
            "duration": "Induction: 14 days (amphotericin B). Consolidation + maintenance: 12 months (itraconazole). Secondary prophylaxis: Until immune recovery (CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen). Total duration: Minimum 12-18 months."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Induction: 14 days (amphotericin B). Consolidation + maintenance: 12 months (itraconazole). Secondary prophylaxis: Until immune recovery (CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen). Total duration: Minimum 12-18 months.",
            "monitoring": "Every 2-4 weeks: Histoplasma antigen (should decrease by >50% at 4-8 weeks, goal: negative). Clinical status (fever, weight, symptoms). Itraconazole levels (target trough >1 mcg/mL, check after 2 weeks, then every 3 months). Every 3 months: CD4 count (if HIV/AIDS, monitor for immune recovery, goal CD4 >150 cells/μL). HIV viral load (if HIV/AIDS, monitor for virologic suppression, goal <50 copies/mL). Clinical improvement expected within 7-14 days (decreased fever, weight gain, improved symptoms).",
            "stop_criteria": "Discontinue amphotericin B after 14 days + clinical improvement. Start itraconazole after completing amphotericin B. Discontinue itraconazole after 12 months + immune recovery (CD4 >150 cells/μL x 6 months on ART) + negative Histoplasma antigen. Start secondary prophylaxis (itraconazole 200mg PO daily) after completing 12 months of treatment. Discontinue secondary prophylaxis when CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen. Do NOT stop treatment early (increases relapse risk 30-40%)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <150 cells/μL (most important risk factor, 80-90% of disseminated histoplasmosis). Induction: Amphotericin B liposomal 3mg/kg IV daily x 14 days. Consolidation + maintenance: Itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months. Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). IRIS: Worsening symptoms after starting ART (10-20%, usually 2-4 weeks after starting ART), requires corticosteroids + continue ART + continue antifungals.",
            "drug_interactions": "Itraconazole interacts with protease inhibitors, NNRTIs (CYP3A4 inhibitor and substrate). Monitor itraconazole levels (target trough >1 mcg/mL, check after 2 weeks, then every 3 months). Avoid rifampin (CYP3A4 inducer, decreases itraconazole levels, use rifabutin if needed). Avoid proton pump inhibitors (decrease itraconazole absorption, use with acidic beverage like cola if PPI required).",
            "itraconazole_toxicity": "Hepatotoxicity (5-10%, monitor LFTs monthly). Heart failure (1-2%, avoid if history of heart failure or ejection fraction <30%). QTc prolongation (1-2%, monitor EKG if on other QTc-prolonging drugs). Hypokalemia (5-10%, monitor potassium monthly). Discontinue itraconazole if severe toxicity (ALT >5x ULN, heart failure, QTc >500 ms). Alternative: Posaconazole 300mg PO daily.",
            "pregnancy": "Disseminated histoplasmosis in pregnancy: Rare (pregnancy is relative contraindication in advanced HIV/AIDS). Amphotericin B: Safe in pregnancy (preferred antifungal in pregnancy). Itraconazole: Avoid in pregnancy (teratogenic in animals). Infectious disease + obstetrics consult. Amphotericin B liposomal 3mg/kg IV daily x 14 days, then consider fluconazole 400-800mg PO daily (less teratogenic than itraconazole).",
            "counseling": "Disseminated histoplasmosis is life-threatening (mortality 10-20% with treatment + ART, 80-90% if untreated). Treatment: Amphotericin B liposomal 3mg/kg IV daily x 14 days, then itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months. Clinical improvement expected within 7-14 days (decreased fever, weight gain). HIV/AIDS: Start ART after 2 weeks of antifungal therapy (immune recovery prevents relapse). Monitor itraconazole levels (target trough >1 mcg/mL). Future: Lifelong ART + secondary prophylaxis (itraconazole 200mg PO daily) until CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for blood culture if high clinical suspicion, mortality increases with delayed treatment)",
              "Amphotericin B liposomal 3mg/kg IV daily x 14 days (induction), then Itraconazole 200mg PO TID x 3 days (loading), then 200mg PO BID x 12 months (consolidation + maintenance)",
              "Start ART after 2 weeks of antifungal therapy (reduces IRIS risk)",
              "Monitor itraconazole levels (target trough >1 mcg/mL, check after 2 weeks, then every 3 months)",
              "Secondary prophylaxis: Itraconazole 200mg PO daily (after completing 12 months of treatment, continue until CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + weight loss + hepatosplenomegaly + immunocompromised host + positive Histoplasma antigen)",
              "Is amphotericin B started immediately? (Amphotericin B liposomal 3mg/kg IV daily x 14 days)",
              "Is itraconazole started after completing amphotericin B? (Itraconazole 200mg PO TID x 3 days, then 200mg PO BID x 12 months)",
              "Are itraconazole levels monitored? (Target trough >1 mcg/mL, check after 2 weeks, then every 3 months)",
              "Is Histoplasma antigen repeated at 4-8 weeks? (Should decrease by >50%, goal: negative)",
              "Is ART started appropriately? (HIV/AIDS: Start ART after 2 weeks of antifungal therapy, reduces IRIS risk)"
            ],
            "avoid_unnecessary_treatment": "Avoid fluconazole (less active than itraconazole against Histoplasma, use only if itraconazole intolerance). Do NOT delay treatment while awaiting blood culture. Do NOT skip itraconazole loading dose (200mg PO TID x 3 days). Do NOT forget to monitor itraconazole levels (target trough >1 mcg/mL, subtherapeutic levels increase relapse risk). Do NOT stop treatment early (increases relapse risk 30-40%).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + weight loss + hepatosplenomegaly + immunocompromised host + living in endemic area). Histoplasma antigen (urine or serum, 90-95% sensitive for disseminated histoplasmosis, gold standard). Blood culture (Histoplasma, 50-70% sensitive). Tissue biopsy (bone marrow, liver, lymph node, 80-90% sensitive). Do NOT delay treatment while awaiting blood culture if high clinical suspicion.",
            "prevention": "Primary prophylaxis: Itraconazole 200mg PO daily (if HIV/AIDS CD4 <150 cells/μL + living in endemic area + high-risk exposure) until CD4 >150 cells/μL x 6 months on ART. Secondary prophylaxis: Itraconazole 200mg PO daily (after disseminated histoplasmosis until immune recovery: CD4 >150 cells/μL x 6 months on ART + negative Histoplasma antigen). Avoid high-risk exposure (caves, old buildings, chicken coops, soil contaminated with bird or bat droppings) if severely immunocompromised."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for the Management of Histoplasmosis (2007, Reaffirmed 2020)",
              "url": "https://academic.oup.com/cid/article/45/7/807/364512"
            },
            {
              "label": "WHO Guidelines on the Treatment of Histoplasmosis (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "coccidioidomycosis-disseminated",
      "name": "Coccidioidomycosis (Disseminated)",
      "synonyms": [
        "Disseminated coccidioidomycosis",
        "Valley fever (disseminated)"
      ],
      "icd10": [
        "B38.7",
        "B38.4",
        "B38.1"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Opportunistic fungal infection requiring fluconazole 400-800mg PO daily x 12+ months (disseminated) or amphotericin B if severe",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Opportunistic fungal infection caused by Coccidioides immitis or C. posadasii. Occurs in immunocompromised hosts: HIV/AIDS (CD4 <250 cells/μL, 40-50% of disseminated coccidioidomycosis), SOT (20-30%), TNF-alpha inhibitors (10-20%), pregnancy (5-10%), African American or Filipino ethnicity (increased risk). Endemic organism (Southwestern US: Arizona, California, Nevada, New Mexico, Texas; Mexico, Central America, South America). Transmission: Inhalation of arthroconidia (soil, dust storms, construction, earthquakes). Incidence: 10,000-15,000 cases per year in US (most are pulmonary, 1-5% disseminate). Mortality: 10-30% (disseminated disease with treatment), 70-90% (if untreated or CNS involvement).",
            "clinical_presentation": "Pulmonary coccidioidomycosis (60-70%): Subacute onset (weeks to months), cough (60-70%), fever (50-60%), chest pain (40-50%), dyspnea (30-40%), weight loss (30-40%). Chest X-ray: Nodules (40-50%), infiltrates (30-40%), cavitation (20-30%), hilar lymphadenopathy (20-30%). Disseminated coccidioidomycosis (1-5%, higher in immunocompromised): Skin lesions (papules, nodules, ulcers, 30-40%), bone/joint involvement (osteomyelitis, arthritis, 20-30%), CNS involvement (meningitis, 10-20%, mortality 70-90%), hepatosplenomegaly (10-20%). Complications: CNS meningitis (10-20%, mortality 70-90%), respiratory failure (10-20%), septic shock (5-10%).",
            "diagnostic_criteria": "Clinical diagnosis: Cough + fever + chest pain + immunocompromised host + living in endemic area. Laboratory: Positive Coccidioides serology (IgM, IgG, complement fixation, 70-90% sensitive) OR Positive culture (Coccidioides, 50-70% sensitive, requires 3-7 days to grow, HIGHLY CONTAGIOUS in lab) OR Positive tissue histology (spherules with endospores, 80-90% sensitive). Definitive diagnosis: Positive serology OR Positive culture OR Positive tissue histology.",
            "risk_factors": [
              "HIV/AIDS with CD4 <250 cells/μL (40-50% of disseminated coccidioidomycosis)",
              "Living in endemic area (Southwestern US: Arizona, California, Nevada, New Mexico, Texas; Mexico, Central America, South America)",
              "Solid organ transplant (SOT, 20-30%)",
              "TNF-alpha inhibitors (infliximab, adalimumab, 10-20%)",
              "Pregnancy (5-10%, especially third trimester, increased risk of dissemination)",
              "African American or Filipino ethnicity (increased risk of dissemination, 5-10x higher than Caucasian)"
            ],
            "red_flags": [
              "CNS meningitis - headache, altered mental status, cranial nerve palsies (10-20%, mortality 70-90%), requires fluconazole 400-1200mg PO daily (lifelong) OR amphotericin B liposomal 5mg/kg IV daily x 4-6 weeks, then fluconazole",
              "Respiratory failure - severe pulmonary disease, ARDS (10-20%), requires ICU admission + amphotericin B liposomal 3-5mg/kg IV daily",
              "Septic shock - hypotension, tachycardia, altered mental status (5-10%), requires ICU admission + amphotericin B liposomal 3-5mg/kg IV daily + vasopressors",
              "Pregnancy - third trimester (5-10%, increased risk of dissemination), requires fluconazole 400mg PO daily (after delivery, avoid in pregnancy) OR amphotericin B liposomal 3mg/kg IV daily (safe in pregnancy)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Cough + fever + chest pain + immunocompromised host + living in endemic area. Coccidioides serology (IgM, IgG, complement fixation, 70-90% sensitive). Culture (Coccidioides, 50-70% sensitive, HIGHLY CONTAGIOUS in lab, notify lab). Tissue histology (spherules with endospores, 80-90% sensitive). Chest X-ray (nodules, infiltrates, cavitation, hilar lymphadenopathy).",
            "essential_tests": [
              "Coccidioides serology (IgM, IgG, complement fixation): Positive (70-90% sensitive). IgM (early infection, 1-3 weeks). IgG (later infection, >3 weeks). Complement fixation titer (quantitative, higher titers suggest disseminated disease, titer >1:16 suggests dissemination). Turnaround: 1-3 days.",
              "Chest X-ray: Nodules (40-50%), infiltrates (30-40%), cavitation (20-30%), hilar lymphadenopathy (20-30%). Turnaround: Same day.",
              "HIV testing: If HIV status unknown. CD4 count (if HIV-positive, disseminated coccidioidomycosis risk if CD4 <250 cells/μL). Turnaround: 1-2 days."
            ],
            "conditional_tests": [
              "Culture (sputum, BAL, tissue): Coccidioides (50-70% sensitive, requires 3-7 days to grow, HIGHLY CONTAGIOUS in lab, notify lab, biosafety level 3 required). Turnaround: 3-7 days (preliminary), 7-14 days (final identification).",
              "Tissue biopsy (lung, skin, bone, lymph node): Spherules with endospores (80-90% sensitive, pathognomonic). GMS stain positive. Turnaround: 1-2 days (histology), 3-7 days (culture).",
              "Lumbar puncture: CSF analysis (if CNS symptoms: headache, altered mental status, 10-20%). CSF Coccidioides serology (complement fixation, 70-80% sensitive for CNS meningitis). CSF culture (Coccidioides, 30-50% sensitive). Turnaround: 1-3 days (serology), 3-7 days (culture).",
              "CT chest: Nodules (40-50%), infiltrates (30-40%), cavitation (20-30%), hilar lymphadenopathy (20-30%). More sensitive than chest X-ray. Turnaround: Same day.",
              "Coccidioides antigen (urine, serum): Positive (60-70% sensitive for disseminated disease, experimental, not widely available). Turnaround: 1-3 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting culture if high clinical suspicion (start empiric fluconazole 400mg PO daily, mortality increases with delayed treatment). Do NOT handle Coccidioides cultures without biosafety level 3 precautions (HIGHLY CONTAGIOUS, lab-acquired infections reported). Do NOT confuse with tuberculosis (both cause pulmonary nodules, cavitation, but Coccidioides serology is specific).",
            "turnaround_time": "Coccidioides serology: 1-3 days. Chest X-ray: Same day. HIV testing: 1-2 days. CD4 count: 1-2 days. Culture: 3-7 days (preliminary), 7-14 days (final identification). Tissue biopsy: 1-2 days (histology), 3-7 days (culture). Lumbar puncture: 1-3 days (serology), 3-7 days (culture). CT chest: Same day. Coccidioides antigen: 1-3 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Coccidioides immitis (California) or C. posadasii (Arizona, other endemic areas). Dimorphic fungus (mold in environment, spherules in tissue). Endemic organism (Southwestern US: Arizona, California, Nevada, New Mexico, Texas; Mexico, Central America, South America). Transmission: Inhalation of arthroconidia (soil, dust storms, construction, earthquakes). Pathogenesis: Inhalation of arthroconidia → germination in lungs → conversion to spherules (large, 20-80 microns, filled with endospores) → endospore release → dissemination (if immunocompromised) → skin, bone, CNS, other organs. Host immune response: Cell-mediated immunity critical for control (disseminated coccidioidomycosis occurs when CD4 <250 cells/μL or immunosuppression).",
            "pathogenesis": "Inhalation of arthroconidia → germination in lungs → conversion to spherules (large, 20-80 microns, filled with endospores) → endospore release → dissemination (if immunocompromised) → skin (papules, nodules, ulcers, 30-40%), bone/joint (osteomyelitis, arthritis, 20-30%), CNS (meningitis, 10-20%, mortality 70-90%), hepatosplenomegaly (10-20%). Host immune response: Cell-mediated immunity critical for control (disseminated coccidioidomycosis occurs when CD4 <250 cells/μL or immunosuppression). Complications: CNS meningitis (10-20%, mortality 70-90%), respiratory failure (10-20%), septic shock (5-10%).",
            "resistance_patterns": {
              "fluconazole_resistance": "Fluconazole resistance: Rare (<5%). Treatment: Increase fluconazole dose (800-1200mg PO daily) OR Switch to itraconazole 200mg PO BID OR Posaconazole 300mg PO daily OR Voriconazole 200-400mg PO BID (if fluconazole-resistant Coccidioides). Infectious disease consult REQUIRED.",
              "amphotericin_resistance": "Amphotericin B resistance: Rare (<5%). Treatment: Increase amphotericin B dose (liposomal amphotericin B 5mg/kg IV daily) OR Switch to posaconazole 300mg PO daily (if amphotericin B-resistant Coccidioides). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for culture if high clinical suspicion, mortality increases with delayed treatment). Pulmonary coccidioidomycosis (mild-moderate): Fluconazole 400mg PO daily x 3-6 months. Disseminated coccidioidomycosis: Fluconazole 400-800mg PO daily x 12+ months (lifelong if CNS meningitis). Severe disease: Amphotericin B liposomal 3-5mg/kg IV daily x 4-6 weeks, then fluconazole 400-800mg PO daily x 12+ months."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "pulmonary_mild_moderate": "Fluconazole 400mg PO daily x 3-6 months (if mild-moderate pulmonary coccidioidomycosis, no dissemination, hemodynamically stable). Monitor Coccidioides serology (complement fixation titer should decrease, goal: <1:2). Infectious disease consult REQUIRED.",
            "disseminated_disease": "Fluconazole 400-800mg PO daily x 12+ months (if disseminated coccidioidomycosis: skin, bone, joint, hepatosplenomegaly). Monitor Coccidioides serology (complement fixation titer should decrease, goal: <1:2). Duration: Minimum 12 months, extend to 18-24 months if slow response. Infectious disease consult REQUIRED.",
            "cns_meningitis": "Fluconazole 400-1200mg PO daily (lifelong, if CNS meningitis). Start with 800-1200mg PO daily x 4-6 weeks, then reduce to 400-800mg PO daily (lifelong). Alternative: Amphotericin B liposomal 5mg/kg IV daily x 4-6 weeks, then fluconazole 400-800mg PO daily (lifelong). Repeat lumbar puncture at 4-6 weeks (confirm CSF sterilization, negative CSF Coccidioides serology). Neurology + infectious disease consult REQUIRED. Do NOT stop treatment (lifelong therapy required, relapse rate 80-90% if stopped).",
            "severe_disease": "Amphotericin B liposomal 3-5mg/kg IV daily x 4-6 weeks (if severe disease: respiratory failure, septic shock, diffuse pulmonary infiltrates, high complement fixation titer >1:32), then fluconazole 400-800mg PO daily x 12+ months. ICU admission. Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid short duration (<3 months for pulmonary, <12 months for disseminated, increases relapse risk 30-40%). Do NOT delay treatment while awaiting culture (mortality increases with delayed treatment). Do NOT stop treatment early for CNS meningitis (lifelong therapy required, relapse rate 80-90% if stopped). Do NOT use fluconazole in pregnancy (teratogenic, use amphotericin B instead)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_pulmonary_coccidioidomycosis": "Fluconazole 400mg PO daily x 3-6 months (if mild-moderate pulmonary coccidioidomycosis, no dissemination). Monitor Coccidioides serology (complement fixation titer should decrease, goal: <1:2). Duration: 3-6 months (pulmonary), extend to 12 months if slow response or immunocompromised.",
            "confirmed_disseminated_coccidioidomycosis": "Fluconazole 400-800mg PO daily x 12+ months (if disseminated coccidioidomycosis: skin, bone, joint, hepatosplenomegaly). Monitor Coccidioides serology (complement fixation titer should decrease, goal: <1:2). Duration: Minimum 12 months, extend to 18-24 months if slow response. Infectious disease consult REQUIRED.",
            "confirmed_cns_meningitis": "Fluconazole 400-1200mg PO daily (lifelong). Start with 800-1200mg PO daily x 4-6 weeks, then reduce to 400-800mg PO daily (lifelong). Repeat lumbar puncture at 4-6 weeks (confirm CSF sterilization, negative CSF Coccidioides serology). Neurology + infectious disease consult REQUIRED. Do NOT stop treatment (lifelong therapy required, relapse rate 80-90% if stopped).",
            "hiv_aids_specific": "Fluconazole 400-800mg PO daily x 12+ months (if disseminated coccidioidomycosis). Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). Continue antifungals until immune recovery (CD4 >250 cells/μL x 6 months on ART) + negative or low Coccidioides serology (complement fixation titer <1:2). Secondary prophylaxis: Fluconazole 400mg PO daily (after completing treatment, continue until CD4 >250 cells/μL x 6 months on ART). If CNS meningitis: Lifelong fluconazole (do NOT stop, even if immune recovery).",
            "treatment_response": "Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms). Repeat Coccidioides serology at 4-8 weeks (complement fixation titer should decrease by >50%, goal: <1:2). Repeat chest X-ray at 4-8 weeks (assess for improvement: decreased nodules, infiltrates). If no improvement after 4-8 weeks: Increase fluconazole dose (800-1200mg PO daily) OR Switch to itraconazole 200mg PO BID OR Amphotericin B liposomal 3-5mg/kg IV daily. Infectious disease consult.",
            "duration": "Pulmonary (mild-moderate): 3-6 months. Disseminated: 12+ months (minimum 12 months, extend to 18-24 months if slow response). CNS meningitis: Lifelong. HIV/AIDS: Until immune recovery (CD4 >250 cells/μL x 6 months on ART) + negative or low Coccidioides serology (complement fixation titer <1:2), except CNS meningitis (lifelong)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Pulmonary (mild-moderate): 3-6 months. Disseminated: 12+ months (minimum 12 months, extend to 18-24 months if slow response). CNS meningitis: Lifelong. HIV/AIDS: Until immune recovery (CD4 >250 cells/μL x 6 months on ART) + negative or low Coccidioides serology (complement fixation titer <1:2), except CNS meningitis (lifelong).",
            "monitoring": "Every 4-8 weeks: Coccidioides serology (complement fixation titer should decrease, goal: <1:2). Clinical status (fever, symptoms). Chest X-ray (assess for improvement: decreased nodules, infiltrates). Every 3 months: CD4 count (if HIV/AIDS, monitor for immune recovery, goal CD4 >250 cells/μL). HIV viral load (if HIV/AIDS, monitor for virologic suppression, goal <50 copies/mL). If CNS meningitis: Repeat lumbar puncture at 4-6 weeks (confirm CSF sterilization, negative CSF Coccidioides serology). Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms).",
            "stop_criteria": "Discontinue fluconazole after 3-6 months (pulmonary) or 12+ months (disseminated) + clinical improvement + negative or low Coccidioides serology (complement fixation titer <1:2). If CNS meningitis: Do NOT stop treatment (lifelong therapy required, relapse rate 80-90% if stopped). If HIV/AIDS: Discontinue after immune recovery (CD4 >250 cells/μL x 6 months on ART) + negative or low Coccidioides serology, except CNS meningitis (lifelong). Do NOT stop treatment early (increases relapse risk 30-40%)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hiv_aids": "CD4 <250 cells/μL (40-50% of disseminated coccidioidomycosis). Fluconazole 400-800mg PO daily x 12+ months. Start ART after 2 weeks of antifungal therapy (reduces IRIS risk). Continue antifungals until immune recovery (CD4 >250 cells/μL x 6 months on ART) + negative or low Coccidioides serology (complement fixation titer <1:2). Secondary prophylaxis: Fluconazole 400mg PO daily (after completing treatment, continue until CD4 >250 cells/μL x 6 months on ART). If CNS meningitis: Lifelong fluconazole (do NOT stop, even if immune recovery).",
            "cns_meningitis": "CNS meningitis (10-20%, mortality 70-90%). Fluconazole 400-1200mg PO daily (lifelong). Start with 800-1200mg PO daily x 4-6 weeks, then reduce to 400-800mg PO daily (lifelong). Repeat lumbar puncture at 4-6 weeks (confirm CSF sterilization, negative CSF Coccidioides serology). Neurology + infectious disease consult REQUIRED. Do NOT stop treatment (lifelong therapy required, relapse rate 80-90% if stopped). Intrathecal amphotericin B (if refractory CNS meningitis, neurology consult).",
            "pregnancy": "Pregnancy (5-10%, especially third trimester, increased risk of dissemination). Fluconazole: Avoid in pregnancy (teratogenic, especially first trimester). Amphotericin B: Safe in pregnancy (preferred antifungal in pregnancy). Treatment: Amphotericin B liposomal 3mg/kg IV daily x 4-6 weeks, then fluconazole 400mg PO daily (after delivery). Infectious disease + obstetrics consult. Monitor closely (increased risk of dissemination in third trimester).",
            "african_american_filipino": "African American or Filipino ethnicity (increased risk of dissemination, 5-10x higher than Caucasian). Monitor closely for dissemination (skin lesions, bone/joint involvement, CNS meningitis). Lower threshold for treatment (treat even mild-moderate pulmonary coccidioidomycosis). Fluconazole 400mg PO daily x 6-12 months (pulmonary), 12+ months (disseminated).",
            "counseling": "Coccidioidomycosis is life-threatening if disseminated (mortality 10-30% with treatment, 70-90% if untreated or CNS involvement). Treatment: Fluconazole 400mg PO daily x 3-6 months (pulmonary) or 400-800mg PO daily x 12+ months (disseminated). CNS meningitis: Lifelong fluconazole (do NOT stop, relapse rate 80-90% if stopped). Clinical improvement expected within 4-8 weeks (decreased fever, improved symptoms). HIV/AIDS: Start ART after 2 weeks of antifungal therapy (immune recovery prevents relapse). Future: Lifelong ART + secondary prophylaxis (fluconazole 400mg PO daily) until CD4 >250 cells/μL x 6 months on ART, except CNS meningitis (lifelong)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for culture if high clinical suspicion, mortality increases with delayed treatment)",
              "Pulmonary (mild-moderate): Fluconazole 400mg PO daily x 3-6 months",
              "Disseminated: Fluconazole 400-800mg PO daily x 12+ months",
              "CNS meningitis: Fluconazole 400-1200mg PO daily (lifelong, do NOT stop, relapse rate 80-90% if stopped)",
              "Monitor Coccidioides serology (complement fixation titer should decrease, goal: <1:2)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Cough + fever + chest pain + immunocompromised host + living in endemic area + positive Coccidioides serology)",
              "Is fluconazole started immediately? (Fluconazole 400mg PO daily for pulmonary, 400-800mg PO daily for disseminated)",
              "Is Coccidioides serology repeated at 4-8 weeks? (Complement fixation titer should decrease, goal: <1:2)",
              "Is treatment duration appropriate? (3-6 months for pulmonary, 12+ months for disseminated, lifelong for CNS meningitis)",
              "Is ART started appropriately? (HIV/AIDS: Start ART after 2 weeks of antifungal therapy, reduces IRIS risk)",
              "Is CNS meningitis ruled out? (Lumbar puncture if headache, altered mental status, cranial nerve palsies)"
            ],
            "avoid_unnecessary_treatment": "Avoid short duration (<3 months for pulmonary, <12 months for disseminated, increases relapse risk 30-40%). Do NOT delay treatment while awaiting culture. Do NOT stop treatment early for CNS meningitis (lifelong therapy required, relapse rate 80-90% if stopped). Do NOT use fluconazole in pregnancy (teratogenic, use amphotericin B instead). Do NOT handle Coccidioides cultures without biosafety level 3 precautions (HIGHLY CONTAGIOUS).",
            "diagnostic_stewardship": "Clinical diagnosis (cough + fever + chest pain + immunocompromised host + living in endemic area). Coccidioides serology (IgM, IgG, complement fixation, 70-90% sensitive). Culture (Coccidioides, 50-70% sensitive, HIGHLY CONTAGIOUS in lab, notify lab). Tissue histology (spherules with endospores, 80-90% sensitive). Do NOT delay treatment while awaiting culture if high clinical suspicion.",
            "prevention": "Primary prophylaxis: Fluconazole 400mg PO daily (if HIV/AIDS CD4 <250 cells/μL + living in endemic area) until CD4 >250 cells/μL x 6 months on ART. Secondary prophylaxis: Fluconazole 400mg PO daily (after disseminated coccidioidomycosis until immune recovery: CD4 >250 cells/μL x 6 months on ART). Avoid high-risk exposure (construction, dust storms, soil disturbance) if severely immunocompromised. If CNS meningitis: Lifelong fluconazole (do NOT stop, even if immune recovery)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2023)",
              "url": "https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for the Management of Coccidioidomycosis (2016)",
              "url": "https://academic.oup.com/cid/article/63/6/e112/2389093"
            },
            {
              "label": "WHO Guidelines on the Treatment of Coccidioidomycosis (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "strongyloidiasis-hyperinfection",
      "name": "Strongyloidiasis (Hyperinfection Syndrome)",
      "synonyms": [
        "Hyperinfection syndrome",
        "Disseminated strongyloidiasis"
      ],
      "icd10": [
        "B78.0",
        "B78.1",
        "B78.7"
      ],
      "severity": [
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening parasitic infection requiring ivermectin 200mcg/kg PO daily x 7-14 days (hyperinfection) or x 2 days (uncomplicated)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening parasitic infection caused by Strongyloides stercoralis. Occurs in immunocompromised hosts: Prolonged corticosteroids (>20mg prednisone daily x >2 weeks, 60-70% of hyperinfection syndrome), HTLV-1 infection (10-20%), SOT (5-10%), hematologic malignancies (5-10%). Endemic organism (tropical and subtropical regions: Southeast Asia, Latin America, sub-Saharan Africa, rural Southeastern US). Transmission: Skin penetration by filariform larvae (contaminated soil, walking barefoot). Unique feature: Autoinfection cycle (larvae can reinfect host without leaving body, can persist for decades). Incidence: 30-100 million infected worldwide, hyperinfection syndrome rare (<1% of infected, but mortality 50-90% if untreated). Mortality: 20-40% (hyperinfection syndrome with treatment), 50-90% (if untreated or disseminated with gram-negative bacteremia).",
            "clinical_presentation": "Uncomplicated strongyloidiasis (asymptomatic or mild, 50-70%): Abdominal pain (30-40%), diarrhea (20-30%), urticaria (larva currens, serpiginous rash, 10-20%). Hyperinfection syndrome (severe, immunocompromised): Abdominal pain (70-80%), diarrhea (60-70%), nausea/vomiting (50-60%), ileus (30-40%), GI bleeding (20-30%), respiratory symptoms (cough, dyspnea, hemoptysis, 40-50%). Disseminated strongyloidiasis (critical, 20-30%): Multiple organ involvement (lungs, CNS, liver, kidneys), gram-negative bacteremia (larvae carry enteric bacteria from GI tract to bloodstream, 30-40%, E. coli, Klebsiella, Enterobacter), septic shock (20-30%, mortality 70-90%), meningitis (10-20%, gram-negative meningitis). Laboratory: Eosinophilia (50-70% in uncomplicated, often ABSENT in hyperinfection syndrome due to corticosteroids). Complications: Gram-negative bacteremia (30-40%), septic shock (20-30%, mortality 70-90%), gram-negative meningitis (10-20%), respiratory failure (20-30%), ileus (30-40%).",
            "diagnostic_criteria": "Clinical diagnosis: Abdominal pain + diarrhea + respiratory symptoms + immunocompromised host (prolonged corticosteroids, HTLV-1, SOT) + history of living in endemic area. Laboratory: Positive stool ova and parasites (O&P, 30-50% sensitive for uncomplicated, 70-80% sensitive for hyperinfection syndrome, requires 3 stool samples) OR Positive Strongyloides serology (IgG ELISA, 80-90% sensitive for uncomplicated, may be negative in hyperinfection syndrome due to immunosuppression) OR Positive sputum or BAL (larvae, 50-70% sensitive for hyperinfection syndrome with pulmonary involvement). Definitive diagnosis: Larvae identified in stool, sputum, BAL, or tissue biopsy.",
            "risk_factors": [
              "Prolonged corticosteroids (>20mg prednisone daily x >2 weeks, 60-70% of hyperinfection syndrome, most important risk factor)",
              "HTLV-1 infection (human T-lymphotropic virus type 1, 10-20%, endemic in Japan, Caribbean, sub-Saharan Africa)",
              "Solid organ transplant (SOT, 5-10%)",
              "Hematologic malignancies (lymphoma, leukemia, 5-10%)",
              "History of living in endemic area (tropical and subtropical regions: Southeast Asia, Latin America, sub-Saharan Africa, rural Southeastern US)"
            ],
            "red_flags": [
              "Gram-negative bacteremia - fever, hypotension, tachycardia (30-40%, larvae carry enteric bacteria from GI tract to bloodstream), requires blood cultures + ivermectin 200mcg/kg PO daily x 7-14 days + broad-spectrum antibiotics (ceftriaxone + metronidazole)",
              "Septic shock - hypotension, altered mental status (20-30%, mortality 70-90%), requires ICU admission + ivermectin 200mcg/kg PO daily x 7-14 days + vasopressors + broad-spectrum antibiotics",
              "Gram-negative meningitis - headache, altered mental status, CSF pleocytosis with gram-negative bacteria (10-20%), requires lumbar puncture + ivermectin 200mcg/kg PO daily x 7-14 days + ceftriaxone 2g IV q12h",
              "Respiratory failure - severe pulmonary involvement, ARDS (20-30%), requires ICU admission + mechanical ventilation + ivermectin 200mcg/kg PO daily x 7-14 days"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Abdominal pain + diarrhea + respiratory symptoms + immunocompromised host (prolonged corticosteroids, HTLV-1, SOT) + history of living in endemic area. Stool ova and parasites (O&P, 30-50% sensitive for uncomplicated, 70-80% sensitive for hyperinfection syndrome, requires 3 stool samples). Strongyloides serology (IgG ELISA, 80-90% sensitive for uncomplicated, may be negative in hyperinfection syndrome). Sputum or BAL (if respiratory symptoms, larvae, 50-70% sensitive for hyperinfection syndrome with pulmonary involvement). Blood cultures (if fever, rule out gram-negative bacteremia).",
            "essential_tests": [
              "Stool ova and parasites (O&P): Larvae (30-50% sensitive for uncomplicated, 70-80% sensitive for hyperinfection syndrome). Requires 3 stool samples (increases sensitivity). Turnaround: 1-2 days per sample.",
              "Strongyloides serology (IgG ELISA): Positive (80-90% sensitive for uncomplicated strongyloidiasis). May be negative in hyperinfection syndrome (immunosuppression reduces antibody production). Turnaround: 1-3 days.",
              "CBC: Eosinophilia (50-70% in uncomplicated, often ABSENT in hyperinfection syndrome due to corticosteroids). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "Sputum or BAL (if respiratory symptoms): Larvae (50-70% sensitive for hyperinfection syndrome with pulmonary involvement). Turnaround: 1-2 days.",
              "Blood cultures: Gram-negative bacteria (E. coli, Klebsiella, Enterobacter, 30-40% in hyperinfection syndrome, larvae carry enteric bacteria from GI tract to bloodstream). Turnaround: 1-2 days (preliminary), 2-3 days (final identification).",
              "Chest X-ray: Diffuse infiltrates (40-50%), nodules (20-30%), normal (30-40%). Turnaround: Same day.",
              "Lumbar puncture (if altered mental status, headache): CSF pleocytosis with gram-negative bacteria (10-20%, gram-negative meningitis). Turnaround: 1-2 hours (cell count, Gram stain), 1-2 days (culture).",
              "Duodenal aspirate or biopsy: Larvae (70-80% sensitive, more sensitive than stool O&P, requires endoscopy). Turnaround: 1-2 days."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting stool O&P if high clinical suspicion (start empiric ivermectin 200mcg/kg PO daily, mortality increases with delayed treatment). Do NOT rely on single stool O&P (30-50% sensitive, requires 3 stool samples to increase sensitivity to 70-80%). Do NOT rely on eosinophilia (often ABSENT in hyperinfection syndrome due to corticosteroids). Do NOT confuse with other helminth infections (hookworm, ascariasis, but Strongyloides is the ONLY helminth that can cause hyperinfection syndrome due to autoinfection cycle).",
            "turnaround_time": "Stool ova and parasites: 1-2 days per sample (requires 3 samples). Strongyloides serology: 1-3 days. CBC: 1-2 hours. Sputum or BAL: 1-2 days. Blood cultures: 1-2 days (preliminary), 2-3 days (final identification). Chest X-ray: Same day. Lumbar puncture: 1-2 hours (cell count, Gram stain), 1-2 days (culture). Duodenal aspirate: 1-2 days."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Strongyloides stercoralis. Intestinal nematode (roundworm). Endemic organism (tropical and subtropical regions: Southeast Asia, Latin America, sub-Saharan Africa, rural Southeastern US). Transmission: Skin penetration by filariform larvae (contaminated soil, walking barefoot). Unique feature: Autoinfection cycle (rhabditiform larvae in GI tract can transform into filariform larvae and penetrate intestinal mucosa or perianal skin, reinfecting host without leaving body, can persist for decades). Pathogenesis: Skin penetration → bloodstream → lungs → trachea → swallowed → small intestine → adult worms (females only, parthenogenesis) → eggs hatch in intestine → rhabditiform larvae → excreted in stool OR autoinfection (if immunocompromised) → hyperinfection syndrome (massive larval burden, GI and pulmonary involvement) → disseminated strongyloidiasis (larvae in multiple organs: lungs, CNS, liver, kidneys, carry enteric bacteria from GI tract to bloodstream → gram-negative bacteremia, septic shock, meningitis). Host immune response: Th2 immunity critical for control (hyperinfection syndrome occurs when immunosuppressed, especially corticosteroids suppress Th2 immunity).",
            "pathogenesis": "Autoinfection cycle (if immunocompromised, especially corticosteroids) → hyperinfection syndrome (massive larval burden, GI and pulmonary involvement, abdominal pain, diarrhea, ileus, GI bleeding, cough, dyspnea, hemoptysis) → disseminated strongyloidiasis (larvae in multiple organs: lungs, CNS, liver, kidneys, carry enteric bacteria from GI tract to bloodstream → gram-negative bacteremia 30-40%, septic shock 20-30%, gram-negative meningitis 10-20%). Host immune response: Th2 immunity critical for control (hyperinfection syndrome occurs when immunosuppressed, especially corticosteroids suppress Th2 immunity). Complications: Gram-negative bacteremia (30-40%), septic shock (20-30%, mortality 70-90%), gram-negative meningitis (10-20%), respiratory failure (20-30%), ileus (30-40%).",
            "resistance_patterns": {
              "ivermectin_resistance": "Ivermectin resistance: Rare (<5%). Treatment: Increase ivermectin dose (200mcg/kg PO BID x 7-14 days) OR Add albendazole 400mg PO BID x 7-14 days (combination therapy). Infectious disease consult REQUIRED.",
              "alternative_therapy": "Albendazole 400mg PO BID x 7-14 days (if ivermectin intolerance or resistance, less effective than ivermectin, cure rate 40-60% vs 80-90% for ivermectin). Thiabendazole 25mg/kg PO BID x 3 days (if ivermectin and albendazole intolerance, NOT available in US, significant side effects: nausea, vomiting, dizziness)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for stool O&P if high clinical suspicion, mortality increases with delayed treatment). Uncomplicated strongyloidiasis: Ivermectin 200mcg/kg PO daily x 2 days. Hyperinfection syndrome: Ivermectin 200mcg/kg PO daily x 7-14 days (longer duration, continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart). Disseminated strongyloidiasis with gram-negative bacteremia: Ivermectin 200mcg/kg PO daily x 7-14 days + Broad-spectrum antibiotics (ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h). Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "uncomplicated_strongyloidiasis": "Ivermectin 200mcg/kg PO daily x 2 days (if uncomplicated strongyloidiasis, asymptomatic or mild symptoms, no hyperinfection syndrome). Repeat stool O&P at 2-4 weeks (confirm cure, negative stool O&P). Cure rate: 80-90%.",
            "hyperinfection_syndrome": "Ivermectin 200mcg/kg PO daily x 7-14 days (if hyperinfection syndrome: severe GI symptoms, pulmonary involvement, immunocompromised host). Continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart. Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success). Infectious disease consult REQUIRED. Cure rate: 60-80% (lower than uncomplicated due to severity).",
            "disseminated_strongyloidiasis": "Ivermectin 200mcg/kg PO daily x 7-14 days + Broad-spectrum antibiotics (ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h, if gram-negative bacteremia, septic shock, or gram-negative meningitis). ICU admission. Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success). Blood cultures (rule out gram-negative bacteremia). Lumbar puncture (if altered mental status, rule out gram-negative meningitis). Infectious disease consult REQUIRED. Mortality: 20-40% (with treatment), 70-90% (if septic shock or gram-negative meningitis).",
            "alternative_therapy": "Albendazole 400mg PO BID x 7-14 days (if ivermectin intolerance or resistance, less effective than ivermectin, cure rate 40-60% vs 80-90% for ivermectin). Combination therapy: Ivermectin 200mcg/kg PO daily + Albendazole 400mg PO BID x 7-14 days (if severe hyperinfection syndrome or ivermectin resistance, observational data suggest improved outcomes).",
            "avoid_list": "Avoid corticosteroids (suppress Th2 immunity, increase risk of hyperinfection syndrome, reduce or discontinue corticosteroids if possible). Do NOT delay treatment while awaiting stool O&P (mortality increases with delayed treatment). Do NOT use short duration (x 2 days) for hyperinfection syndrome (requires x 7-14 days, longer duration). Do NOT forget to treat gram-negative bacteremia (broad-spectrum antibiotics REQUIRED if bacteremia, septic shock, or meningitis)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_uncomplicated_strongyloidiasis": "Ivermectin 200mcg/kg PO daily x 2 days. Repeat stool O&P at 2-4 weeks (confirm cure, negative stool O&P). Cure rate: 80-90%. If stool O&P still positive at 2-4 weeks: Repeat ivermectin 200mcg/kg PO daily x 2 days.",
            "confirmed_hyperinfection_syndrome": "Ivermectin 200mcg/kg PO daily x 7-14 days. Continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart. Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success). Repeat stool O&P and sputum (if pulmonary involvement) weekly (monitor for larval clearance). Infectious disease consult REQUIRED. Cure rate: 60-80%.",
            "confirmed_disseminated_strongyloidiasis": "Ivermectin 200mcg/kg PO daily x 7-14 days + Broad-spectrum antibiotics (ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h, if gram-negative bacteremia, septic shock, or gram-negative meningitis). Continue ivermectin until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart. Continue antibiotics until blood cultures negative + clinical improvement. Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success). ICU admission. Infectious disease consult REQUIRED. Mortality: 20-40% (with treatment), 70-90% (if septic shock or gram-negative meningitis).",
            "treatment_response": "Clinical improvement expected within 7-14 days (decreased abdominal pain, diarrhea, respiratory symptoms). Repeat stool O&P and sputum (if pulmonary involvement) weekly (monitor for larval clearance, goal: negative x 2 consecutive samples 1 week apart). If no improvement after 7-14 days: Increase ivermectin dose (200mcg/kg PO BID x 7-14 days) OR Add albendazole 400mg PO BID x 7-14 days (combination therapy). Infectious disease consult.",
            "duration": "Uncomplicated strongyloidiasis: 2 days. Hyperinfection syndrome: 7-14 days (continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart). Disseminated strongyloidiasis: 7-14 days (ivermectin) + 7-14 days (antibiotics, until blood cultures negative + clinical improvement)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Uncomplicated strongyloidiasis: 2 days. Hyperinfection syndrome: 7-14 days (continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart). Disseminated strongyloidiasis: 7-14 days (ivermectin) + 7-14 days (antibiotics, until blood cultures negative + clinical improvement).",
            "monitoring": "Weekly (during treatment): Stool O&P (monitor for larval clearance, goal: negative x 2 consecutive samples 1 week apart). Sputum (if pulmonary involvement, monitor for larval clearance). Clinical status (abdominal pain, diarrhea, respiratory symptoms). Blood cultures (if gram-negative bacteremia, monitor for clearance). At 2-4 weeks (after completing treatment): Repeat stool O&P (confirm cure, negative stool O&P). Clinical improvement expected within 7-14 days (decreased abdominal pain, diarrhea, respiratory symptoms).",
            "stop_criteria": "Discontinue ivermectin after 2 days (uncomplicated) or 7-14 days (hyperinfection syndrome, continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart). Discontinue antibiotics after blood cultures negative + clinical improvement (if gram-negative bacteremia). Repeat stool O&P at 2-4 weeks (confirm cure, negative stool O&P). If stool O&P still positive: Repeat ivermectin 200mcg/kg PO daily x 2 days (uncomplicated) or x 7-14 days (hyperinfection syndrome)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "corticosteroids": "Prolonged corticosteroids (>20mg prednisone daily x >2 weeks, 60-70% of hyperinfection syndrome, most important risk factor). Corticosteroids suppress Th2 immunity (critical for control of Strongyloides). Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success). Screen for strongyloidiasis BEFORE starting corticosteroids (if history of living in endemic area, Strongyloides serology, treat if positive). Ivermectin 200mcg/kg PO daily x 7-14 days (if hyperinfection syndrome). Infectious disease consult REQUIRED.",
            "htlv_1": "HTLV-1 infection (human T-lymphotropic virus type 1, 10-20% of hyperinfection syndrome, endemic in Japan, Caribbean, sub-Saharan Africa). HTLV-1 suppresses Th2 immunity (critical for control of Strongyloides). Screen for HTLV-1 (if hyperinfection syndrome or refractory strongyloidiasis). Ivermectin 200mcg/kg PO daily x 7-14 days (if hyperinfection syndrome). Infectious disease consult REQUIRED.",
            "gram_negative_bacteremia": "Gram-negative bacteremia (30-40% in hyperinfection syndrome, larvae carry enteric bacteria from GI tract to bloodstream: E. coli, Klebsiella, Enterobacter). Septic shock (20-30%, mortality 70-90%). Gram-negative meningitis (10-20%). Treatment: Ivermectin 200mcg/kg PO daily x 7-14 days + Broad-spectrum antibiotics (ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h). Blood cultures (rule out bacteremia). Lumbar puncture (if altered mental status, rule out meningitis). ICU admission.",
            "pregnancy": "Strongyloidiasis in pregnancy: Rare (pregnancy is relative contraindication in endemic areas). Ivermectin: Avoid in pregnancy (teratogenic in animals, use only if life-threatening hyperinfection syndrome). Albendazole: Avoid in pregnancy (teratogenic in animals). Treatment: Delay treatment until after delivery (if uncomplicated strongyloidiasis). If hyperinfection syndrome: Ivermectin 200mcg/kg PO daily x 7-14 days (benefits outweigh risks). Infectious disease + obstetrics consult.",
            "counseling": "Strongyloidiasis is life-threatening if hyperinfection syndrome (mortality 20-40% with treatment, 50-90% if untreated or disseminated with gram-negative bacteremia). Treatment: Ivermectin 200mcg/kg PO daily x 2 days (uncomplicated) or x 7-14 days (hyperinfection syndrome). Clinical improvement expected within 7-14 days (decreased abdominal pain, diarrhea, respiratory symptoms). Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success). Screen for strongyloidiasis BEFORE starting corticosteroids (if history of living in endemic area). Future: Avoid corticosteroids if possible (increase risk of hyperinfection syndrome). Repeat stool O&P at 2-4 weeks (confirm cure)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for stool O&P if high clinical suspicion, mortality increases with delayed treatment)",
              "Uncomplicated strongyloidiasis: Ivermectin 200mcg/kg PO daily x 2 days",
              "Hyperinfection syndrome: Ivermectin 200mcg/kg PO daily x 7-14 days (continue until larvae no longer detected in stool or sputum x 2 consecutive samples 1 week apart)",
              "Disseminated strongyloidiasis: Ivermectin 200mcg/kg PO daily x 7-14 days + Broad-spectrum antibiotics (if gram-negative bacteremia, septic shock, or meningitis)",
              "Reduce or discontinue corticosteroids if possible (CRITICAL for treatment success)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Abdominal pain + diarrhea + respiratory symptoms + immunocompromised host + history of living in endemic area + positive stool O&P or Strongyloides serology)",
              "Is ivermectin started immediately? (Ivermectin 200mcg/kg PO daily x 2 days for uncomplicated, x 7-14 days for hyperinfection syndrome)",
              "Are corticosteroids reduced or discontinued? (CRITICAL for treatment success)",
              "Are blood cultures obtained? (If fever, rule out gram-negative bacteremia)",
              "Are broad-spectrum antibiotics started? (If gram-negative bacteremia, septic shock, or meningitis)",
              "Is stool O&P repeated weekly? (Monitor for larval clearance, goal: negative x 2 consecutive samples 1 week apart)",
              "Is stool O&P repeated at 2-4 weeks? (Confirm cure, negative stool O&P)"
            ],
            "avoid_unnecessary_treatment": "Avoid corticosteroids (suppress Th2 immunity, increase risk of hyperinfection syndrome, reduce or discontinue if possible). Do NOT delay treatment while awaiting stool O&P. Do NOT use short duration (x 2 days) for hyperinfection syndrome (requires x 7-14 days). Do NOT forget to treat gram-negative bacteremia (broad-spectrum antibiotics REQUIRED if bacteremia, septic shock, or meningitis). Do NOT rely on single stool O&P (30-50% sensitive, requires 3 stool samples). Do NOT rely on eosinophilia (often ABSENT in hyperinfection syndrome due to corticosteroids).",
            "diagnostic_stewardship": "Clinical diagnosis (abdominal pain + diarrhea + respiratory symptoms + immunocompromised host + history of living in endemic area). Stool ova and parasites (O&P, 30-50% sensitive for uncomplicated, 70-80% sensitive for hyperinfection syndrome, requires 3 stool samples). Strongyloides serology (IgG ELISA, 80-90% sensitive for uncomplicated, may be negative in hyperinfection syndrome). Sputum or BAL (if respiratory symptoms, larvae, 50-70% sensitive for hyperinfection syndrome with pulmonary involvement). Do NOT delay treatment while awaiting stool O&P if high clinical suspicion.",
            "prevention": "Screening: Strongyloides serology (if history of living in endemic area + planning to start corticosteroids or other immunosuppression). Treat if positive: Ivermectin 200mcg/kg PO daily x 2 days (BEFORE starting corticosteroids). Avoid walking barefoot (in endemic areas, skin penetration by filariform larvae). No specific prophylaxis (ivermectin prophylaxis NOT recommended, treat only if diagnosed)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Strongyloidiasis (2023)",
              "url": "https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for the Treatment of Strongyloidiasis (2018)",
              "url": "https://academic.oup.com/cid/article/67/8/e1/5046622"
            },
            {
              "label": "WHO Guidelines on the Treatment of Strongyloidiasis (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    }
  ]
}

